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RNA interference technology, based on the use of siRNA, has emerged as a promising approach 
in the treatment strategy to suppress disease-causing genes such as those associated with breast 
cancer (BC). Despite its potential as a form of therapy, instability and poor cellular uptake of the 
therapeutic nucleic acid have posed daunting challenges. The major hurdle for siRNA-based 
therapy is the evolution of nontoxic, stable and efficient delivery systems to channel siRNA into 
target cells. Accordingly, this study assesses the efficacy of two cationic lipid-based delivery 
systems to deliver intact siRNA which would target the Human Epidermal Growth Factor 
Receptor 2 (HER2/neu) oncogene in a BC cell model.  
 A series of cationic liposomes were formulated using an equimolar ratio of the respective 
cytofectins together with the neutral lipid dioleoylphosphatidylethanolamine (DOPE). Sterically 
stabilized or stealth liposomes contained a 0-5 mol.% 1,2-Distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000) grafting.  
 Cryogenic-transmission electron microscopy (cryo-TEM) and dynamic light scattering 
measurements revealed that PEGylation generated smaller, defined structures when compared to 
their non-PEGylated counterparts. The hydrodynamic size ranges of the liposomal formulations 
and lipoplexes were 65-127 nm and 103-237 nm respectively, with moderate particle size 
distributions (polydispersity indices were <0.4). Liposomes bound and efficiently compacted 
pCMV-luc plasmid DNA (pDNA) and siRNA as evidenced in band shift and ethidium bromide 
intercalation assays respectively, while nuclease digestion assays demonstrated that the 
degradative effect of serum on lipoplex-associated nucleic acid was minimal.  
 Cytotoxicity studies, involving the reduction of 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-
diphenyl-2H-tetrazolium bromide (MTT), indicated that the pDNA and siRNA lipoplexes 
elicited a dose-dependent cytotoxic effect, with cell viability remaining above 70% and 50% 
respectively. Effective in vitro pCMV-luc pDNA and HER2/neu-specific siRNA transfections 
were achieved in all BC cell lines tested in the presence of serum. Gene expression studies 
indicated that the Chol-T:DOPE (0% PEG)/siRNA complexes induced the highest HER2/neu 
silencing effect at all tested N/P charge ratios, as observed from the significant fold-decrease in 
gene expression (> 10 000-fold, P<0.001). Western blot analysis further confirmed this trend and 
revealed a dose-dependent decrease in HER2/neu protein expression levels as indicated by a 
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160.28, 163.89 and 212.80-fold decrease in protein expression relative to the untreated SKBR-3 
cells. Furthermore, the most active non-PEGylated Chol-T formulations were less cytotoxic and 
exceeded the knockdown level of Lipofectamine
®
 3000 control (4.1-fold decrease). Results 
suggest that these cytofectin-based cationic liposomes with moderate degree of PEGylation have 
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Figure 2.1: A diagrammatic representation of human mammary gland development. (A) An illustration 
of the five different stages of human mammary gland development, beginning with pubertal growth, 
followed by progression from adult to lactating breasts and finally waning at involution. Depicted are 
mammary fat pads (pink) and ductal epithelium (purple). The circular objects represent lobulo-alveolar 
units during pregnancy, lactation, and involution. (B) A model of mammary epithelial cell hierarchy as 
proposed by Shore and Rosen (2014).                 11 
 
Figure 2.2: Outline of BC progression. Breast cancer is believed to advance through a series of well-
defined stages. This sketch depicts cross-sections of the mammary duct at different stages of BC 
progression: Normal duct, Atypical ductal hyperplasia (ADH), Ductal carcinoma in situ (DCIS), and 
Invasive ductal carcinoma (IDC) (Mukhopadhyay et al., 2011; Shore and Rosen, 2014).           13 
 
Figure 2.3: Portrait of the HER2/neu structure (A). The extracellular domain consists of four subdomains 
(I-IV); two leucine-rich domains (L 1/ I and L 2/ III) which are marked with a stop symbol as they do not 
participate in ligand binding, and two cysteine-rich domains (CR 1/ II and CR 2/ IV) responsible for 
receptor dimerization. Depicted are the transmembrane domain; the amino- (NH) and carboxyl-terminal 
lobes of the kinase domain and the carboxyl-terminal tail containing several tyrosine residues that can be 
phosphorylated. Inhibitors of HER2/neu mediated signalling using monoclonal antibody (Trastuzumab) 
and small molecule tyrosine kinase inhibitor (Lapatinib) are also indicated. Key HER2/neu signalling 
pathways involved in tumorigenesis are also schematically illustrated (B). HER2/neu dimerizes with the 
activated HER receptor resulting in the phosphorylation of the tyrosine residues and signal transduction in 
the intracellular domain. This activates the lipid kinase phosphatidyl inositol 3 kinase (PI3K), which 
phosphorylates a phosphatidylinositol that in turn binds and phosphorylates the enzyme Ak transforming 
factor (Akt). Among the Akt multiple targets is the mammalian target of rapamycin (mTOR), which 
drives cell survival by promoting cell cycle progression and inhibiting pro-apoptotic members of the Bcl-
2 family. On the other hand, the mammalian homologue of the son of sevenless (SOS), a guanine 
nucleotide exchange factor, activates the rat sarcoma (RAS) enzyme which, in turn, activates the receptor 
activation factor (RAF) and then mitogen extracellular signal kinase (MEK). MEK then phosphorylates 
the mitogen-activated protein kinase (MAPK), which results in cell cycle progression and proliferation 
(Adapted from Colombo et al., 2010; Roskoski Jr, 2014; Seliger and Kiessling, 2013; Thery et al., 2014; 
Videira et al., 2014).                   19 
 
Figure 2.4: A graphic representation of the widespread application of gene therapy in clinical trials 
(Wirth et al., 2013).                   25 
 
Figure 2.5: A schematic representation of the siRNA-mediated gene silencing pathway. 1) Introduction 
of exogenous long dsRNA is recognized by Dicer-2 in the cytoplasm; 2) Long dsRNA is cleaved by 
Dicer-2 into siRNA duplexes of 21-23 nucleotides in length followed by interaction with R2D2; 3) 
Synthetic siRNAs bypass the requirement for Dicer-2 processing and are recognized by both Dicer-2 and 
R2D2; 4) Dicer-2 and R2D2 facilitate the transport of siRNA to Ago-2, followed by formation of RISC; 
5) Ago-2 protein promotes the unwinding of the duplexed siRNA, and the sense (passenger) strand is 
rapidly cleaved and dissociated; 6) The anti-sense (guide) strand remains bound to the RISC complex and 
mediates recognition of the target RNA; 7) Anti-sense RNA strand guides RISC and binds to the 
complementary site in the target mRNA; 8) RISC engages the endonucleolytic activity of Ago-2, 
resulting in target mRNA cleavage which shuts off translation of the corresponding protein (Adapted 




Figure 2.6: Depicted are unilamellar liposomes (bottom) bearing different densities of PEG polymers on 
their surfaces. Presented from left are total, intermediate and partial surface coverage of the liposomal 
bilayer. A detailed zoom (top) of the three PEGylated liposomes shows the respective PEG regimens 
formed as a result of the different surface densities. When the density of PEG on the surface is low, it 
takes on a heavily coiled flat “pancake” configuration (D > Rf). Increasing PEG densities cause the 
conformations to switch to low coiled “mushroom” or to extend further into “brush” structures (D < Rf) 
This figure is adapted from Buyens et al. (2012) and Wang and Thanou (2010).            43 
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with neutral co-lipids into liposomes (B).                 45 
 
Figure 3.1: Plasmid map of the pCVM-luc vector. The vector comprises cDNA of the firefly luciferase 
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r
). The vector is driven by the cytomegalovirus 
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cholesterylformyl hydrazide (MS09).                 82 
 
Figure 4.2: Transmission electron micrographs of cationic and PEGylated cationic liposomes prepared 
according to Table 1: A, Chol-T:DOPE; B, Chol-T:DOPE:2% PEG; C, Chol-T:DOPE:5% PEG; D, 
MS09:DOPE; E, MS09:DOPE:2% PEG; F, MS09:DOPE:5% PEG. Bar = 100 nm or 200 nm.          87 
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1.1 Background to the Study 
 
Since its discovery in 1998 as a powerful sequence specific post-transcriptional gene silencing 
mechanism, RNA interference (RNAi) has opened up a range of opportunities for target gene 
function validation and therapeutic applications in several genetic disorders. In mammalian cells, 
transfected synthetic double stranded small interfering RNAs (siRNAs), generally 21-23 
nucleotides in length, target messenger RNA (mRNA) sequences with a high degree of 
specificity, inducing gene silencing. This versatile technique of target specific gene silencing has 
potential for use against any mRNA transcribed from an organism’s genome, thereby offering a 
unique class of drug molecules comparable to antibody based therapeutics. Based on 
conceptually simple beginnings, the evolution of siRNA gene silencing technology has inspired a 
new paradigm of therapeutic intervention strategies for a wide spectrum of disorders, including 
cancer (Huang et al., 2008; Oh and Park, 2009), Huntington’s disease (DiFiglia et al., 2007), 
respiratory syncytial virus (Bumcrot et al., 2006), and neurodegenerative disorders (Porras and 
Bezard, 2008). 
Malignant tumours, namely cancers, are complex and intrinsically heterogeneous 
diseases with approximately 8 million people dying from numerous types of cancers in 2008 
(Benson and Jatoi, 2012; Graham et al., 2012). In South Africa, cancer is an escalating public 
health problem. The most prevalent malignancy is breast cancer (BC), a major cause of cancer 
death among women, as is the global trend (DeSantis et al., 2011, Núñez et al., 2016, Shah and 
Osipo, 2016). Based on projections of BC incidences and population estimations, the annual 
global incidence of BC is expected to reach approximately 3.2 million by 2050 (Hortobagyi et 
al., 2005; WPP, 2004). These statistics clearly highlight the increasing threat that BC poses 
worldwide. Hence there is an urgernt need to investigate the molecular biology of BC to identify 
alterations associated with malignant behaviour for clinical use as diagnostic markers and as 
targets for therapy. 
Malignant breast tumours form when an individual cell gains and sustains a selective 
survival advantage, due to a series of somatic alterations that allow the cell to evade the 
checkpoints that would normally suppress its growth. In particular, overexpression of the Human 
Epidermal Growth Factor Receptor 2 (HER2/neu) oncogene, many researchers believe, is 
predictive of adverse BC prognosis. Overexpression of HER2/neu has been found in 
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approximately 30% of all invasive BCs and correlates with more unfettered and destructive 
tumour growth and greater resistance to cancer chemotherapy (Menard et al., 2000; Núñez et al., 
2016; Press et al., 2002; Rubin and Yarden, 2001; Slamon et al., 1989). Despite recent advances 
in treatment strategies, most, if not all conventional treatments such as chemotherapy, are limited 
by a lack of specificity for tumour cells and the cell cycle dependence of many chemotherapeutic 
agents. This has spurred efforts to develop unique anticancer agents with improved molecular 
target specificity. In this context, tailored treatments using siRNA to down-regulate the 
transcription or function of defective genes through specific cleavage of their associated mRNA, 
introduces an innovative, cutting-edge assemblage of treatment options for BC. 
Silencing of the HER2/neu oncogene expression using siRNA may be effective in 
treating patients with HER2/neu-overexpressing BCs. Despite the versatility, effectiveness and 
specificity of siRNAs’ use in tumour targeted therapy, the delicate and precise mechanism of 
action required for gene silencing is the same. However, the delivery of therapeutic siRNA to 
intracellular targets for the induction of sequence-specific mRNA degradation creates an 
encumberance which limits the success of siRNA therapy in clinical trials for several reasons. 
Firstly, the polyanionic nature, hydrophilic character and relatively high molecular weight of 
siRNA hamper its direct association with the cell membrane. This makes entry into cells via a 
passive diffusion mechanism difficult for these molecules (Whitehead et al., 2009). Furthermore, 
siRNA molecules in the physiological milieu are prone to degradation by serum nuleases, non-
targeted biodistribution and activation of immune response, thereby limiting systemic 
applications of this powerful tool to perform gene knockdown (Haupenthal et al., 2006; Juliano 
et al., 2009; Medarova et al., 2007).  
The major challenge for siRNA-based gene silencing therapy is the development of non-
toxic nanocarriers capable of efficiently transporting siRNAs into target cells. Numerous 
research efforts focusing on the development of lipid- and polymer-based systems have been 
directed at meeting this challenge. In particular, cationic liposomes have emerged as the most 
widely studied non-viral vectors for the transport of negatively charged gene medicines via the 
formation of lipoplexes. The main component of cationic liposomes, namely the cationic 
cytofectins, generally comprise four regions: cationic headgroups, hydrophobic lipid tails, spacer 
segments, and linkers (Ariatti, 2015). Despite progress in cationic liposome-mediated delivery, 
cell toxicity and the reduced cellular uptake efficiency of siRNA in the presence of serum 
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nucleases are still major drawbacks for in vitro and vivo application. The key challenges are to 
synthesize cytofectins with a unique combination of their domains, which are capable of self-
assembling into liposomes. Moreover, a deeper insight into the structure-activity associations of 
liposomal carriers with siRNA, in order to achieve high transfection performance is imperative. 
This leaves BC gene therapy at a point where the need for an optimal gene delivery vector has 
become the rate limiting step. Therefore, this study aims to develop cationic lipid-based delivery 
systems for siRNA that can increase serum stability and transfection efficiency. Clearly, the 
development of an agent with the ability to successfully inhibit cellular growth, migration, and 
invasion of BC cells is crucial for the suppression of cancer metastasis and progression, thus 
resulting in reduced mortality. 
 
1.2 Scope of the Present Study 
 
The major challenge for siRNA-based therapy is the development of non-toxic, stable and 
efficient delivery systems to channel siRNA into target cells. Since their introduction, non-viral 
vector-mediated nanocarriers have developed to a stage where they have demonstrable 
advantages over their viral counterparts, in particular where safety issues are concerned, making 
them an attractive alternative for nucleic acid delivery platforms. Research in this area, however, 
has to address low levels of gene delivery and transfection efficiency which compromise non-
viral gene delivery vector therapy. Undoubtably, non-viral carriers have emerged as essential 
components in siRNA gene delivery systems. Although research initiatives are being directed at 
improving current vector technologies, further development of non-viral nanocarrier systems 
with superior biocompatibility and higher transfection efficiencies is crucial for the success of 
gene silencing-based therapeutics. Accordingly, this study assesses the ability of two cationic 
lipid-based delivery systems to efficiently deliver intact siRNA targeting the Her2/neu oncogene 








1.2.1 Hypothesis tested 
 
This study, which examines the efficacy with which liposomes-vehiculated siRNA induces 
silencing of HER2/neu oncogene expression in a BC cell model in vitro, hinges on the hypothesis 
that cationic liposome-based delivery systems that incorporate cytofectins: 3β-[N-(N', N'-
dimethylaminopropane)-carbamoyl] cholesterol (Chol-T) and N, N-dimethylaminopropyl 
aminylsuccinylcholesterylformylhydrazide (MS09) increase the serum stability of  the nucleic 
acid in their associated deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) lipoplexes 





The following objectives premise the testing of the above hypothesis: 
 To prepare and characterize a series of cationic liposomes (PEGylated and non-
PEGylated) in terms of imaging and lamellarity by cryogenic-transmission electron 
microscopy (cryo-TEM), and size and zeta potential using dynamic light scattering 
(DLS). 
 To characterize the formulated liposomes and their interactions with plasmid DNA 
(pDNA) and small interfering RNA (siRNA) for the purpose of optimizing their 
bifunctionality. 
 To evaluate cytotoxicity in vitro using the 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-
2H-tetrazolium bromide (MTT) test. To measure transfection activity of the cationic 
lipoplexes using the luciferase assay as well as HER2/neu targeted siRNA. 
 To monitor gene expression and silencing using standard reporter gene assays, 










 To prepare a series of cationic liposomes (Chol-T and MS09) with and without 
PEGylation (sterically stable) at two different mole percentages, and to explore and 
compare the effects these formulations may have on the transfection of pDNA and 
siRNA. 
 To prepare Chol-T- and MS09-liposome/ pDNA- and siRNA-lipoplexes, and to assess 
these complexes in terms of size, polydispersity index and zeta potential. To further 
characterize lipoplexes using gel retardation, nuclease protection and ethidium bromide 
intercalation displacement assays. 
 To perform transfection activity studies using both pDNA and siRNA, and to evaluate the 
results of MTT cytotoxicity tests on various cancer cell lines. 
 To extract total RNA and proteins from transfected cells, and to determine their 
concentration, quality and integrity. 
 To conduct qRT-PCR by reverse transcribing total RNA, and then to separate total 
proteins and check for the presence of HER2/neu proteins via Western Blotting. 
 
1.3 Novelty of Study 
 
This study evaluates the ability of two cationic lipid-based carrier systems to efficiently deliver 
target specific siRNA into breast cancer cells. The two cationic cholesteryl cytofectins (CCCs), 
Chol-T and MS09, were previously synthesized in our laboratory (Singh and Ariatti, 2006; Singh 
et al., 2001). Liposomes were formulated with an equimolar ratio of the respective cytofectin 
with dioleoylphosphatidylethanolamine (DOPE); the degree of PEGylation varied from 0-5 
mol.%. Although these cationic liposomes have shown potential for nucleic acid delivery into 
mammalian cells, detailed studies on their ability to bind target specific siRNA have not been 
conducted. Accordingly, this study aims to assess the ability of these two cationic lipid-based 
delivery systems to efficiently deliver intact siRNA, which targets the HER2/neu oncogene in a 





1.4 Overview of the Thesis 
 
 Chapter One  
 
This chapter provides an introduction and background to the study. It highlights the challenges 
encountered in siRNA gene therapy and non-viral gene delivery systems. Finally, it outlines the 
rationale, scope, objectives and aims of the study. 
 
 Chapter Two  
 
This chapter reviews the relevant literature. Firstly, it details the biology and classification of BC 
with particular reference to the HER2/neu receptor and its role in BCs. Secondly, it assesses 
HER2/neu as a target for BC therapy, together with current treatment options and their 
limitations. Lastly, it explores the therapeutic potential of siRNA gene silencing technology and 
delivery into cells using non-viral gene delivery systems. 
 
 Chapter Three 
 
Chapter Three describes the research design and details the laboratory procedures undertaken. 
The formulation and preparation of six cationic liposomes (PEGylated and non-PEGylated at two 
different mole percentages) are detailed, followed by physical characterization of the liposomes 
and liposome-nucleic acid interactions. These characterizations are based on particle imaging 
using Cryo-TEM, particle size distribution, and zeta potential analysis. Again, the formulated 
lipoplexes are comprehensively characterized to establish nucleic acid binding capacity (gel 
retardation assay), protection from nucleases (serum digestion assay), and condensation 
capabilities (ethidium bromide intercalation assay) provided by the vector. In vitro transfection 







 Chapter Four  
 
Here, the focus is on the results obtained and a comprehensive report of all experimental work 
completed. This is followed by a robust interpretation of the results, with detailed discussion 
which lends shape, contour, and perpective to the study. 
 
 Chapter Five 
 
This chapter concludes the study by highlighting findings which are significant to the aims and 
objectives of the research. Possible limitations and shortcomings of the study are also conceded. 
Finally, the extent to which the study conceivably contributes to the body of knowledge in this 
area of research is objectively evaluated, and recommendations for further research initiatives are 
made. 
 































2.1 The Nature of Cancer 
 
The human genome, comprising a total length of over 3 billion base pairs, controls the fate of 
cells in a systematic and precise manner. Genetic material, namely genomic DNA, is under 
constant attack from both genotoxic and non-genotoxic mechanisms, often resulting in 
modifications which can potentially transform a normal cell into a premalignant lesion 
(Nowsheen et al., 2014). Eventually, accumulation of dynamic alterations in the genome and a 
complex network of interactions among mutated cells with multiple distinct cell types lead to 
metastatic cancer with uncontrolled growth of tissues. According to Hanahan and Weinberg 
(2000; 2011), cancer may be characterized by six distinctive biological aptitudes: sustained 
proliferative signaling, insensitivity to growth suppressors, resistance to apoptosis, replicative 
immortality, induction and sustainment of angiogenesis, invasion through capillary walls and 
basal membranes and metastasis to other sites of the body. 
Globally, cancer rates are escalating at an alarming rate. In developing countries, in 
particular, an overburdened health sector further exacerbated by economic constraints makes 
cancer a serious health issue, resulting in the disease being the leading cause of death. Despite 
considerable advances in diagnostic technology and treatment modalities, the invasive, 
aggressive growth profile, the complexity of the signaling web involved in cancer development 
and propagation, coupled with multiple mechanisms to evade apoptosis, pose a formidable 
challenge to the quest for cancer treatment and a cure (Hanahan and Weinberg, 2000; Li et al., 
2013). Traditional cancer therapies such as chemotherapy, radiotherapy and surgery are 
ineffectual in more advanced cases, primarily because these interventions lack specificity and 
therefore induce adverse side-effects on normal cells. In most cases, these treatment options 
result in incomplete eradication of the invasive primary tumour or disseminated disease. 
Furthermore, when cancer treatments fail or when relapse occurs, cross-resistance with several 
structurally unrelated anticancer agents or multidrug resistance (MDR) is a common occurence 
(Fatemian et al., 2014). These phenotypes are the most prevalent form of tumour resistance, 
accounting for 90% of cancer treatment failure (Ozben, 2006). The urgency of the quest for 





2.2 Breast Cancer 
 
The estimated global new incidence of BC cases in women was approximately 1.7 million with 
approximately half a million deaths in 2012, accounting for 25% of all cancer cases and 15% of 
all cancer deaths among the female population (Torre et al., 2015). According to a cancer report 
by the American Cancer Society, BC is over 100 times more common in women than in men 
(ACS, 2015). Although there is a higher incidence of BC in industrialized countries, adoption of 
urbanized lifestyles and changes in reproductive behaviour could possibly be the reasons for the 
increase of BC in non-industrialized countries (Porter, 2008). Based on BC incidence projections 
and population estimations, the annual global incidence of BC is expected to reach 
approximately 3.2 million by 2050 (Hortobagyi et al., 2005; WPP, 2004). Clearly, these statistics 
presage a global BC increase of alarming proportions. 
Although BCs are sporadic in nature, approximately, 5-10% of BC cases are genetic in 
provenance. Generally, BC develops in cells which line the milk ducts and the lobules that 
supply the ducts with milk, classified as ductal and lobular carcinomas respectively. The most 
common, invasive ductal carcinomas constitute approximately 80% of BCs; 10-15% are invasive 
lobular carcinomas; and additional rare types make up less than 5-10% of BCs (Perou et al., 
2000; Sørlie et al., 2003). Breast cancer tumours are heterogeneous, and pathological 
characteristics such as morphology, grade and hormone-receptor profile stratify tumours into 
biologically and clinically distinct groups (Simpson et al., 2005). 
 
2.3 The Normal Mammary Gland and the Biology of Breast Cancer 
 
2.3.1 Development of the mammary gland 
 
The human mammary gland is a unique organ; it originates in the embryonic stage of human 
development and undergoes a series of changes post-puberty to senescence (Cowin and 
Wysolmerski, 2010; Watson and Khaled, 2008). In normal physiological conditions, the 
mammary gland consists of a branching tubulo-alveolar system composed of a highly dynamic 
stratified epithelium surrounded by a basement membrane. This glandular structure is embedded 
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within a matrix of stroma composed of varying amounts of adipose and connective tissue, 
nerves, blood vessels and lymphatics (Osborne, 2000; Stingl et al., 2006). 
In newborn infants, the palpable mammary fat pad consists of a simple epithelial ductal 
structure that quiescently lies beneath the nipple until puberty. In both males and females, pre-
pubertal mammary glands are analogous in structure and cellularity with specialized cell biology 
(Howard and Gusterson, 2000; Javed and Lteif, 2013). Structural modifications of the breast 
observed at different stages in females (menstrual cycle, pregnancy, lactation and regression) led 
to the postulation of the existence of progenitor cells that are capable of developing new duct-
lobular systems (Raouf et al., 2012; Shore and Rosen, 2014; Villadsen et al., 2007) [Figure 2.1]. 
In females, the normal range of thelarche is from 8½ to 13 years. During this period, the release 
of ovarian and pituitary hormones such as estrogen, progesterone and growth hormones stimulate 
proliferation of the mammary epithelial cells resulting in the generation of an elaborate network 
of terminal end bud structures (Stingl, 2011). These are dynamic, highly proliferative structures 
located at the tips of the invading ducts that expand and increase extensively to allow complex 
branching, ductal elongation and lumen formation (Brisken and O'Malley, 2010; Hennighausen 
and Robinson, 2001; Sternlicht, 2006). In the adult, the epithelial ducts form into a branched, 
bilayered ductal structure, comprising an inner layer of polarized luminal epithelial cells and an 
outer basal layer of cells which are believed to arise from a common bipotent stem cell (Shore 
and Rosen, 2014; Visvader, 2009). The luminal cells can be further subdivided into luminal 
progenitors and mature luminal cells, i.e., ductal luminal cells, lining the inside of the ducts, and 
alveolar luminal cells which are the milk producing cells of the mammary gland. The outer basal 
layer consists of basal progenitor cells and a population of contractile myoepithelial cells. These 
are muscle-like cells which, in the presence of oxytocin, contract to force the movement of milk 
out of the alveoli into the ducts to be ejected from the nipples during lactation (Howard and 
Gusterson, 2000; Russo and Russo, 2004). Luminal and basal progenitors are believed to 
produce alveolar progenitors (Visvader, 2009). During pregnancy, these primary ducts that reach 
the nipple form a complex of auxiliary ducts, which undergo a stepwise process of differentiation 
to form several alveolar cells or acini (Brisken and Rajaram, 2006). A collection of alveolar cells 
arising from one terminal duct forms the functional unit of the breast, termed a terminal duct 
lobular unit. The morphogenesis and systematized differentiation of the mammary gland allow 
the secretory units of the mammary gland to be inactive, rather than persisting in a functionally 
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differentiated, milk producing state (Smith et al., 2012). During involution, the process when 
lactation stops and the mammary gland turns in on itself, the majority of differentiated alveolar 
cells undergo rounds of apoptosis in a controlled manner, reverting the gland to a pubertal state. 
Importantly, the mammary gland becomes fully differentiated only with the onset of pregnancy, 
which brings about the next major change in the hormonal environment (Anderson et al., 2007). 
 
 
Figure 2.1: A diagrammatic representation of human mammary gland development. (A) An illustration 
of the five different stages of human mammary gland development, beginning with pubertal growth, 
followed by progression from adult to lactating breasts and finally waning at involution. Depicted are 
mammary fat pads (pink) and ductal epithelium (purple). The circular objects represent lobulo-alveolar 
units during pregnancy, lactation, and involution. (B) A model of mammary epithelial cell hierarchy as 
proposed by Shore and Rosen (2014). 


























2.3.2 The biology of breast cancer 
 
Breast cancer is not a single disease but a highly heterogeneous group of neoplasms (Perou et al., 
2000). Regardless of the histological type of the tumour, almost all are believed to originate from 
the epithelial cells lining the milk ducts (Tavassoli and Devilee, 2003). The initiation of BC, i.e., 
deregulated cell growth and apoptosis, is due to both genetic and epigenetic modifications in a 
single cell. These changes include: point mutations, duplications, insertions, deletions, 
translocations, chromosome aberrations, and epigenetic inactivation such as histone 
deacetylation and promoter hypermethylation (Nowsheen et al., 2014). The most well 
characterized pre-malignant lesions studied and recognized were obtained from the ductal and 
lobular units of the mammary gland. These are termed atypical ductal or lobular hyperplasias, 
and ductal or lobular carcinomas in situ (Allred et al., 2001). The prevailing model focuses 
specifically on the progression of lesions present within the ductal region of the mammary gland 
[Figure 2.2]. Essentially, the natural history of breast tumourigenesis assumes a sequential 
progression through defined pathophysiological stages, beginning with atypical ductal 
hyperplasia (ADH), to ductal carcinoma in situ (DCIS), with subsequent evolution into invasive 
ductal carcinoma (IDC) and metastatic carcinoma (Burstein et al., 2004; Polyak, 2007). 
Collectively, clinical and experimental data suggest that ADH is a pre-malignant tumour and a 
precursor lesion of DCIS, characterized by abnormal epithelial cells that have proliferated and 
formed numerous layers within the lumen. Based on molecular and pathological studies, DCIS 
(also referred to as intraductal carcinoma) is the precursor lesion of invasive BC. DCIS is a 
clonal proliferation of pre-malignant cells, capable of rupturing the basement membrane 
surrounding the mammary ducts and invading into the adjacent stroma. Despite being a crucial 
stage in tumour progression, there is no consensus about its nature. Some researches suggest that 
it is the result of the accumulation of additional genetic changes coupled with clonal expansion 
and selection (Place et al., 2011). The most prominent changes observed in epithelial cells at 
both the ADH and DCIS stages are the loss of polarity, abnormal cell morphology, and the 
ability to hyperproliferate within the mammary duct (Shore and Rosen, 2014). Numerous 
changes in the cellular composition from normal mammary gland to IDC have been documented. 
These included loss of epithelial cells, increase in fibroblasts, mast cells, macrophages (immune-
competent cells) in the stroma, and enhanced vascularization, which is the most common 
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(Gudjonsson et al., 2005; Lewis and Pollard, 2006; Shekhar et al., 2003). Following basement 
membrane invasion, the spread of malignant mammary epithelial cells to distant organs results in 
metastatic disease. A range of motility mechanisms facilitate invasion of cancerous breast tissues 
and metastasis. These include: epithelial mesenchymal transition, structural modifications of the 
actin cytoskeleton, as well as the control of membrane proteins through endocytosis. These 
cellular responses within the tumour environment are tightly regulated as each of the constituents 
within the niche is able to secrete growth factors, chemokines, cytokines and proteins capable of 
remodelling the extracellular matrix (Jiang et al., 2009; Mathias et al., 2013; van Zijl et al., 
2011). Taken together, invasive and metastasized lesions display a variety of morphological 
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Figure 2.2: Outline of BC progression. Breast cancer is believed to advance through a series of well-
defined stages. This sketch depicts cross-sections of the mammary duct at different stages of BC 
progression: Normal duct, Atypical ductal hyperplasia (ADH), Ductal carcinoma in situ (DCIS), and 
Invasive ductal carcinoma (IDC) (Mukhopadhyay et al., 2011; Shore and Rosen, 2014). 
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2.4 Classification of Breast Cancer 
 
2.4.1 Immunohistochemical classification 
 
Traditional, histopathological subclassification of BCs by immunohistochemistry has resulted in 
a clinically relevant classification system which contextualizes pathogenesis and therapeutic 
approaches for its treatment. Typically, this procedure uses the immunostaining technique in 
paraffin sections of BC (Goldhirsch et al., 2009). In clinical practice three predictive biomarkers 
in BC, not mutually exclusive, have been identified and addressed (Bertos and Park, 2011). 
These immunohistological biomarkers are categorized on the basis of the 
amplification/overexpression of the Human Epidermal Growth Factor Receptor 2 (HER2/neu), 
and the presence or absence of expression of the estrogen receptors (ER) and progesterone 
receptors (PgR) (Hammond et al., 2010; Patani et al., 2013; Wolff et al., 2007). Breast cancers 


























 (triple negative which has none of the abovementioned receptors). 
Numerous ecological/lifestyle and hereditary risk factors associated with the aetiology of BC 
also play a role in the hormone-receptor status of the tumour. For example, early menarche, 
nulliparity, late age at first birth, as well as obesity among postmenopausal women have been 
more strongly linked to ER and/or PgR
+
 than the ER
-
 tumours (Colditz et al., 2004; Cotterchio et 
al., 2003; Rusiecki et al., 2005). The majority of BCs express ER and PgR, and the percentage of 
positive tumours increases with age at diagnoses. Thus in women younger than 35 years, ER
+
 
varies from 60-70%, whereas in women over 60 years it increases to 80% (Mavaddat et al., 




 tumours remains approximately the 
same over all age groups. The issue of heterogeneity which the existing accepted classification 
posits may explain diversity in tumour proliferative capability and resistance to therapy (Bauer et 







2.4.2 Molecular classification 
 
Breast cancer classification based on gene expression microarrays has revealed both biologically 
and clinically meaningful molecular profiles, each with distinct characteristics (Sørlie et al., 
2001; 2003). Computational systems have enabled the simultaneous gene expression analysis of 
large cohorts of BC samples in a single experiment in order to generate gene signatures 
(Rivenbark et al., 2013). In 2000, Perou et al. were the first to classify BC into intrinsic subtypes 
based on common gene expression patterns determined by overexpressed genes. In the pivotal 
study, the group screened 38 BC cases using complementary DNA (cDNA) microarray, and 
reported a defined list of intrinsic genes. Based on these intrinsic gene signatures, a hierarchical 
cluster analysis identified four major molecular subtypes of BC: Luminal, HER2/neu enriched, 
Basal-like and Claudin-low (Perou et al., 2000; Sørlie et al., 2001; 2003; Sotiriou et al., 2005). 
The subsequent expansion of transcription profiling studies in a larger cohort of BC patients 
provided additional information and created new classifications validated by independent groups. 
Currently, the Luminal group has been divided into two subcategories, namely, Luminal A and 
Luminal B. These novel classifications group breast tumours according to their biological 
characteristics regardless of their prognostic and clinical features (Eroles et al., 2012). This study 
focuses primarily on the HER2/neu molecular subtype which is discussed in greater detail below. 
 
2.5 The Human Epidermal Growth Factor Receptor 2 (HER2/neu) 
 
2.5.1 Physiological role of HER2/neu 
 
The HER2/neu, also termed HER2, ErbB-2 or c-erbB2, is a 185 kDa transmembrane 
glycoprotein (p185
HER2/neu
), encoded by the ERBB2 gene located at the long arm of human 
chromosome 17 (17q21-q22) (Burgess, 2008; Coussens et al., 1985; Yarden and Sliwkowski, 
2001). HER2/neu is a member of the HER (ErbB) lineage of proteins, which includes three other 
structurally related Epidermal Growth Factor Receptors (EGFR): HER1 (EGFR, ErbB-1), HER3 
(ErbB-3) and HER4 (ErbB-4). These receptors form part of a group of 90 protein-tyrosine 
kinases, of which 58 are receptor and 32 are non-receptor kinases (Alonso et al., 2004; Klapper 
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et al., 2000; Roskoski Jr, 2014). Structurally, the ErbB family of receptors is expressed as single-
pass integral transmembrane receptor proteins. 
Under normal physiological conditions, HER2/neu is usually expressed at low levels, 
anchored in the membrane of epithelial cells in a wide variety of tissues, viz., the placenta, 
ovary, breast, gastrointestinal tract, endometrium, lung, kidney and the central nervous system 
(Lemoine et al., 1990; Natali et al., 1990). In humans, HER2/neu is over-expressed on the 
surface of trophoblasts and foetal epithelial cells during the final stages of trophoblastic 
differentiation (Mielke et al., 1998; Press et al., 1990). HER2/neu is believed to be an orphan 
receptor, as none of the epidermal growth factor ligands which are capable of dimerizing with 
the other HER family members is able to activate it. At the molecular level, HER2/neu has no 
known ligand and its receptors are activated upon homo- or hetero-dimerization with the other 
members of the HER family or by proteolytic cleavage of their extracellular domain (termed 
HER2/neu shedding) (Olayioye, 2001; Tsé et al., 2012). Upon activation, HER2/neu is normally 
involved in the signal transduction pathways leading to cell growth and differentiation. 
 
2.5.2 HER2/neu receptor biology  
 
Based upon the primary amino acid structure and cDNA analysis of the HER2/neu receptor, 
three distinct regions have been identified: a glycosylated N-terminal extracellular domain, a 
single hydrophobic α-helical transmembrane domain, and an intracellular portion with a 
juxtamembrane segment, a protein tyrosine kinase domain, and a carboxyterminal tail (Ullrich et 
al., 1984; Olayioye et al., 2000) [Figure 2.3A]. Similar to all HER receptors, the N-terminal 
extracellular domain of the HER2/neu receptor is the largest of the three domains (95-115 kDa), 
and is organized into four subdomains (I-IV) (Cho et al., 2003). Subdomains I and III are related 
leucine-rich segments that form a binding site for the receptor's potential ligands, and 
subdomains II and IV, which are cysteine-rich residues, participate in disulfide homo- and 
hetero-dimerization (Lax et al., 1988; Pietras et al., 1995). In particular, subdomain II contains a 
short hairpin loop dimerization arm which protrudes on the outer surface of this subdomain. 
Therefore, subdomain II is believed to be the main contributor to dimerization, capable of 
connecting with the dimerization arm of HER family members (Tai et al., 2010a). Based on the 
X-ray crystal structure of the extracellular domain, two conformations are known to exist: a 
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closed (inactive) configuration and an open (active) configuration (Garrett et al., 2003). In the 
inactive conformation, the interplay between domains II and IV prevents the association with 
dimerization arms from other HER receptors because these receptors possess a tethered and 
closed structure. In contrast, binding of its native ligand to the receptor induces the interaction 
between subdomains I and III, resulting in an extended and open conformation in which the 
dimerization arm of subdomains II and IV are exposed and not buried, effectively forming an 
active conformation state. Except the HER2/neu receptor, all other members of the HER family 
of receptors (ErbB-1/3/4), employ a receptor-only mediated dimerization mechanism (Lemmon, 
2009). HER2/neu receptors in their native form exist in an open configuration, indicating that the 
dimerization arm remains constitutively extended and capable of dimerizing with the other 
receptors (Burgess et al., 2003; Garrett et al., 2003; Tai et al., 2010a). Together, the four HER 
family members are able to form 28 homo- and hetero-dimers, with HER2/neu being the 
preferred dimerization partner for all the other HER (ErbB-1/3/4) receptors (Graus-Porta et al., 
1997; Pinkas-Kramarski et al., 1996). 
Connecting the extracellular region to the intracellular protein tyrosine kinase domain is a 
single α-helical transmembrane domain comprised of 19-25 amino acid residues. Fleishman et 
al. (2002) recognize a molecular activation switch in the HER2/neu transmembrane region, and 
show that there are two motifs with a conserved sequence of approximately 5 residues. Further, 
these two dimerization motifs play a major role for receptor dimerization. The dimerization is 
triggered by strong dimerization interactions which are created by hydrogen bonds and van der 
Waal forces between hydrophobic segments within the dimerization motifs (Bazley and Gullick, 
2005). This mechanism has been substantiated by crystallographic analysis of the HER2/neu 
transmembrane homodimers (Tai et al., 2010a). 
The intracellular protein tyrosine kinase region has approximately 570 residues, and is 
divided into three major subdomains: (i) a cytoplasmic juxtamembrane linker, (ii) a tyrosine 
kinase domain, and (iii) a carboxyl-terminal tail. The juxtamembrane is a small flexible segment 
which links the transmembrane domain and tyrosine kinase domain. The tyrosine kinase domain 
has several short amino-terminal lobes/loops containing several conserved α-helices and β-stands 
which form the enzyme active site (Knighton et al., 1991; Telesco and Radhakrishnan., 2009). 
This region is the most complicated of the HER2/neu protein receptor. Numerous studies have 
focused on this segment of the receptor, and it has been extensively reviewed (Jones et al., 2006; 
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Roskoski Jr, 2014; Schulze et al., 2005). The carboxyl-terminal tail contains several tyrosine 
residues which are available for phosphorylation, and serve as docking sites for adaptor proteins 
or enzymes containing either modular Src homology 2 or phosphotyrosine binding domains (or 
both) (Roskoski Jr, 2014). 
 
2.5.3 HER2/neu receptor mechanism of action and signaling pathways 
 
In the physiological quiescent state, HER2/neu receptors are inactive monomers. Receptor 
dimerization is a fundamental requirement for HER2/neu signalling activities that govern 
essential cellular processes (Olayioye et al., 2000). Among the different dimers formed by the 
HER receptors, HER2/neu-containing heterodimers are characterized by the most powerful 
signal transduction cascade; this markedly reduces the rate of ligand dissociation, allowing 
potent and prolonged activation of downstream signaling pathways (Rubin and Yarden, 2001). 
Dimerization results in the phosphorylation of tyrosine residues which are catalyzed by the 
juxtaposed cytoplasmic kinase domains leading to protein kinase activation. The response to 
HER2/neu activation depends largely on the different dimeric combinations of HER proteins 
within the dimers and the pattern of dimerization, mediated by the activation of at least three 
different pathways, namely, phosphatidyl inositol 3 kinase (PI3K)/ Ak transforming factor (Akt)/ 
mammalian target of rapamycin (mTOR), mitogenic Ras/ receptor activation factor 
(RAF)/mitogen-activated protein kinase (MAPK), and phospholipase C-γ (PLCγ) pathways 
(Citri and Yarden, 2006; Rubin and Yarden, 2001) [Figure 2.3B]. Depending on which of the 
signal cascades are activated, HER2/neu receptors can be involved in the regulation of complex 
cellular processes including proliferation, cell survival, differentiation, adhesion and migration. 
Typically, induction of the PI3K cascade is stimulated by the (HER2/neu)/HER3 heterodimer, 
this dimerization pair being the most robust of the HER homo- and hetero-dimers (Tzahar et al., 
1996). On the other hand, HER2/neu dimerization with all of the HER (ErbB-1/3/4) members 
can activate the MAPK pathway (Yarden and Sliwkowski, 2001). Both the PI3K and MAPK 
pathways are known to provide the key signaling cascades that prevent apoptosis, promote cell 
growth and proliferation, cellular migration and angiogenesis (Tai et al., 2010a). 
   
 
 
Figure 2.3: Portrait of the HER2/neu structure (A). The extracellular domain consists of four subdomains (I-IV); two leucine-rich domains (L 
1/ I and L 2/ III) which are marked with a stop symbol as they do not participate in ligand binding, and two cysteine-rich domains (CR 1/ II 
and CR 2/ IV) responsible for receptor dimerization. Depicted are the transmembrane domain; the amino- (NH) and carboxyl-terminal lobes 
of the kinase domain and the carboxyl-terminal tail containing several tyrosine residues that can be phosphorylated. Inhibitors of HER2/neu 
mediated signalling using monoclonal antibody (Trastuzumab) and small molecule tyrosine kinase inhibitor (Lapatinib) are also indicated. 
Key HER2/neu signalling pathways involved in tumorigenesis are also schematically illustrated (B). HER2/neu dimerizes with the activated 
HER receptor resulting in the phosphorylation of the tyrosine residues and signal transduction in the intracellular domain. This activates the 
lipid kinase phosphatidyl inositol 3 kinase (PI3K), which phosphorylates a phosphatidylinositol that in turn binds and phosphorylates the 
enzyme Ak transforming factor (Akt). Among the Akt multiple targets is the mammalian target of rapamycin (mTOR), which drives cell 
survival by promoting cell cycle progression and inhibiting pro-apoptotic members of the Bcl-2 family. On the other hand, the mammalian 
homologue of the son of sevenless (SOS), a guanine nucleotide exchange factor, activates the rat sarcoma (RAS) enzyme which, in turn, 
activates the receptor activation factor (RAF) and then mitogen extracellular signal kinase (MEK). MEK then phosphorylates the mitogen-
activated protein kinase (MAPK), which results in cell cycle progression and proliferation (Adapted from Colombo et al., 2010; Roskoski Jr, 





2.5.4 The role of HER2/neu in breast cancer 
 
One of the most common malignant transformations of mammary cells leads to amplification 
and/or over-expression of the HER2/neu oncogene, accounting for ~30% of all invasive BC 
cases (Menard et al., 2000; Press et al., 2002; Rubin and Yarden, 2001; Slamon et al., 1989).  
HER2/neu mutations are rare in BCs. In a novel study, Bose et al. (2013) concluded that 
approximately 1.6% of BC patients possess an HER2/neu gene mutation. These mutations were 
reported to occur in the extracellular domain, carboxyterminal tail as well as in the protein kinase 
domain. Gene amplification and transcriptional up-regulation have major roles in HER2/neu 
over-expression. In HER2/neu-amplified breast carcinomas, HER2/neu expression levels are 
significantly higher, varying from five hundred thousand to more than two million receptors per 
tumour cell, compared to twenty-five to one-hundred and eighty-five thousand receptors per 
tumour cell in non-amplified tumours (Tsé et al., 2012; Yarden, 2001). Over-expression of 
HER2/neu receptors is an adverse prognostic marker associated with poor disease-free survival. 
At the time of diagnosis, patients with HER2/neu-enriched subtype are likely to have a higher 
incidence of advanced disease, coupled with reduced overall survival rate and time of relapse 
(Kennecke et al., 2010; Voduc et al., 2010). It has been found to correlate with tumours which 
are larger in size, of high nuclear grade, and with a decrease in the expression of steroid hormone 
receptors (Konecny et al., 2003; Nielsen et al., 2009). They are characterized as a more 
aggressive tumour phenotype associated with increased cell proliferation, a greater likelihood of 
lymph node involvement, increased tumour invasiveness, and metastasis (Moasser, 2007; 
Slamon et al., 1987). In addition, HER2/neu enhances angiogenesis by increasing vascular 
endoethelial growth factor production, and reduces apoptosis by increasing the expression of 
survivin (Siddiqa et al., 2008; Zhou et al., 2000). 
Although HER2/neu BCs usually display several genomic aberrations, cell proliferation 
and survival depend critically on HER2/neu activation and signalling. Thus far, two different 
mechanisms have been described. In the first and more common type, HER2/neu permanently 
forms self-dimerization or partners with one of the other HER family of receptors to form homo- 
and/or hetero-dimers, whereupon an increase in cell signal transduction cascades is triggered 
(Graus-Porta et al., 1997; Pinkas-Kramarski et al., 1996; Warren and Landgraf, 2006; Yarden, 
2001). In the second, HER2/neu signalling transduction can be induced via formation of 
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truncated HER2/neu carboxy-terminal fragments, which constitutively maintain kinase activity 
(Anido et al., 2006; Pedersen et al., 2009). HER2/neu hetero-dimers are capable of evading 
inactivation processes as they contain strong bonds which decrease the rate of ligand 
dissociation. Moreover, they are able to bypass the degradative pathway by returning to their 
primary site on the cell surface (Harari and Yarden, 2000). 
 
2.5.5 HER2/neu as a target for breast cancer therapy 
 
In recent years, targeted molecular therapeutics for BC has been changing considerably. 
Research efforts have focused mainly on the identification of the precise molecular abnormalities 
responsible for tumourigenesis (Workman, 2005). In the late 1980s, Slamon et al. (1987) were 
the first to associate HER2/neu amplification with negative clinical outcomes. In addition, they 
described HER2/neu protein over-expression as a likely predictive target for treatment. The 
discovery of HER2/neu and its role in malignant progression constituted a major breakthrough, 
and led to the development of a number of targets for anticancer drugs. 
There are several reasons for the exploitation of the HER2/neu receptor as a therapeutic 
target for BC. Firstly, the identification and molecular characterization of HER2/neu, indicated 
that all three domains are involved in a specific aspect of the signalling cascade responsible for 
abnormal growth and malignant transformation. Therefore, each domain can be targeted 
separately to inhibit the HER2/neu signalling pathway. Secondly, HER2/neu is over-expressed in 
cancer cells and is present in high numbers in both pre-malignant tumours and metastasized 
organs (Moasser, 2007). Finally, as mentioned in the previous section, HER2/neu-containing 
hetero-dimers have the greatest mitogenic potential among all HER2/neu dimers. Thus, blocking 
the extracellular domain inhibits HER2/neu dimerization and prevents the activation of 
intracellular signalling pathways involved in the onset and progression of BC. Currently, several 
novel HER2/neu targeted therapies are used in clinical trials to test their efficacy in BC 
therapeutics. Recent reviews on HER2/neu targeted therapies include those published by 
Figueroa-Magalhães et al., 2014; Gullo et al., 2013; Hurvitz et al., 2013; Nandy et al., 2014; 





2.6 Current Treatment Options for HER2/neu 
 
To date, several anti-HER2/neu targeted therapies have been developed and approved in the 
United States and elsewhere based on their role in increasing survival outcomes in patients. Most 
notably, Trastuzumab and Lapatinib are the main targeted therapies exclusively associated with 
HER2/neu gene amplification and/or over-expression of the protein, which have demonstrable 
benefits in the clinical setting. Traditionally, these treatments are first administered and analyzed 
in the metastatic disease state, and then in neoadjuvant trials (Campone et al., 2011; Figueroa-
Magalhães et al., 2014; Shah and Osipo, 2016). 
 
2.6.1 Antibody targeting the extracellular domain 
 
The extracellular domain of HER2/neu has been the target of several monoclonal antibodies used 
to suppress its dimerization with other HER family members. The binding of antibody blocks the 
activation of all HER2/neu dimers, thereby preventing phosphorylation of the tyrosine kinase 
domain as well as retarding or inactivating its downstream signalling pathway (Tai et al., 2010a). 
In 1998, the recombinant humanized monoclonal antibody Trastuzumab (Herceptin
®
) 
(Genentech Inc. San Francisco, CA, USA; Hoffmann-La Roche Ltd. Basel, Switzerland) was 
approved by the USA Food and Drug Administration (FDA) for the treatment of HER2/neu 
positive BC (Schaefer et al., 2006; Shawver et al., 2002; Tokunaga et al., 2006; Yeon and 
Pegram, 2005). Trastuzumab is currently recommended as first-line treatment for patients with 
HER2/neu over-expressing metastatic tumours, either as a single agent or in combination with 
endocrine therapy and/or chemotherapy. It has also been used as a treatment option in early stage 
BC, as well as in the adjuvant setting (Awada et al., 2012). It is recommended that 3+ over-
expression or gene amplification by immunohistochemical and fluorescent in situ hybridization, 
respectively, is essential for likely benefits from treatment (Nielsen et al., 2009). 
Basically, Trastuzumab acts by binding to domain IV on the juxtamembrane region of the 
extracellular domain [Figure 2.3A] of HER2/neu protein (Azim and Azim Jr, 2008). Although 
the precise mechanism of Trastuzumab’s anti-tumour action has not been fully elucidated, 
several proposed mechanisms exist based upon preclinical and clinical trials (Colombo et al., 
2010). These include: the down-regulation of the HER2/neu receptor resulting in the reduction of 
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available receptors; blockage of HER2/neu extracellular proteolysis, thus preventing the 
formation of truncated highly active receptors; anti-angiogenesis leading to reduced micro vessel 
development in vivo, coupled with decreased cellular migration in vitro; induction of apoptosis 
mediated through the activation of antibody-dependent cellular cytotoxicity; and induction of 
cell cycle arrest during the G1 phase, followed by reduction of proliferation (Dean-Colomb and 
Esteva, 2008; Klos et al., 2003; Molina et al., 2001; Spector and Blackwell, 2009). 
There are, however, a number of concerns associated with its use in the clinical setting. 
For one, cardiac toxicity has raised a major safety concern, and remains the hallmark side effect. 
This is primarily due to the pivotal role of HER2/neu in embryonic cardiac development (Negro 
et al., 2004; Perez, 2008), thus precluding its use in patients with poor cardiac function. Again, 
not all patients respond positively to Trastuzumab (Tai et al., 2010a), with a significant number 
of patients acquiring intrinsic resistance within a year of treatment. Resistance to Tratuzumab has 
been shown to develop via several mechanisms, including; (1) impaired receptor-antibody 
binding, (2) truncated HER2/neu protein, (3) gene mutations, (4) signalling via alternative 
pathways, (5) co-expression of insulin growth factor receptor, (6) loss of phosphatase and tensin 
homolog (PTEN), and (7) cancer-associated fibroblasts (Browne et al., 2011; Mao et al., 2015; 
Nahta et al., 2005; 2006; Pohlmann et al., 2009; Saini et al., 2011). Furthermore, BC recurrence 
has been observed in early BC, and disease progression has been reported with most metastatic 
disease cases within a year of administering treatment. Large trials, too, have documented an 
increase in central nervous system metastasis (primary site of tumour recurrence) (Collins et al., 
2009; Montemurro et al., 2006). Finally, the high cost of Trastuzumab limits its use, and all these 
constraints have prompted research aimed at developing more efficient and better tolerated 
HER2/neu targeted therapies. 
 
2.6.2 Tyrosine kinase inhibitors to HER2/neu receptor 
 
Tyrosine kinase inhibitors are small molecules which constitute another group of agents designed 





) (GlaskoSmithKline, Middlesex, UK), was approved by the 
FDA and the European Medicines Agency as an effective drug for the treatment of  HER2/neu 
and HER1 overexpressing breast carcinomas (Geyer et al., 2006; Spector et al., 2005). Lapatinib 
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is a reversible dual HER2/neu and HER1 tyrosine kinase inhibitor that has a unique mechanism 
of action compared to other tyrosine kinase inhibitors. Small molecule inhibitors are designed to 
compete with adenosine triphosphate (ATP) for the intracellular ATP-binding pocket of the 
tyrosine kinase domain. The nature of the contact between Lapatinib and the domain results in a 
very slow dissociation, enabling prolonged inhibition of tyrosine kinase phosphorylation. 
Lapatinib selectively interrupts signal transduction, which leads to inhibition of downstream 
pathways that control proliferation and survival of tumour cells (Tevaarwerk and Kolesar, 2009). 
In addition, Lapatinib inhibits the downstream signalling proteins such as cyclin D, extracellular 
signal-related kinase (Erk) and Akt (Collins et al., 2009; Xia et al., 2002). 
Unlike Trastuzumab, Lapatinib is able, as a small molecule, to cross the blood brain barrier 
and could therefore be effective in dealing with brain metastasis. Moreover, cardiac toxicity risks 
associated with Trastuzumab are considerably lower with Lapatinib (Collins et al., 2009; Saini et 
al., 2011). Lapatinib clearly demonstrates significant clinical activity. However, both in the 
adjuvant and neoadjuvant setting, Lapatinib has been associated with a high incidence of 
diarrhoea, hepatic toxicity, skin rash, anorexia, fatigue, nausea, headache, and vomiting (Collins 
et al., 2009; Moy and Gross, 2006; 2007; Metzger Filho et al., 2012; Vu et al., 2014). 
 
2.7  Overview of Gene Therapy 
 
Gene therapy is a unique therapeutic technique which has been developed as an alternative to 
conventional medicine to favourably modify or cure both contracted and inherited genetic 
defects (Fischer and Cavazzana-Calvo, 2008). Significant advances in basic gene therapy 
research are occurring in countries all around the world.  To date, gene therapy has been used to 
address a wide variety of diseases at their root cause, ranging from cancer (Faneca et al., 2008; 
Li and Huang, 2006; Nakase et al., 2005; Xing et al., 1998) to neurological disorders (Kaplitt et 
al., 2007; Zhang et al., 2003). Numerous clinical trials are ongoing worldwide (Edelstein et al., 
2004; 2007), with the majority focussing on cancer, the latter comprising approximately 64% of 
all on-going clinical gene therapy trials, followed by monogenic and cardiovascular diseases 






Figure 2.4: A graphic representation of the widespread application of gene therapy in clinical trials 
(Wirth et al., 2013). 
 
Current legislature permits gene therapy only in somatic cells. This means that the genetic 
material is inserted into some target cells of an individual, and genetic changes occur only in the 
targeted cells, and cannot be passed on to the next generation. Prior to developing gene therapy 
for any specific condition, the following challenges need to be addressed: genetic malfunctions 
must be precisely characterized and the causal gene identified; the specific cells in the host 
requiring treatment must be identified and accessible; and a functional copy of the gene involved 
must be available. Furthermore, a gene delivery vehicle must be available to efficiently carry the 
functional copy of the gene into target cells where it can be stably expressed for an extended 
period. 
The spectrum of gene therapy applications includes the use of nucleic acids (DNAs or 
RNAs) with regulatory function. Presently, these molecules belong to one of at least six possible 
classes, namely, DNA oligonucleotides, small regulatory RNAs, long anti-sense RNAs, other 
molecular binding RNAs, small catalytic RNAs and DNAs and decoy RNAs and DNAs (Giacca, 
2010). Unlike traditional pharmaceutical drugs, gene therapy has the potential to treat almost any 
disease. Due to their diverse biological activities and unique mechanisms of action, gene-based 
therapeutics has resulted in several approaches for modifying defective genes (Wang et al., 
2015). These include: 1) replacing an abnormal gene with a normal gene through homologous 
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location within the genome; 3) repairing an abnormal gene through selective reverse mutation; 
and 4) altering the expression of a particular gene (gene knockdown) (Grimm and Kay, 2007). 
Plasmid DNA (pDNA) and small interfering RNA (siRNA) are the two major classes of genetic 
materials which have been applied to mediate their effects at the transcriptional and/or 
translational level (Bumcrot et al., 2006; Gary et al., 2007; Park et al., 2006). DNA-based gene 
therapy is founded on the episomal or integrated presence and expression of corrective DNA in 
the host cell. This entails the delivery of exogenous pDNA encoding a particular gene and the 
subsequent stable or transient expression of the resulting transgene. The expression of 
therapeutic proteins thus ameliorates a specific pathological condition (Anderson, 1998; Verma 
and Somia, 1997). More recently, the field of new therapies based on RNAi has become the 
focus of the pharmaceutical industry as an attractive approach for investigating physiological 
gene function validation and for the potential treatment of human disease (de Fougerolles et al., 
2007; Pecot et al., 2011; Wittrup and Lieberman, 2015). RNAi is a biological process which 
makes use of siRNA to induce sequence-specific post transcriptional gene silencing via the 
cleavage of homologous mRNA. This leads to the targeted inhibition of gene expression both in 
vivo and in vitro (de Fougerolles et al., 2007; Kim and Rossi, 2007; Kurreck, 2009; Leung and 
Whittaker, 2005; Takahashi et al., 2009). 
 
2.8 History, Uniqueness and Mechanism of siRNA Gene Silencing 
 
2.8.1  Advances in RNA interference 
 
RNA interference represents an exclusive form of post-transcriptional gene silencing.  It is an 
evolutionarily conserved cellular mechanism which is exploited for RNA-guided regulation of 
gene expression in mammalian cells and model organisms. This phenomenon was first 
discovered in Petunia flowers in the late 1980s by Napoli and co-workers (1990). Its molecular 
mechanism, however, remained unclear for almost a decade until Fire et al. (1998), using the 
nematode Caenorhabditis elegans, concluded that RNAi is a natural gene knockdown 
mechanism. This discovery was lauded by the Science magazine as “Breakthrough of the year” 
in 2002. Four years later Andrew Fire and Craig Mello were awarded the Nobel Prize for 
Medicine or Physiology for their pioneering work (Fire et al., 1998; Reinhart et al., 2000). In 
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2001, Elbashir et al., using synthetic siRNA, demonstrated the occurrence of RNAi in 
mammalian cell lines. These significant breakthroughs have highlighted the enormous potential 
of this technology to create selective gene silencing and to develop a new transgenic research 
field. Spurred by this development, the scientific community has engaged in intensive research 
efforts focused on siRNA therapeutics and its applications. Numerous scientific and 
technological breakthroughs in related fields have steered a rapid transition of potential 
therapeutic siRNAs from in vitro studies to clinical trials, resulting in remarkable progress in just 
over a decade (Davis, 2009; de Fougerolles, 2008). 
 
2.8.2 Mechanism of siRNA gene silencing 
 
Small interfering RNAs belong to a class of macromolecules (oligonucleotides) which are 21-23 
nucleotide RNA duplexes derived from the digestion of larger double stranded RNA (dsRNA) 
trigger duplexes (> 30-50 bp) by an RNase III-like endonuclease known as Dicer-2 (Tuschl et 
al., 1999; Zhang et al., 2004). Alternatively, chemically or enzymatically synthesized siRNAs 
may be used as precursors to trigger the pathway (Amarzguioui et al., 2005; Elbashir et al., 
2001). In each case, these siRNAs are characterized as ‘small’ dsRNA molecules with 2-
nucleotides unpaired in the 5’-phosphorylated ends and with 3’-unphosphorylated ends (Elbashir 
et al., 2001; Hannon, 2002). Figure 2.5 depicts the siRNA-mediated gene silencing pathway. In 
mammalian cells, within the cytoplasm, siRNA duplexes are incorporated into RNA induced 
silencing complex (RISC). Contained within the core of RISC is the multifunctional protein-
RNA endonuclease, Argonaute-2 (Ago-2), which is involved in RISC activation (Liu et al., 
2004a). Ago-2 is composed primarily of three domains, namely, the PAZ, MID and PIWI 
domains. The PAZ and MID domains are involved in the anchoring and docking of RNA, 
whereas PIWI functions in the mRNA silencing activity (Kim et al., 2009). ATP-dependent 
helicase unwinds the duplex, followed by Ago-2 mediated cleavage of the passenger (sense) 
strand (Matranga et al., 2005; Rand et al., 2005). The guide (anti-sense) strand remains bound to 
RISC via the divalent ion Mg
2+
 (Ma et al., 2005a), and guides it to anneal to complementary 
target mRNA molecules in the mid region between nucleotide bases ten and eleven relative to 
the 5’-phosphorylated end of the anti-sense siRNA strand (Elbashir et al., 2001; Matranga et al., 
2005). Following this, the PIWI domain cleaves the target phosphodiester bond of the mRNA, 
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thereby rendering mRNA dysfunctional (Elbashir et al., 2001). mRNA silencing may be 
achieved via two mechanisms depending on the degree of complementarity between the anti-
sense strand and the cognate mRNA: 1) site-specific cleavage of the message in the region of the 
siRNA-mRNA duplex leading to sequence-specific degradation, or 2) through translational 
repression (Caudy et al., 2003; Doench et al., 2003). The guide strand is recycled, thus 
permitting cleavage of numerous mRNA copies. The degree to which this process occurs 
depends mostly on the dissociation rate of the cleaved mRNA from the RISC assembly (Haley 
and Zamore, 2004). RISC recycling is a feature which distinguishes siRNA from other nucleic 
acid therapeutics such as anti-sense oligonucleotides, as it may demonstrate a silencing effect for 
up to seven days in dividing cells and for several weeks in non-dividing cells. Additionally, 
repeated administration of siRNA can result in stable long term target gene knockdown (Bartlett 
and Davis, 2006). The intrinsic capacity of siRNAs to selectively silence mRNA in a temporal 
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Figure 2.5: A schematic representation of the siRNA-mediated gene silencing pathway. 1) 
Introduction of exogenous long dsRNA is recognized by Dicer-2 in the cytoplasm; 2) Long dsRNA is 
cleaved by Dicer-2 into siRNA duplexes of 21-23 nucleotides in length followed by interaction with 
R2D2; 3) Synthetic siRNAs bypass the requirement for Dicer-2 processing and are recognized by both 
Dicer-2 and R2D2; 4) Dicer-2 and R2D2 facilitate the transport of siRNA to Ago-2, followed by 
formation of RISC; 5) Ago-2 protein promotes the unwinding of the duplexed siRNA, and the sense 
(passenger) strand is rapidly cleaved and dissociated; 6) The anti-sense (guide) strand remains bound 
to the RISC complex and mediates recognition of the target RNA; 7) Anti-sense RNA strand guides 
RISC and binds to the complementary site in the target mRNA; 8) RISC engages the endonucleolytic 
activity of Ago-2, resulting in target mRNA cleavage which shuts off translation of the corresponding 
protein (Adapted from Yang et al., 2013a). 
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2.9 Therapeutic Potential of siRNA Gene Silencing  
 
2.9.1 Identifying targets for siRNA-induced gene silencing 
 
The mapping of the human genome in the new millennium paved the way for scientists Perou et 
al. (2000) to classify human BC tumours based on their molecular portraits and unique gene 
expression profiles. They described four distinct BC subtypes: HER2/neu-positive, luminal, 
basal, and normal breast-like. A critical event in the progression of each of these BC subtypes is 
the initiation of specific gene expression patterns as a consequence of gene aberrations or 
upstream activation. The ability to selectively silence the expression of an activated oncogene at 
the mRNA level inhibits the production of abnormal proteins. This novel therapeutic strategy 
may be exploited in BC to modulate the expression of any protein, even undruggable target 
proteins (e.g., transcription factors) which are involved in tumour initiation, growth, and 
metastasis formation, thus providing an attractive, useful and promising technique for targeted 
therapeutics in gene therapy (Scherr et al., 2005). The identification of molecular targets is a 
prime research area in the pursuit of ‘personalized’ therapies for metastatic types of BC. The 
heterogeneous nature of BC and its attendant diversity in gene expression patterns present a 
range of specific targets for siRNA therapeutics. Furthermore, different signalling pathways have 
been determined and incorporated within the BC network. These will help identify key molecular 
relays which may be exploited to discover surrogate biomarkers for prognosis and siRNA 
therapy assessment. In the main, siRNA mediated BC therapies include: inhibition of tumour 
survival and induction of apoptosis (Huang et al., 2008) via HER2/neu gene silencing (Tan et al., 
2007); Bcl-2 gene silencing (Beh et al., 2009); p53 gene silencing (Martinez et al., 2002) or 
inhibiting Wnt pathway (Wieczorek et al., 2008); angiogenesis (Xie et al., 2004); and 
chemoresistance (Creixell and Peppas, 2012). 
 
2.9.1.1 Inhibition of angiogenesis 
 
The development of new blood vessels from the existing vascular network (angiogenesis) 
significantly regulates tumour growth, invasion and metastasis of BC (Boudreau and Myers, 
2003; Hobday and Perez, 2005; Sobel et al., 1992). Irrespective of cellular origin, initiation of 
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tumour angiogenesis at the molecular level is mediated by either a switch between up-regulation 
of inducers/activators or suppression of inhibitors of angiogenesis. Some key angiogenic 
activators include the vascular endothelial growth factor (VEGF), fibroblast growth factor 
(FGF), and transcription factor for hypoxia inducible factor-1 (HIF-1), whereas inhibitors 
include thrombospondin-1, angiostatin, interferon α/β and endostatin (Hanahan and Weinberg, 
2000; Klagsbrun and Moses, 1999; Şalva et al., 2015). Research suggests that the VEGF 
(glycoprotein) family in particular is a vital angiogenesis oncogene target, and high levels of 
VEGF produced by tumour cells are attested as key contributors to tumour angiogenesis and 
growth (Davidoff and Nathwani, 2004; Dvorak et al., 1999; Sledge et al., 2006; Zelnak and 
O’Regan, 2007). In breast carcinoma cells, high VEGF levels are thought to act in an autocrine 
manner for cell survival (Bachelder et al., 2001), to induce disruption of endothelial cell 
basement membrane, contributing to metastasis (Weis and Cheresh, 2005), and decreasing 
response to conventional hormonal- and chemo-therapies (Toi et al., 1995). In addition, tumour 
cells overexpressing VEGF have been associated with poor prognosis and decreased survival 
rates (Linderholm et al., 1998; 2000). Intratumoural delivery of siRNA targeting VEGF was 
reported to inhibit breast tumour growth in an MDA-435 xenograft model (Xie et al., 2004). 
Some transcription factors such as ER-α (Stoner et al., 2004), HIF-1 (Forsythe et al., 1996) and 
polyomavirus enhancer activator 3 (PEA3) (Hua et al., 2009) can influence the activation VEGF 
transcription. In a study conducted by Hua et al. (2009), chromatin immunoprecipitation and 
luciferase assays were used to demonstrate the binding of PEA3 to the VEGF promoter, and 
PEA3 activation of VEGF promoter activity in cells overexpressing PEA3, respectively. PEA3 
siRNA was reported to reduce VEGF promoter activity as well as attenuate the binding of PEA3 
to the VEGF promoter in SKBR-3 cells. These researches suggest that PEA3 siRNA provides a 





The apoptotic system comprises an organization of sensors that detect pro-apoptotic stimuli, a 
signal transduction network, and execution machinery. This complex system is effected by the 
activation of a well-defined family of caspase proteases that influence cells through proteolytic 
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activity (Kerr et al., 1972). Activation of caspases mainly occurs through one of two pathways, 
namely, the intrinsic pathway which includes cell stress such as DNA damage or growth factor 
withdrawal, or the extrinsic pathway which is triggered by death ligands such as TNF-related 
apoptosis-inducing ligand (TRAIL). In normal cells, programmed cell death is closely controlled 
by a balance between pro-apoptotic and anti-apoptotic factors. At each level of pro-apoptotic 
stimulation, specific proteins are able to negatively regulate caspases and block apoptosis (Liu et 
al., 2004b). These include several members of the Bcl-2 family, nuclear factor-kB family of 
transcription factors, and inhibitor of apoptosis proteins (IAP) (Fulda, 2007; Hunter et al., 2007; 
Yang et al., 2003). These proteins and their regulators act in combination during “programmed” 
cell death. On the other hand, dysregulation due to aberrations in many genes that regulates the 
apoptotic system results in a blockage of cell death which ultimately leads to disease 
progression, and to chemio- and radio-resistance. Abnormalities have been identified in many 
genes that regulate the apoptotic cascade; these include Bcl-2 (Piché et al., 1998), bax (Su et al., 
1998), and p53 (Elledge and Allred, 1994). Bcl-2 and Bcl-XL from the Bcl-2 anti-apoptotic 
family, for example, are overexpressed in cancer cells and have a strong anti-apoptotic effect. 
Basically, they counteract the activity of Bid, Bax and Bak (pro-apoptotic molecules), thereby 
supressing pro-apoptotic signalling in the mitochondria. The expression levels of Bcl-2 generally 
correlate with chemotherapy resistance (Buchholz et al., 2005; Ferlini et al., 2003; Tophkhane et 
al., 2007). siRNA-mediated down-regulation of Bcl-2 in MCF-7 cells results in an increase in 
apoptosis by 9% (at 72 h) and 11% (at 96 h) in comparison with the positive control (Lima et al., 
2004). Foster et al. (2009) reported that siRNA-based depletion of a member of the IAP family 
XIAP increased apoptosis in response to Trastuzumab, Lapatinib or Gefitinib in Her2/neu-
overexpressing BT-474 cells. Moreover, depleting the cells of XIAP overcomes the intrinsic 
resistance of BT-20 and MDA-MB-468 cells to TRAIL. Another frequent genetic abnormality is 
the elevated expression of c-Myc which is also involved in the apoptotic casade (Doisneau-Sixou 
et al., 2003; Liao and Dickson, 2000). Wang et al. (2005) found that 31.1% of MCF-7 cells 
transfected with pSilencer-c-Myc (short hairpin RNAs ligated into pSilencer) underwent 
apoptosis after serum starvation. Furthermore, they showed that on the 5
th
 day of transfection the 
plasmids endogenously expressing siRNA could successfully deplete up to 80% of c-Myc 
expression in MCF-7 cells. Tumour inhibition effects persisted for at least 12 days after 
transfection in vitro and for 2 months in nude mice respectively. 
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2.9.1.3 Cell cycle regulation 
 
Silencing of certain genes associated with the development of tumours, poor prognosis, as well 
as resistance to anticancer agents can halt cell division and regulate the cell to enhance apoptosis. 
An example is the Akt pathway which is constitutively activated in BC cells (Nicholson and 
Anderson, 2002). In a report by Santi and Lee (2011), siRNA down-regulation of the Akt2 
isoform in MDA-MB-231 BC cells showed a pronounced decrease in cell proliferation. The 
authors further reported that this was due, in part, to the unique role of Akt2 in the promotion of 
cell cycle progression, as the silencing of Akt2 decreases the levels of Cdk2 and cyclin D 
(responds to oncogenes and various growth factors). Since complexes are formed between Cdk2 
and cyclin A or E, and between cyclin D with Cdk4 or Cdk6 (Rivard et al., 1996), the down-
regulation of only two proteins (Cdk2 and cyclin D) in Akt2-siRNA transfected cells ensured the 
effective cell cycle arrest in the G0/G1 phase. Futher, upregulation of the E2F3 transcription 
factor also plays a role in controlling cell cycle progression (Vimala et al., 2012). More 
specifically, siRNA targeting cyclin E overexpression in SKBR-3, MDA-MB-157 and MDA-
MB-436 cell lines promoted apoptosis, blocking their proliferation and transformation 
phenotypes. In addition, cyclin E siRNA synergistically enhanced the cell killing effects of 
doxorubicin in cell culture, and this combination significantly suppressed tumour growth in mice 
(Liang et al., 2010). In a comprehensive study utilizing E2F3 overexpressed BC cell lines, E2F3-
siRNA markedly blocked the expression of the E2F3 proteins in the MCF-7 cell line, thus 
controlling rapid tumour cell proliferation (Vimala et al., 2012). In another study, siRNA 
mediated silencing of the anterior-gradient 2 (an estrogen-responsive secreted protein) in an ER-
α positive BC cell line resulted in down-regulation of ER and cyclin D1 (Vanderlaag et al., 
2010). These findings presage the likelihood of positive outcomes of the therapeutic application 




Overexpression of growth factor receptors results in an increase of hetero-dimers, which in turn 
leads to an overall increase in intracellular signalling and activation of genes involved in cell 
proliferation (Fernández Val et al., 2002; Ross and Fletcher, 1999). This is naturally concomitant 
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with unabated aggressive tumour growth and death. As mentioned before, HER2/neu is 
associated with more aggressive tumour phenotypes, a greater likelihood of lymph node 
involvement, and increased resistance to cancer endocrine/chemotherapy (Bartsch et al., 2007; 
Engel and Kaklamani, 2007; Menard et al., 2000; Moasser, 2007; Slamon et al., 1987). 
In response, scientists have therefore focussed on HER2/neu as a logical target for siRNA 
based BC therapies (Tan et al., 2007; Urban-Klein et al., 2005). Complications which arise are 
attributed to the primary resistance of HER2/neu gene-amplified breast carcinomas to HER-
targeted therapies. This has been explained in the context of overactive HER2/neu-independent 
downstream pro-survival pathways by Oliveras-Ferraros et al. (2011). These authors addressed a 
specific role of the IAP survivin on the molecular efficacy of HER2/neu targeting drugs, and 
discovered that the up-regulation of survivin contributed to the enhanced survival of JIMT-1 
cells, intrinsically displaying cross-resistance to HER1/2-targeted molecular therapies. 
Moreover, siRNA down-regulation of survivin (up to 80% survivin reduction 72 h after siRNA 
transfection) was sufficient to competently inhibit cell growth and survival as well as allow a 
combined anti-proliferative effect with HER antagonists. Wong et al. (2010) investigated the 
effects of siRNA knockdown of the PP2A catalytic subunit in two HER2/neu-positive BC cell 
lines, BT-474 and SKBR-3. PP2A-siRNA down-regulation demonstrably caused the silenced 
HER2/neu BC cells to undergo apoptosis, which was mediated by p38 MAPK-caspase 3/PARP 
activation. In a clinical study reported by Konecny et al. (2004), 87.7% of HER2/neu positive 
BCs were associated with overexpressed VEGF. Tai et al. (2010b) examined the effect of dual 
silencing of HER2/neu and VEGF genes on tumour growth and invasiveness. Their 
comprehensive study included nine HER2/neu and ten VEGF siRNAs which were capable of 
silencing the target genes by up to 75-83.5%. Furthermore, dual silencing of HER2/neu and 
VEGF resulted in significant change in cell morphology, substantial suppression of migration, 
cell adhesion, and proliferation. These observations suggested that HER2/neu-positive breast 
carcinomas may be more effectively treated by dual silencing of HER2/neu and VEGF gene 







2.9.1.5 Sensitizing drug resistant proteins to conventional therapies 
 
Chemotherapy entails the use of cytotoxic drugs commonly implemented in the treatment of 
many cancer types, including BC (Tack et al., 2004). A significant variety of cells, however, 
demonstrate suboptimal therapeutic responses associated with MDR. In essence, cancerous cells 
present altered strategies to prevent apoptosis induced by chemotherapy. Two main mechanisms 
exist, which enable cells to become multidrug resistant; firstly by increasing drug efflux pumps 
present on the cell membrane, and secondly by upregulating anti-apoptotic pathways 
(Gottesman, 2002). Using siRNA to down-regulate the activity of overexpressed genes encoding 
efflux pump proteins has become a feasible approach to sensitize cells to chemotherapeutic 
agents. The P-glycoprotein (P-gp), a 170 kDa membrane-associated drug efflux transporter, is 
often overexpressed, thereby impeding the permeability of several cytotoxic drugs such as 
doxorubicin, paclitaxel, and anthracycline, amongst others. Patil et al. (2010) encapsulated 
paclitaxel into a biodegradable polymer poly(D,L-lactide-coglycolide) mixed with 
polyethyleneimine (PEI) to form micelles. siP-gp was complexed to the nanoparticle via 
electrostatic interactions and the nanoplex was transfected into drug resistant JC cells. P-gp gene 
knockdown increased intracellular paclitaxel accumulation in vitro and enhanced in vivo 
cytotoxicity of paclitaxel, ultimately resulting in a reduction of tumour growth. Li et al. (2010) 
analyzed gene expression profiles of 115 breast carcinomas from women and conducted a 
neoadjuvant chemotherapy trial. Overexpression of YWHAZ (an anti-apoptotic gene) and 
LAPTM4B (a lysosomal gene) was associated with poor tumour response to anthracycline 
administration. They demonstrated the synergistic effect of co-delivering target specific siRNA 
and anthracycline using a lipid-mediated siRNA vector, and reported that the down-regulation of 
these genes enhanced the drug concentrations within the nucleus. Similarly, cationic 
biodegradable polymeric nanoparticles were reported to encapsulate siRNA targeting Plk1, 
MDR-1, and Bcl-2 into MDA-MB-435 and MDA-MB-231 breast carcinoma cell lines, thereby 
sensitizing the cells to paclitaxel and doxorubicin respectively (Sun et al., 2011; Wang et al., 






2.10 Challenging Pharmacokinetic Characteristics of Synthetic siRNA 
 
By definition, pharmacokinetic characteristics refer to the process by which a drug is 
internalized, distributed, metabolized and eliminated by the body. Synthetic siRNAs have been 
intensively investigated in basic and pre-clinical science as a versatile gene expression silencer. 
However, most published research on pre-clinical animal models concern siRNA’s low 
biological stability, i.e., rapid degradation by nucleases (~15 min half-life in serum) (Aagaard 
and Rossi, 2007; Bumcrot et al., 2006; Kuhn et al., 2007; Ozpolat et al., 2014), and non-specific 
organ accumulation and rapid elimination through glomerular filtration (Aigner, 2006; Akhtar 
and Benter, 2007; Braasch et al., 2004; de Fougerolles et al., 2007; Kawakami and Hashida, 
2007; van de Water et al., 2006; Xie et al., 2006). Overall, these investigations suggest that 
siRNAs, with their relatively large molecular weight (~13 kDa), behave as typical 
macromolecules of less than 50 kDa and 7 nm, thereby limiting their use in naked form. At the 
level of target cells, in vitro applications of siRNA demonstrated a short serum half-life and 
limited binding to and passive diffusion across lipophilic cell membranes because of their 
anionic surface charge (~40 negative phosphate charges) and hydrophilic nature (Moreira et al., 
2008; Paroo and Corey, 2004). Additionally, within the cytoplasm, siRNA has to escape from the 
endocytic pathway and avoid lysosomal destruction prior to being incorporated into the RNAi 
machinery (Dams et al., 2000; Knop et al., 2010). 
Moreover, major concerns were raised regarding the adverse effects of siRNA therapeutics, 
which include off-target silencing (Svoboda, 2007), saturation of the RNAi machinery (Grimm et 
al., 2006) and unwanted immune activation (Judge and Maclachlan, 2008). The intertwining of 
cellular anti-viral systems with the siRNA system leads to greater complexity and 
unpredictability in the action of siRNA. Synthetic siRNAs may thus induce type I interferon 
responses and stimulate the production of pro-inflammatory cytokines. The development of an 
appropriate and efficient delivery system for synthetic siRNA to target sites in the body is 
consequently the main hurdle preventing successful clinical applications. Delivery systems 
should be designed to address the vagaries of the pharmacokinetic and biodistribution properties 
of siRNA. The resolution of these issues, clearly, would pave the way for the envisioned role of 




2.11 Nanocarriers for siRNA Gene Delivery 
 
Delivery vectors employed in gene therapy applications are broadly classified as viral or non-
viral. Viral vectors are generally able to transfect target cells efficiently following systemic 
administration. Their development for application in humans, however, is still limited by 
inherent immune responses to the vector envelope and potential toxicity. Therefore, research 
efforts increasingly focus on non-viral vectors which, although currently less efficient, have a 
superior safety profile (Al-Dosari and Gao, 2009). Non-viral vectors are relatively easy to 
produce in large scale and provide a cost effective alternative to deliver large amounts of siRNA 
to target cells. Nanocarrier engineering is employed to enhance the stability, specificity and 
efficiency of non-viral nucleic acid delivery systems. An important advantage of this approach is 
that it makes use of naturally occurring or synthetic materials that may eliminate immune 
responses and exhibit low toxicity. Additionally, the unique morphological and phenotypic 
features of BC cells or tissues may be exploited to achieve tumour targeted delivery. Moreover, 
non-viral vectors may be designed to protect siRNA cargoes from nuclease digestion, avoid 
endosomal compartmentalization, and promote localization in the cytoplasm where the siRNA 
can be recognized by the RISC. In summary, nanocarrier engineering of non-viral vectors offers 
superior pharmacodynamic and pharmacokinetic characteristics (Table 2.1). However, ensuring 
the successful expression of these design features in non-viral delivery systems is both 
challenging and arduous. For the purposes of this study, the literature review focuses on lipid and 









Table 2.1: Examples of non-viral nanocarriers for siRNA gene delivery into breast cancer cell models 











Applicationsd Cell line Reference 




~0.20 a a 
siRNAs directed 
against cyclin D1 
MCF-7 (in vitro) 
Lavigne and 
Thierry (2007) 
DC-Chol/DOPE  130 - 150 +30 - +65 
Not 
informed 
PEG a anti-HER-2 siRNA SKBR-3 (in vitro) 
Zhang et al. 
(2010) 
BHEM-Chol 170 +13.8 0.216 mPEG-PLA a 
siRNA directed 
against Plk1  
MDA-MB-435s murine 
xenograft model (in vivo: i. v. 
administration) 
Yang et al. 
(2011) 









MCF-7 (in vitro) 
Bedi et al. 
(2011) 
DDAB/CHOL/TPGS/HSA 79.5 ± 5.5 +15.3 
Not 
informed 
a a phrGFP siRNA 
MCF-7, MDA-MB-231 and 
SKBR-3- phrGFP (in vitro) 
Piao et al. 
(2013) 
Stabilized nucleic acid lipid particles 
(SNALP) 












anti-eGFP siRNA MDA-MB-435s-eGFP (in vitro) 
Gomes-da-Silva 
et al. (2012) 
Anionic lipids         
DOPG/DOPE/Ca2+ 324.2 ±19.6 -22.9 ± 0.1 
Not 
informed 
a a anti-eGFP siRNA MDA-MB-231-eGFP (in vitro) 
Kapoor and 
Burgess (2012) 
Polymers         





PEG a anti-EGFR siRNA 
MCF-7 nude mice xenograft 
model (in vivo: i. v. 
administration) 
Zhao et al. 
(2012) 
mPHA-g-bPEI <200 +33 - +43 0.16 - 0.22 a a anti-luc siRNA MCF-7-luc (in vitro) 
Zhou et al. 
(2012) 







BT-474 murine xenograft 
model (in vivo:  i. v. 
administration) 
Mao et al. 
(2011) 
mP3/4HB-b-PEG-b-lPEI 158 +28 <0.33 PEG a anti-luc siRNA MCF-7-luc (in vitro) 
Zhou et al. 
(2013) 
P(MDSco-CES) <250 +70 1.57 PEG a 
siRNA directed 
against Bcl-2 
MDA-MB-231 (in vitro) 
Beh et al. 
(2009) 




0.121 a TAT ligand 
siRNA directed 
against survivin 
4T1-luc mice xenograft model 
(in vivo: i. t.  administration) 
Yang et al. 
(2013b) 







SKBR-3 (in vitro) 







a a anti-luc siRNA MDA-MB-231-luc (in vitro) 




Abbreviations: PDI: polydispersity index; siRNA: small interfering RNA; i. v.: intravenous; i. t.: intratumourally; PEG: polyethylene glycol; DOGS: dioctadecylamidoglycylspermidine; DOPE: 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine; DC-Chol: 3β-[N-(Nˊ,Nˊ-dimethylaminoethane) carbamoyl] cholesterol; BHEM-Chol: N,N-bis(2-hydroxyethyl)-N-methyl-N-(2-cholesteryloxycarbonyl 
aminoethyl) ammonium bromide; mPEG-PLA: poly(ethylene glycol)-b-poly(d,l-lactide); Plk1: polo-like kinase 1; DODAP: 1,2-dioleoyl-3-dimethylammonium-propane; DSPC: 1,2-distearoyl-sn-
glycero-3-phosphocholine; CHOL: cholesterol; CerC16-PEG2000: N-palmitoyl-sphingosine-1-[succinyl(methoxypolyethylene glycol)2000]; DSPE-PEG-MAL/F3: 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[maleimide(polyethylene glycol)2000] ammonium salt; ePC: L-α-phosphatidylcholine; DPPG: 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] sodium salt; DOTAP: 
1,2-dioleoyl-3-trimethylammonium-propane chloride salt; PEG-PE: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)2000] ammonium salt; DDAB: Dimethyl 
dioctadecyl ammonium bromide; TPGS: D-α-tocopheryl-polyethylene glycol 1000 succinate; HSA: human serum albumin; Ca2+: calcium ions; DOPG: 1,2-dioleoyl-sn-glycero-3-phospho-(1′-rac-
glycerol); mPEG2000-PLA3000: monomethoxy poly(ethylene glycol)-block-poly(d,l-lactide); b-R15: polyarginine; EGFR: Epidermal growth factor receptor; mPHA: monomethoxy-
poly(hydroxyalkanoates); bPEI: branched poly(ethyleneimine); mPEG: monomethoxy poly(ethylene glycol); b-PCL: block-poly(ϵ-caprolactone); b-PPEEA: block-poly(2-aminoethyl ethylene 
phosphate); mP3/4HB-b-PEG-b-lPEI: mono-methoxy-poly (3-hydroxybutyrate-co-4-hydroxybutyrate)-block-polyethylene glycol-block-linear polyethyleneimine; P(MDSco-CES): poly(N-
methyldietheneamine sebacate)-co-[(cholesteryl oxocarbonylamido ethyl) methyl bis(ethylene) ammonium bromide] sebacate); CS: chitosan; QD: quantum dot; NP: nanoparticle; F5-P: anti-HER-2 
single-chain antibody fragment with protamine; DNMT: DNA methyltransferase; PIL: PEGylated DC-Chol/DOPE immunoliposomes; anti-HER-2 Fab’: Fab’ of recombinant humanized anti-HER-2 
monoclonal antibody; TLPD-FCC: targeted DOTAP/Chol liposome-polycation-DNA complex conjugated with anti-EGFR Fab’; PEI-C-AuNPs: polyethyleneimine-coated gold nanoparticles using 
catechol-conjugated PEI. 
a: Absence 
b: Depending on the methodology 
c: Depending on the ± charge ratio 
d: The application to breast cancer therapy is indicated when it exists; otherwise, reporter genes were used as mentioned (eGFP: enhanced green fluorescent protein; luc: firefly luciferase reporter gene. 
  
Single-chain antibody (fusion 
proteins) 
        





BT-474 murine xenograft  
model (in vivo: i. v.  
administration) 
Dou et al. 
(2012) 
RNA aptamers    
     
HER-2 aptamer N/A N/A N/A N/A HER-2 
siRNA directed 
against Bcl-2 
N202.1A (in vitro: HER2/neu 
transgenic mouse) 
Thiel et al. 
(2012) 
Immunoliposomes    
     
Lyophilized PIL ~400 ~35 
Not 
informed 
PEG anti-HER-2 Fab’ anti-RhoA siRNA SKBR-3 (in vitro) 
Gao et al. 
(2010) 








MDA-MB-231-luc nude mice 
xenograft  
model (in vivo: i. v. 
administration) 
Gao et al. 
(2011) 
Gold nanoparticles    
     
PEI-C-AuNPs 15.3 +5 
Not 
informed 
a a anti-GFP siRNA MDA-MB-435-GFP (in vitro) Lee et al. (2011) 
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2.11.1 Stealth technology - nanocarrier biological stability  
 
When systemically applied, nanocarriers have to overcome several biological barriers within the 
bloodstream and the extracellular matrix. Blood plasma is rather complex, containing 
approximately 3700 identified proteins, i.e., 60-80 g L
-1
 serum total protein. In particular, 
liposomes are not inert with respect to blood components and they may interact with proteins and 
lipoproteins resulting in substantial changes in liposome identity. Unfavourable pharmacokinetic 
profiles follow, mainly due to the rapid clearance of particles by the tissues of the mononuclear 
phagocytic system (MPS) (Sharma and Sharma, 1997). Following introduction, nanocarriers are 
immediately surrounded by free protein, a process which is initiated either by a diffusion 
mechanism or an energy gradient (Caracciolo, 2015). Under thermodynamically favourable 
conditions, delivery systems are subject to unspecific interactions with the serum proteins 
(opsonins), influencing their fate in vivo (Scholz and Wagner, 2012; Walkey and Chan, 2012). In 
particular, liposomes bearing charged (anionic or cationic) phospholipid headgroups may have 
more efficiency to adsorb more proteins than those bearing neutral surfaces (Kabanov, 1999). 
Cationic lipids have a tendency to activate complement adsorption with acidic plasma proteins, 
whereas their anionic counterparts preferentially adsorb the basic proteins (Caracciolo, 2015). 
The tight binding of selected proteins on the surface of the liposomes forms a protein-corona 
which is recognized by the organism’s biological system. Therefore, it is not the liposomes 
themselves that are recognized by the MPS, but rather the opsonins on the interface of the 
liposome. As such, liposomes are efficiently taken up by the macrophages and consequently 
eliminated from circulation by the reticulo-endothelial system (RES) or by renal excretion, 
depending on the size of the particle (Reischl and Zimmer, 2009). In addition, protein binding 
may promote liposomal aggregation, as well as hinder cellular uptake of the lipoplex (Zhang et 
al., 2012). 
 These major obstacles in the field of liposome technology have prompted research to 
progress from conventional liposomal delivery vehicles to the field of “second-generation 
liposomes”. Here, conventional liposomes are surface modified by the incorporation of 
biocompatible, hydrophilic moieties (Allen, 1989; Sen and Mandal, 2013; Wang and Thanou, 
2010). The polymer most often employed is poly(ethylene glycol) (PEG) as it is neither toxic nor 
immunogenic, and is easily excreted from the biological system (Ishida and Kiwada, 2008; 
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Zalipsky, 1995). PEGylation involves PEG grafting on functionalized lipids or the integration of 
PEG conjugated phospholipid molecules into the liposomal bilayer (Klibanov et al., 1990; 
Torchilin et al., 1994). PEG polymers (ethylene oxide monomers) are inert and biocompatible, 
and have been FDA approved for use in humans (Harris et al., 2001). 
 PEGylation has become the best and most commonly employed strategy to impart 
promising pharmacodynamic and pharmacokinetic properties to increase the longevity of 
lipoplexes in circulation (Drummond et al., 1999; Immordino et al., 2006; Kolate et al., 2014; 
Perche and Torchilin, 2013). When tethered to the surface of liposomes, resulting vesicles are 
referred to as PEGylated-stealth or sterically stabilized liposomes, and are often depicted 
displaying a protective “cloud”. PEG chains hinder the close association or aggregation of lipid 
nanoparticles, thereby providing steric stabilization to the liposomes. In addition, PEG ‘masks’ 
the liposome surface (charge density), which obstructs opsonin protein adsorption and reduces 
recognition and uptake by macrophages of the RES (Papahadjopoulos et al., 1991; Yan et al., 
2005). Together, these factors aid in prolonging their plasma circulation time thus improving 
localization of the liposomes at the tumour site (passive targeting) (Gaumet et al., 2008), with the 
caveat that the presence of PEG chains may impede liposomal binding and internalization by 
cancer cells. 
 A typical PEG polymer comprises an anchor connected via ethylene glycol repeats to a 
distal terminal group. The anchor portion penetrates the liposome surface and the terminal group 
extends and interacts with the environment. The ethylene glycol repeats may vary in number and 
therefore determine the length and molecular weight of the PEG molecule. Strategies to 
immobilize PEG onto liposomal surfaces include simple direct adsorption, chemical and 
radiation cross-linking and self-assembled monolayers (Thalla et al., 2013). A technique, widely 
used is to anchor the polymer on the liposome bilayer through coupling to a phospholipid, e.g., 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)] (Allen et 
al., 1991). The arrangement and the activity of the PEG layer is dependent on three prime 
factors; PEG molecular weight, PEG chain length, and the concentration of PEG chains (surface 
densities) (Ho et al., 2010; Vonarbourg et al., 2006). Lipids containing covalently linked PEG2000 
have been the focus of attention, as the molecular weight of PEG was found to optimize blood 
circulation times of liposomes (Zhang et al., 2012). Ideally, a liposome layered by a near perfect 
PEG coat would be necessary to ensure suitable steric stabilization and reduced protein 
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adsorption. The volume which each flexible PEG chain occupies (Rf) and the distance between 
each PEG molecule (D) on the liposomal surface affect the resultant conformation of the PEG 
chains [Figure 2.6]. Low PEG densities allow the PEG chains to self-assemble into tightly 
coiled, “flat pancake”-like structures (D > Rf). An increase in PEG density creates a moderate 
lateral pressure between the PEG chains, forcing the pancake regimen to extend into an 
intermediate random coil-like “mushroom” conformation. A higher PEG density increases the 
lateral pressure between PEG “mushrooms” even further. This forces the PEG chains to uncoil 
and extend away from the liposomal surface, forming low-coiled, more linear “brush” structures 
(D < Rf). These findings have suggested that the PEG density is somewhat more important than 
the size of the polymer (Buyens et al., 2012; Dos Santos et al., 2007; Wang and Thanou, 2010). 
PEG polymers used in these applications are characterized by low polydispersity and solubility 
in aqueous solutions and numerous organic solvents. The solubility of PEGs is facilitated by the 
directional bonds formed between the PEG and water molecules (Sofia et al., 1998). This 
favourable polymer-solvent contact creates a “hydration shell” around the PEG chains. The PEG 
chain entangles 2-3 water molecules per oxyethylene unit, increasing its apparent molecular 
weight to 5-10 times that of a globular protein of similar molecular weight (Kolate et al., 2014). 
Upon hydration, the PEG chain swells, and this plays an important role in stabilizing PEG-
grafted liposomes. Tirosh et al. (1998) reported that grafting PEG-lipid at concentrations of 
about 5 to 7 mol.% onto the surface of liposomes compresses the liposomal lipid bilayer as water 
is being released from the lipid head group region. This enhances the lateral packaging of the 
phospholipid acyl chains, and, at the same time, decreases bilayer defects resulting in good 
stealth liposomes. In general, an 8-10 mol.% of PEG-lipid present in the liposomal formulation 
equates to the formation of a “brush” regime (Buyens et al., 2012); this generates greater protein 
repulsion. However, higher PEG-lipid concentrations result in lateral repulsion of the PEG 
chains (simultaneous micelle formation) which acts as a liposomal destabilization agent (Li and 
Huang, 2009). Moreover, high mol.% of PEG-lipid densities apparently hamper the release of 



























Figure 2.6: Depicted are unilamellar liposomes (bottom) bearing different densities of PEG polymers on 
their surfaces. Presented from left are total, intermediate and partial surface coverage of the liposomal 
bilayer. A detailed zoom (top) of the three PEGylated liposomes shows the respective PEG regimens 
formed as a result of the different surface densities. When the density of PEG on the surface is low, it 
takes on a heavily coiled flat “pancake” configuration (D > Rf). Increasing PEG densities cause the 
conformations to switch to low coiled “mushroom” or to extend further into “brush” structures (D < Rf) 
This figure is adapted from Buyens et al. (2012) and Wang and Thanou (2010). 
 
2.11.2 Lipid-based systems 
 
In the biological milieu, the inherent properties of phospholipids (e.g. phosphatidylcholine) and 
cholesterol allow them to self-assemble into flexible biological bilayers forming an integral 
feature of membrane systems, which enables the trafficking of biomolecules within as well as 
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among cells. Many lipid-based systems designed for siRNA delivery are based on this natural 
phenomenon and make use of natural or synthetic biocompatible materials for interaction with 
the cell membrane to promote efficient delivery. Typically, lipid systems comprise a neutral, 
anionic or cationic lipid, a fusigenic helper/co-lipid [such as DOPE and 1,2-dioleoyl-sn-glycero-
3-phosphocholine (DOPC)] and, in some cases, a PEG-lipid, which together form self-closed 
spherical particles, referred to as liposomes [Figure 2.7B].  
Liposomes are vesicular colloidal particles which have gained interest and popularity as 
efficient siRNA delivery vehicles. Comprising natural membrane constituents, these vesicles, 
with an aqueous core, are biocompatible and biodegradable in vivo, and their by-products are 
non-toxic (Kesharwani et al., 2012; Oh and Park, 2009; Shim et al., 2013). Importantly, 
liposomes are readily prepared, as they form spontaneously when the constituent lipid mixture is 
dispersed in an aqueous solution. In addition, they may be prepared controllably to form 
structures varying in size, number of bilayers and entrapped aqueous phase. Liposome 
formulations may also include target-specific ligands that enhance their selectivity for tumour 
delivery (Guo et al., 2010). Pirollo and Chang (2008) reported specific knockdown of HER2/neu 
expression in BC animal models using siRNA immunolipoplexes containing an anti-transferrin 
receptor antibody ligand. Based on the molecular make-up of the polar head component, 
liposomes are categorized as anionic, cationic, zwitterionic and non-ionic in nature. Generally, 
cationic and anionic-lipidic nanoscaled vehicles have shown promise for successful siRNA 
delivery in BC therapeutics. Their unique characteristics in respect of their interactions with 
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Figure 2.7: A scheme of the typical components of a cationic lipid (A) and their spontaneous 
assembly with neutral co-lipids into liposomes (B). Adapted from Hong and Nam (2014); Natarajan et 
al. (2014).  
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2.11.2.1 Cationic liposomes 
 
Cationic liposomes comprise cationic lipids which are amphiphilic molecules displaying a net 
positive charge. In general, these cationic lipid molecules are composed of three basic modules: a 
hydrophilic positively charged head group which functions as a binding site for siRNA; a lipid 
hydrophobic tail moiety which anchors the head group to the liposomal membrane bilayer; and a 
linker which connects the hydrophilic and hydrophobic regions (Gao and Hui, 2001; Li and Jr 
Szoka, 2007; Liu and Huang, 2010; Schroeder et al., 2010) [Figure 2.7 (A)]. In general, head 
groups fall into the following categories: primary, secondary and tertiary amines, quaternary 
ammonium moieties, lipoamines, guanidinium or amidine salts, and heterocyclic rings (Heyes et 
al., 2002; Niculescu-Duvaz et al., 2003). The lipophilic tail domain is mainly comprised of 
aliphatic chains of lengths ranging from 12 to 20 carbons or cholesteryl groups (Wasungu and 
Hoekstra, 2006). The connecting linker bonds are usually ether, ester (Leventis and Silvius, 
1990), amide (Behr et al., 1989), urethane (Lee et al., 1996), or carbamate groups (Koynova and 
Tenchov, 2010). The nature of each of these components influences directly or indirectly the 
cohesive charge-charge interactions in siRNA-liposome complexes (lipoplexes). This, in turn, 
affects both transfection efficiency and degree of toxicity. Enhanced endosomal escape and 
efficient transfection are properties associated with lipoplexes formulated with cytofectins 
containing a bulky alkyl chain and a small hydrophilic head group (Tseng et al., 2009). For 
improved transfection in vitro and in vivo, cationic lipids are often mixed with neutral lipids, such 
as DOPE or cholesterol to form liposomes (Dass, 2004; Ramezani et al., 2009; Xu and 
Anchordoquy, 2008). Combinations and relative amounts of cationic lipids and co-lipids 
profoundly influence toxicity and transfection efficiency (Gao and Huang, 1995; Plank et al., 
1996). It is worth noting that some cationic lipids only function effectively as transfecting agents 
upon formulation with DOPE or cholesterol (Banerjee et al., 1999). DOPE seemingly enhances 
fusion of a lipoplex membrane with an endosomal membrane (Fletcher et al., 2006; Hoekstra et 
al., 2007), while cholesterol conceivably stabilizes lipoplexes and reduces interaction with serum 
proteins (Dass, 2004; Xu and Anchordoquy, 2008). Cationic liposome morphology with respect 
to lamellarity and size is largely determined by the method of preparation and, to a lesser extent, 
by lipid composition (Gabizon et al., 2006; Khuller et al., 2004). The facility and reproducibility 
of the electrostatic interaction between the polyanionic phosphate backbone of the siRNA and the 
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positively charged head groups of the cationic liposome to form the vector lipoplex (Felgner et 
al., 1997) have firmly established cationic liposomes as attractive delivery vehicles. 
Lavigne and Thierry (2007) formulated a highly stable and reproducible preparation of 
dioctadecylamidoglycylspermidine (DOGS) and DOPE with a low cationic net charge and 
termed these vectors DLS. As determined by dynamic light scattering, DLS liposome 
suspensions were homogeneous in size (~120 nm) with a low polydispersity. Rhodamine-labelled 
siRNA targeting cyclin D1 was allowed to form stable lipoplexes with the DLS formulation in 
sterile RNase-free water, prior to transfection. MCF-7 BC cells were transfected with DLS 
lipoplexes (50 nM with respect to siRNA). Thereafter, the cells were fixed to decrease non-
specific binding of the antibodies and permeabilized for immunocytochemical analysis using 
FITC-conjugated primary antibody against early endosomal autoantigen (anti-EEA1). Delivery 
by the DLS vector system and subcellular distribution of rhodamine-labelled siRNAs directed 
against cyclin D1 were examined. Results indicated that the rhodamine-labelled siRNA, 
vectorized by the DLS system, was localized to perinuclear regions within the cytoplasm, 
independent of the presence or absence of serum, in areas more distinct than early endosomal 
vesicles. Furthermore, the siRNA did not co-localize with anti-EEA1, as this antibody was 
shown to be specifically associated with the early endosomal membrane. This confirmed that the 
DLS:siRNA lipoplexes were not trapped in the endosomes, but were efficiently delivered into the 
cytoplasm where they enter the RNAi pathway. 
Cationic liposomes composed of 3β-[N-(Nʹ,Nʹ-dimethylaminoethane) carbamoyl] 
cholesterol (DC-Chol) and DOPE (DC-Chol/DOPE liposomes) were reported to stably transfect 
FAM-siRNA into SKBR-3 BC cells at an optimized equimolar DC-Chol/DOPE ratio of 1 (Zhang 
et al., 2010). Moreover, siRNA transfection efficiency of DC-Chol/DOPE liposomes improved 
with increased DC-Chol/DOPE:siRNA weight ratio, until a plateau was reached. Zhang et al. 
(2010) observed that an increase in lipoplex concentration was accompanied by increased 
internalization and more efficient transfection. Although DC-Chol/DOPE:antiHER-2 siRNA 
lipoplex was successfully internalized into the HER-2 overexpressing SKBR-3 cells, low levels 
(< 25%) of HER-2 gene silencing were achieved. Interestingly, siRNA transfection efficiency 
was not significantly affected by the presence of foetal bovine serum. Gene silencing 
competence, however, was greatly reduced to < 6% in the presence of serum. DC-Chol/DOPE 
liposomes exhibited stability in the presence of serum, a property which is desirable in vitro as it 
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ensures increased cell survival and lowers DC-Chol/DOPE:siRNA toxicity. In the same study, 
PEGylation was seen to reduce the size and the surface charge density of the liposomes, resulting 
in considerable reduction of siRNA transfection efficiency compared to their non-PEGylated 
counterparts. Furthermore, DC-Chol/DOPE liposomes containing even a small quantity of PEG 
(1 mol.%) significantly impaired siRNA silencing efficiency. PEGylation is often adopted as it 
prolongs the half-life of the lipoplexes in serum by providing a surface layer that minimizes the 
binding of serum proteins (Ross and Hui, 1999). However, this is sometimes partially offset by 
unfavourable interactions with the cell surface (Masson et al., 2004). 
 
2.11.2.2 Anionic and neutral liposomes 
 
The feasibility of anionic, neutral or zwitterionic lipids as potentially safe siRNA delivery agents 
has also been explored (Kapoor and Burgess, 2012; Pulford et al., 2010; Srinivasan and Burgess, 
2009). These systems, however, showed poor and variable nucleic acid entrapment or 
encapsulation and very low delivery efficiency when transfected as independent entities (Foged 
et al., 2007). It is theorized that the anionic head group prevents efficient siRNA compaction due 
to the lack of complexation-enhancing electrostatic forces that occur between the anionic 
phosphate backbone of the siRNA and the neutral/negatively charged head groups of the lipids. 
Therefore, to negate electrostatic repulsion and to facilitate intense association and lipoplex 






), is incorporated into 
the anionic delivery vehicles. Research efforts have focussed on the use of Ca
2+
 as a bridging 
agent for siRNA delivery, as higher transfection efficiencies have been observed with calcium 
for DNA deliveries (Srinivasan and Burgess, 2009). These authors reported that the strong DNA 
and Ca
2+
 binding affinities are potentially due to the calcium which possesses a small 
hydrodynamic radius and renders a larger charge per unit surface area. 
Ideally, an optimized formulation represents the best charge balance between the anionic 
lipid and siRNA, with a slight excess of Ca
2+
 to facilitate binding between the cellular membrane 
and the lipoplexes. Kapoor and Burgess (2012) conducted formulation optimization studies on 
anionic liposomes composed of 1,2-dioleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DOPG)/ 
DOPE and calcium. These researchers reported ~70% protein knockdown in MDA-MB-231 BC 





and 10 nM anti-eGFP siRNA. Notably, anionic liposome formulations containing > 40 mol.% 
DOPG resulted in no further increment in silencing efficiency as the concentration of DOPG 
reached a point of saturation for DOPG-Ca
2+
-siRNA bridging. Optimal formulations were in the 
size range of 324.2 ± 19.6 nm with a surface charge of -22.9 ± 0.1 mV and an encapsulation 
efficiency of 98.5 ± 1.4%. These optimized anionic lipoplexes were highly stable in the presence 
of serum, and were able to achieve an effective endosomal escape mechanism which resulted in 
increased silencing efficiency. In addition, lipoplexes were several-fold safer than the 




2.11.3 Polymer systems 
 
Polymeric delivery systems have evolved into a dominant strategy for siRNA gene delivery as 
they are biocompatible, biodegradable and offer increased stability and low polydispersity. As is 
the case with lipid based delivery systems, polymers usually comprise cationic moieties which 
allow for self-assemblage with the polyanionic backbone of siRNA forming polyplexes with a 
robust non-covalent interaction. While siRNA molecules are typically 2 nm in diameter and 7 nm 
in length, polyplexes may range from < 100 nm to several 100 nm in size due to siRNA-induced 
aggregation. A variety of polycations or polycation-containing block co-polymers have been 
employed to condense siRNA via electrostatic interactions into polyplexes or other polymeric 
carriers such as micelles (de Martimprey et al., 2009). Cationic polymers can be classified into 
natural and synthetic polymeric delivery systems. Natural polymers include chitosan, 
atelocollagen and cationic polypeptides, whereas synthetic polymers include polyethyleneimine 
(PEI), poly-L-lysine (PLL), poly(amido amine) (PAMAM) and cyclodextrin-based polycations. 
Physicochemical properties such as molecular weight, solubility, charge density and functional 
groups of both biological and synthetic polymers may be appropriately manipulated for a 
particular therapeutic application, due to their structural flexibility. Research efforts which have 







2.11.3.1 Synthetic polymers 
 
PEI is an organic linear or branched polymer which can be synthesized in various lengths with a 
wide range of molecular weights (1 to over 1000 kDa), and can be substituted with different 
functionalized degradable moieties and co-polymers. This protects siRNA from enzymatic 
degradation, reduces cytotoxicity, and enhances transfection efficacy (Meyer et al., 2008; 
Mintzer and Simanek, 2009; Neu et al., 2005; Philipp et al., 2009; Park et al., 2010; Zintchenko 
et al., 2008). PEIs harbour many amino groups, making them highly protonable polymers which 
exhibit a buffering ‘proton sponge effect’ on the cell endosomes. In essence, the amine groups in 
the PEIs have a buffering capability in the low pH environment of the endosome, stimulating the 
rupturing of the endosomal membrane which results in an increased release of siRNA from the 
complex into the cytoplasm (Howard, 2009). PEI transfection efficiency depends largely on its 
molecular weight, size and the amine/phosphate (N/P) ratio of the polyplexes. The N/P ratio is a 
prime formulation factor used to obtain PEI-siRNA polyplexes within a desired size range. It is 
defined as the number of amine groups of the polycation divided by the number of phosphate 
groups of the nucleic acid. In general, polyplexes attain a net positive charge when the N/P ratio 
is above 1. Furthermore, it has been reported that high N/P ratios correspond to a smaller mean 
diameter of the polyplex and vice versa (Grzelinski et al., 2006; Schiffelers et al., 2004). To 
promote cellular uptake, PEIs and similar polycationic polymers deliver nucleic acid material 
across the cell membrane via the formation of transient nanoscale holes. It has been speculated 
that the same destabilizing mechanism of action on cell membranes has a cytotoxic effect, 
suggesting that more efficient polymers are often also more cytotoxic (Hong et al., 2006; 
Lungwitz et al., 2005). High molecular weight PEI (> 25 kDa) polyplexes have been extensively 
explored for highly efficient siRNA transfection (Bologna et al., 2003; Jere et al., 2009; Urban-
Klein et al., 2005). However, high molecular weight PEIs are also characterized by appreciable 
cytotoxicity through cellular mechanisms such as necrosis and apoptosis (Boeckle et al., 2004; 
Hunter, 2006; Nimesh et al., 2006; Swami et al., 2007; Xie et al., 2006). Numerous 
modifications of PEIs have been investigated with the aim of reducing the potential cytotoxicity 
induced by high molecular weight PEIs. These include; PEGylation, conjugation of butyrate or 
alkanoates, and hydrophobic modifications (Aliabadi et al., 2012; Mao et al., 2006; Schiffelers et 
al., 2004; Zhou et al., 2012; Zhou et al., 2013). A range of PEG moieties have been used as 
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block elements, i.e., incorporated onto PEIs for production of block co-polymers to specifically 
reduce cytotoxicity (Mao et al., 2006). In addition, the combination of PEI-PEG is also able to 
coat (PEGylate) the siRNA polyplex structure and prevent non-specific binding to cells or 
proteins in the physiological milieu (Schiffelers et al., 2005). 
Polymer micelles are generated as a result of self-assemblage of amphiphilic block 
polymers i.e. from either di-block co-polymer AB, or tri-block co-polymers ABC or ABA. 
Generally, part A includes polycations such as PEI and PLL and part B is a highly hydrophilic 
polymer such as PEG or dextran. In a study conducted by Zhou et al. (2012), mono-methoxy-
poly(3-hydroxybutyrate-co-4-hydroxybutyrate)-graft-hyperbranched PEI (25 kDa) (mPHA-g-
bPEI) co-polymers displayed higher optimal transfection efficiencies (with low cytotoxicity) 
compared to the unmodified branched PEI (bPEI) in MCF-7-luc cells. In brief, the co-polymers 
were synthesized with various block length poly(hydroxyalkanoates) from 1300 to 2900 Da, 
through Michael addition between acrylated monomethoxy-poly(hydroxyalkanoates) and bPEI. 
Above a 
w
/w ratio of 1:1, bPEI/siRNA complexes were not able to mediate knockdown of 
luciferase (luc) expression without marked cytotoxic effects of bPEI/siRNA complexes. Notably, 
in vitro knockdown of luc expression in this cell line, using an mPHA-g-bPEI (mAP2) complex, 
was comparable (up to 85%) to that of the commercially available transfection agent 
Lipofectamine
TM
 2000. In a recent study, Zhou et al. (2013) synthesized a mono-methoxy-poly 
(3-hydroxybutyrate-co-4-hydroxybutyrate)-block-polyethylene glycol-block-linear PEI (mP3/ 
4HB-b-PEG-b-lPEI) using 1800 Da linear polyethyleneimine. They demonstrated that 
mP3/4HB-b-PEG-b-lPEI co-polymers could effectively bind siRNA, protect it from degradation 
by nucleases, and efficiently release the complexed siRNA under polyanionic heparin 
competition. However, the luc gene silencing efficiency of these micelles was unsatisfactory in 
MCF-7-luc cells, even at high N/P ratios of 70. The researchers deduced that the use of these co-
polymers as efficient siRNA gene delivery vehicles for exogenous gene silencing depended 
largely on cell type and N/P ratios. Cationic micelles composed of the amphiphilic copolymer 
poly(N-methyldietheneamine sebacate)-co-[(cholesteryl oxocarbonylamido ethyl) methyl 
bis(ethylene) ammonium bromide] sebacate) (P(MDSco-CES) were shown to complex with Bcl-
2-targeted siRNA and efficiently deliver it into the MDA-MB-231 BC cell line (Beh et al., 
2009). After transfection with P(MDSco-CES):siRNA micelles, low levels of Bcl-2 mRNA 
expression were reported. Consistent with the down-regulation of Bcl-2 mRNA levels, Bcl-2 
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protein expression was down-regulated by 36-66% in cells treated with micelles. Furthermore, 
the Bcl-2 mRNA down-regulation efficiency was comparable to that mediated by 
Lipofectamine
TM
 2000, but higher than that induced by PEI alone. Increasing the concentration 
of siRNA resulted in a lower Bcl-2 protein expression level; siRNA concentrations of 22 nM and 
1100 nM resulted in approximately 36 and 66% down-regulation respectively. 
Hydrophobic moieties are incorporated onto polymeric carrier systems to enhance the 
interaction with the lipophilic cell membrane to enable more efficient cellular uptake of the 
polymer associated siRNA. Aliabadi et al. (2011) reported the toxicity profile of modified 
polymers in a P-gp over-expressing BC cell line (MDA-MB-435/MDR). Lipid substitution on 
low molecular weight PEI (2 kDa) increased the toxicity of the complexes; however, the level of 
toxicity was significantly lower than the high molecular weight PEI (25 kDa) polymers. In 
another study which explored the feasibility of lipid-substituted low molecular weight (2 kDa) 
PEI as a delivery vector for siRNA-mediated BCRP down-regulation, a significant increase in 
siRNA delivery as a function of lipid substitution for a range of lipids ranging from C8 to C18, 
was reported (Aliabadi et al., 2012). Lipid-substituted polymers that enhanced the cellular uptake 
were most effective in BRCP gene silencing, which effectively lasted for 5 days after a single 
treatment of siRNA. This trend was corroborated by examining the correlation between cellular 
uptake and down-regulation level with a sigmoidal profile that plateaued after a certain level of 
cellular uptake. 
 
2.11.3.2 Natural polymers 
 
Properties of natural polymers which favour their potential application as siRNA delivery 
vehicles include biodegradability, low toxicity and immunogenicity (Frohlich and Wagner, 
2010). Among the biological polymers, chitosan, a linear polysaccharide polymer composed of 
repeating β-(1-4)-linked D-glucosamine and N-acetyl-D-glucosamine units derived from the 
deacetylation of chitin (Rudzinski and Aminabhavi, 2010), is perhaps the most prominent. It 
forms compact polyplexes with siRNA through electrostatic interactions and provides effective 
protection against enzymatic degradation (Katas and Alpar, 2006; Liu et al., 2007). The 
molecular weight and concentration of the polymer, its degree of deacetylation, and the N/P ratio 
of polyplexes and chitosan salt are important parameters that must be considered as they strongly 
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influence the resulting charge of the polyplexes (Mao et al., 2010). Kong et al. (2012) reported 
that low molecular weight chitosan (LMWC) (2 and 5 kDa) tends to form smaller particle size 
chitosan/siRNA complexes with a more favourable siRNA transporting capability compared to 
the higher molecular weight chitosan (20 to 80 kDa). However, poor functional ability to induce 
target luc mRNA knockdown was observed in MDA-MB-231-luc human BC cells. The authors 
suggested that the strong electrostatic interaction between the LMWC and siRNA facilitated 
cellular uptake of the LMWC/siRNA complex, but prevented effective intracellular unpacking of 
siRNA from its LMWC carrier. To overcome this obstacle, the authors utilized a 
phosphorylatable short peptide conjugated LMWC which led to improved intracellular siRNA 
disassociation and increased the target gene silencing effect of the chitosan/siRNA. Yang et al. 
(2013b) assessed the gene silencing level of trans-activated transcription (TAT) surface-modified 
chitosan/siRNA-luc nanoplexes in an endogenous MCF-7-luc cell line. Gene knockdown was 
similar to that achieved with Lipofectamine
TM
 2000; moreover, the gene silencing efficiency of 
TAT-g-chitosan/siRNA-luc nanoparticles (69.2%) was 3.7-fold higher than that of 
chitosan/siRNA-luc nanoparticles (18.8%). In this case, the introduction of TAT into chitosan 
molecules increased the cell penetrating ability of chitosan, and further resulted in the higher 
uptake efficiency of TAT-g-chitosan/siRNA nanoparticles than chitosan/siRNA nanoparticles. In 
another study, Tan et al. (2007) investigated chitosan nanoparticles encapsulating quantum dots, 
complexed to HER2/neu siRNA. The entrapped fluorescent quantum dots allowed the 
investigators to track the nanoparticles and determine the degree of internalization of siRNA 
complexes into SKBR-3 BC cells. HER-2 antibody-labelled chitosan nanoparticles provided 
specific delivery of siRNA to HER-2-overexpressing SKBR-3 BC cells. Gene knockdown of 
HER2/neu siRNA was observed following treatment of the cells. Chitosan, when used as a 
coating material, has also been shown to improve the transfection efficiency of other vectors in 
siRNA delivery. Pille et al. (2006) demonstrated the efficacy of intravenously administered anti-
RhoA siRNA encapsulated in chitosan-coated polyisohexylcyanoacrylate nanoparticles in nude 
mice bearing aggressive BC (MDA-MB-231) xenographs. The authors reported that after 3 
consecutive days of administering the chitosan-coated nanoparticles to mice at a dose of 0.15 or 
1.5 mg/kg body weight, the growth of tumours was inhibited by 90% in the 0.15 mg/kg group. 
Moreover, an even greater inhibition was observed in the 1.5 mg/kg group, signifying the 
potential efficiency of this carrier system. 
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2.12 Cellular Binding, Uptake and Internalization 
  
2.12.1 Cellular binding: Passive and active targeting 
 
Characteristically, newly formed tumour blood vessels are usually irregular in form and 
architecture and are highly permeable due to rapid and defective angiogenesis. Passive targeting 
of tumour cells by siRNA-containing liposomes employs this dysfunctional lymphatic drainage 
system present within tumours. Liposomes are designed with the premise that they will avoid 
clearance by the RES, thus prolonging their circulation in the peripheral blood. They are 
therefore expected to accumulate in tumours due to the enhanced permeability and retention 
effect (Sen and Mandal, 2013; Wang and Thanou, 2010). This phenomenon was identified by 
Maeda and Matsumura (1989) as a means to target anticancer agents onto tumours. Based on this 
effect, the liposomal delivery systems ranging in size from tens to hundreds of nanometers can 
passively escape through the fenestrations of the leaky vasculature into the tumour tissue. This is 
followed by increased accumulation of the liposome in the tumour tissue, i.e., an increased 
proximity to tumour cells compared to the normal tissue (Xu and Wang, 2015), allowing for the 
subsequent internalization of the siRNA-containing liposomes into the cytoplasm by a non-
targeted passive diffusion mechanism. 
On the other hand, liposomes can be formulated with targeting ligand agents such as 
protein (antibody or antibody fragments), and peptides and vitamins which can bind to respective 
receptors that are (over)expressed by target cells. This strategy allows for active targeting 
interactions and improves the therapeutic index by expanding the therapeutic window by 
increasing delivery to the target tissue and reducing toxic side effects. Two prime factors 
determine the binding and targeting efficiency, namely, the receptor density at the cell surface, 
and the affinity and avidity of the coupled ligands (Park et al., 2002; van der Meel et al., 2014). 
The urokinase plasminogen activator, uPA, is a natural protein ligand which targets the 
urokinase plasminogen activator receptor and shows potential as a BC targeting agent. In 
particular, protein fragments containing only the binding region of uPA have been used for 
targeting the over-expressed receptors on BC (Yang et al., 2009). In general, depending on the 
approach adopted, tumour targeting liposomes can accumulate in tumour tissues at levels 
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approximately 10-100 -fold greater than those achieved by passive delivery (Ozpolat et al., 
2014). 
 
2.12.2 Cellular uptake and internalization 
 
Following efficient passive or active target cell binding of the carrier, siRNA must be 
internalized into the cytoplasm of the cell (Zhou et al., 2014). A multitude of internalization 
mechanisms are known to exist, although there is no consensus on how these operate. 
Classically, the uptake mechanisms are divided into two groups: the endocytic and non-
endocytic pathways (David et al., 2010; Xiang et al., 2012). Endocytosis represents the major 
mechanism of entry via which lipoplexes and polyplexes mediate the delivery of siRNA cargo 
into the target cells (ur Rehman et al., 2013a). Within the endocytic group, there are a variety of 
entry pathways, including both clathrin- and caveolae-mediated endocytosis, phagocytosis and 
macropinocytosis, as well as entry portals that are clathrin- and caveolae-independent (Doherty 
and McMahon, 2009; Hillaireau and Couvreur, 2009; Juliano et al., 2008; Resnier et al., 2013). 
Non-endocytic pathways encompass two categories; invasive and non-invasive pathways. In 
particular, the naturally existing non-invasive pathways which include fusion and penetration 
mechanisms are deemed as being more useful to enhance the intracellular availability of non-
viral gene complexes (Xiang et al., 2012). Three fundamental factors are known to influence the 
uptake mechanism: the particle size; surface charge; and the presence of targeting ligands. For 
siRNA-containing liposomes ranging in size from 50 to 150 nm, the preferred uptake mechanism 
is the endocytic pathway. Complexes with a net positive charge show favoured binding to 
heparansulfate proteoglycan-containing negatively charged cell membranes. Alternatively, the 
presence of targeting ligands on the carrier may direct complexes to those cells expressing the 
corresponding receptor on the surface, leading to facilitated internalization of the siRNA-
containing delivery system (Scholz and Wagner, 2012). 
 









3.1 Liposome Formulation 
 
3.1.1 Materials, chemicals and reagents 
 
Dioleoylphosphatidylethanolamine (DOPE, C41H78NO8P) were obtained from the Sigma-Aldrich 
Chemical Co. (St. Louis, MO, USA). Chloroform (CHCl3), absolute ethanol (EtOH, C2H6O), 
sodium chloride (NaCl) and 2-[4-(2-hydoxyethyl)-1-piperazinyl] ethanesulfonic acid (HEPES, 
C8H18N2O4S) were purchased from Merck (Darmstadt, Hesse, Germany). 1,2-Distearoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000), 
hereafter referred to as PEG, was acquired from Avanti Polar Lipids (Alabaster, AL, USA). The 
two CCCs namely; Chol-T and MS09, were previously synthesized and obtained from the Non-
viral Gene Delivery Laboratory, Department of Biochemistry, University of KwaZulu-Natal, 
Durban, South Africa. Nuclear magnetic resonance spectroscopy (NMR spectra) and 
electrospray mass spectra were captured using a Gemini 300 instrument and a Waters APIQ-




C, Appendix A). All other chemicals 
and reagents were of analytical grade or higher, and purchased commercially. Ultrapure 
deionized 18 MΩ water (Milli-Q50) was used throughout.  
 
3.1.2 Liposome preparation 
 
The composition and molar ratio of six liposomal formulations used in the present study are 
outlined in Table 3.1. Cationic liposomes and PEGylated cationic liposomes were prepared 
according to the commonly used thin film evaporation method adapted from that of Gao and 
Huang (1991). The two CCCs, Chol-T and MS09, were previously synthesized in our laboratory 
(Singh and Ariatti, 2006; Singh et al., 2001). Stock solutions of the cytofectins (10 μg μL
-1
), 
DOPE (10 μg μL
-1
) and PEG (1 μg μL
-1
) were prepared separately in CHCl3. Appropriate 
volumes from the respective stock solutions were added to clean quickfit tubes to obtain 2 μmol. 
of total lipid in each case and a constant 1 μmol. cytofectin in each preparation. PEGylated 
liposomes were formulated with 2 or 5 mol.% of PEG, whilst DOPE was adjusted to 
accommodate changes in PEGylation. The lipid mixture was vortexed for 10 s and the CHCl3 
solvent was removed by evaporation (Büchi RE121 Rotavapor, Büchi, Switzerland) at reduced 
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pressure. Pressure equilibration was accomplished using a thin flow of moisture-free nitrogen 
gas at 25 °C. The residual solvent was removed by vacuum-desiccation in a Büchi TO-50 pistol 
drier for at least half-an-hour. The lipid film formed was hydrated overnight at 4 °C in 500 μL of 
filter-sterilized (0.2 μm pore size, Nucleopore, Pleasanton, USA) HEPES Buffered Saline (HBS, 
20 mM HEPES, 150 mM NaCl; pH 7.5). To achieve small unilamellar vesicles, the hydrated 
opalescent lipid film was vigorously vortexed (Vortex Genie 2, Scientific Industries, Bohemia, 
USA), and then sonicated to clarity using a temperature-controlled Transsonic T 460/H bath type 
sonicator (Elma GmbH & Co., Singen, Germany) for 5 min at 21 °C at a frequency of 35 kHz. 
The resulting unilamellar liposome preparations were stored at 4 °C. Liposomal suspensions 
were routinely subjected to DNA/ siRNA binding analyses and, with regular sonication, the 
preparations remained stable for several months.  
 
Table 3.1: Composition and mol. ratios of the different cationic liposomal formulations 
 
Formulation type 
Mol. ratios of the respective cationic liposome 
components (μmol. 500 μL
-1
) 
Total lipid content (μg μL
-1
) 
Cytofectin DOPE PEG 
Chol-T:DOPE 1.00 1.00 - 2.517 
Chol-T:DOPE:2% PEG 1.00 0.96 0.04 2.684 
Chol-T:DOPE:5% PEG 1.00 0.90 0.10 2.938 
MS09:DOPE 1.00 1.00 - 2.746 
MS09:DOPE:2% PEG 1.00 0.96 0.04 2.914 
MS09:DOPE:5% PEG 1.00 0.90 0.10 3.168 
 
Abbreviations: Chol-T: 3β-[N-(N', N'-dimethylaminopropane)-carbamoyl] cholesterol; MS09: N, N-
dimethylaminopropylaminylsuccinylcholesterylformylhydrazide; DOPE: Dioleoylphosphatidylethanol- 









3.2 Physical Characterization of Liposome and Liposome-Nucleic Acid Interactions 
 
3.2.1 Materials, chemicals and reagents 
 
Escherichia coli strain JM109 was sourced from Promega Corp. (Dübendorf, Zürich, 
Switzerland). Plasmid pCMV-luc was purchased from Plasmid Factory (Bielefeld, North Rhine-
Westphalia, Germany). The various siRNAs were obtained from Thermo Scientific Dharmacon 
Products (Lafayette, CO). Agarose was purchased from Bio-Rad Laboratories (Richmond, CA, 
USA). The components of the gel loading buffer (glycerol, bromophenol blue, and xylene 
cyanol) were obtained from Merck (Darmstadt, Hesse, Germany), Sigma-Aldrich Chemical Co. 
(St. Louis, MO, USA), and Saarchem (Muldersdrift, Gauteng, RSA), respectively. Ethidium 
bromide (M 394.3 g mol.
-1
, EtBr) was purchased from Promega Corp. (Madison, WI, USA). Tris 
(hydroxymethyl)-aminomethane (M 121.2 g mol.
-1
, Tris base) and sodium dihydrogen phosphate 
(M 120 g mol.
-1
, NaH2PO4) were acquired from Merck (Darmstadt, Hesse, Germany). N, N, N', 
N'-ethylenediaminetetraacetic acid (M 372.2 g mol.
-1
, EDTA disodium salt) was purchased from 
Saarchem (Wadeville, Gauteng, RSA), and sodium dodecyl sulphate (M 288.4 g mol.
-1
, SDS) 
from Bio-Rad Laboratories (Richmond, WV, USA). HyClone
®
 Research Grade Foetal Bovine 
Serum (triple 0.1 μm sterile filtered, FBS) was purchased from Thermo Scientific 
(Northumberland, UK). Formvar-coated copper grids were prepared by the Electron Microscopy 
Unit, University of KwaZulu-Natal (Durban, KZN, RSA). Ultrapure deionized 18 MΩ water 
(Milli-Q50) was used throughout. All other chemicals and reagents were of analytical purity 
grade or higher, and purchased commercially. 
 
3.2.2 Plasmid DNA 
 
The plasmid used in this study was the pCMV-luc DNA [6.2 kbp] that codes for the firefly 
luciferase (luc) gene and carries the cytomegalovirus promoter (CMV) [Figure 3.1]. The plasmid 
was amplified in E. coli strain JM109 and isolated and purified according to the standard 
protocol. Plasmid purity was confirmed by 1% agarose gel electrophoresis followed by EtBr 
staining. Plasmid preparations with an OD
260
/280 value of more than 1.8 were utilized in this 
study. Short-term working stock concentrations of 1 μg μL
-1
 were prepared with ultrapure 
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deionized 18 MΩ water (Milli-Q50) and stored at -20 °C. Plasmid concentrations were 




Figure 3.1: Plasmid map of the pCVM-luc vector. The vector comprises cDNA of the firefly luciferase 
(luc) gene and β-lactamase for ampicillin resistance (Amp
r
). The vector is driven by the cytomegalovirus 
promoter (CMV). 
 
3.2.3 Small interfering RNA (siRNA) duplexes 
 
siGENOME non-targeting siRNA #1 (D-001210-01-20), sequence: 
UAGCGACUAAACACAUCAA; ON-TARGETplus SMARTpool, and Human ERBB2 (2064) 
(L-003126-00-0020), target sequences: UGGAAGAGAUCACAGGUUA (J-003126-17), 
GAGACCCGCUGAACAAUAC (J-003126-18), GGAGGAAUGCCGAGUACUG (J-003126-
19), GCUCAUCGCUCACAACCAA (J-003126-20) were utilized in this study. siRNA duplexes 
[Figure 3.2] were resuspended according to the manufacturer’s specifications in 1× RNA buffer 
to a final concentration 20 μM. Stock solutions were stored at -80 °C and concentrations were 
routinely confirmed using the NanoDrop 2000c spectrophotometer (Thermo Scientific, 











Figure 3.2: Diagrammatic representation of the siRNA duplex. 
 
3.2.4 Preparation of Chol-T- and MS09-liposome / pCMV-luc or siRNA lipoplexes 
 
Lipoplexes were freshly prepared for use in each of the assays. Chol-T and MS09 liposome 
suspensions were vortexed for 1 min and sonicated for 2 min prior to use. The nucleic acids (1 
μg of pCMV-luc or 0.32 μg siRNA) were mixed directly with various amounts of the appropriate 
cationic liposome suspensions to achieve specific ranges of mass (
w
/w) or N/P (+:‒) ratios. The 
reaction mixtures were brought up to volume (8 μL) with sterile HBS, gently vortexed for 30 s 
and incubated at room temperature for 30 min to allow for the development of complexes. The 
formation of lipolexes was confirmed by nucleic acid binding capacity studies. 
 
3.2.5 Imaging and sizing 
 
3.2.5.1 Cryogenic-transmission electron microscopy (cryo-TEM) 
 
The morphology of the cationic liposomes and lipoplexes (pCMV-luc/ siRNA:liposome 
complexes according to optimal binding capacities) was examined by cryogenic-transmission 
electron microscopy (cryo-TEM) which employed the combined negative staining (uranyl 
acetate)-vitrification protocol. A 2 µL aliquot of liposome:HBS (1:5; 
v
/v) or freshly prepared 
lipoplexes:HBS (1:5; 
v
/v) was deposited onto a 200-mesh copper grid bearing a carbon coated 
Lacey Formvar film (Ted Pella Inc. Redding, CA, USA) and contrasted 1:1 (
v
/v) with 4% 
saturated acidic uranyl acetate negative stain. The aqueous suspensions were allowed to stand for 
2 min at room temperature. Excess fluid was then wicked off with Whatman No. 5 filter paper 
(Sigma-Aldrich Chemical Co., St. Louis, MO, USA) until a very thin layer of fluid formed on 










the grid surface. For vitrificaion of the ultrathin specimens, the prepared grids were immediately 
plunge-frozen in liquid nitrogen at -180 °C (cryo-protectant against freeze thaw damage and ice 
crystal formation) using an injector system (Leica Microsystems EM CPC, Illinois, USA). The 
grids were maintained at -180 °C in a Cryostation 626 single tilt liquid nitrogen cryo-transfer 
holder (Gatan Inc., München, Bavaria, Germany) equipped for low temperature transfer and 
subsequent recording of electron beam sensitive, frozen hydrated specimens in the cryogenic-
TEM. The ultra-structure of liposomes and lipoplexes was then examined under a cryogenic-
TEM JEOL JEM-1010 electron microscope (Jeol, Tokyo, Japan) operating at an accelerating 
voltage of 100 kV under low electron dose. The images were then captured using a Soft Imaging 
System (SIS) MegaView III, bearing a side mounted 3 mega pixel digital camera and analyzed 
using SIS iTEM software (Olympus, Münster, North Rhine-Westphalia, Germany). 
 
3.2.5.2 Determination of particle size, polydispersity index and zeta potential 
 
The hydrodynamic size (Z-average) and the size distribution (polydispersity index, PDI) of the 
liposomes and lipoplexes were determined by dynamic light scattering using the photon 
correlation spectroscopy technique. The light scattering was measured by a Malvern Nano-ZS 
ZetaSizer instrument (Malvern Instruments, Worcestershire, UK) which was equipped with a 5 
mW He-Ne laser beam (633 nm, fixed backscattering detection optics positioned at 173 °) at 25 
°C. Zeta potential (ζ) values of nanoparticles indirectly reflect the surface net charge acquired by 
the vesicle in a given medium. These values can therefore be used to assess the extent of 
interaction of the cationic liposomal surface charges with the anionic charges of DNA or siRNA. 
The zeta potential of the liposomes/lipoplex was measured by the Laser Doppler Velocimetry 
(LDV) electrophoresis technique. The liposome/lipoplex dispersions in filter-sterilized HBS 
(1:99, 
v
/v, 1 mL) were prepared as in the biological studies under dust-free conditions to obtain 
appropriate viscosities for measurement, and loaded into 1.5 mL semi-micro disposable quartz 
cuvettes and universal ‘dip’ cells for particle size analysis and zeta potential studies respectively. 
Liposomes were allowed to equilibrate to room temperature prior to measurement and lipoplex 
preparation. The instrument was programmed within the following parameters: sample refractive 
index, 1.59; viscosity, 0.89 cP; and temperature, 25 °C. Measurements were conducted in 
automatic mode. The particle size of the liposome/lipoplex was measured in triplicate and data 
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was expressed as mean hydrodynamic diameter vs. intensity, i.e., results were reported in terms 
of the intensity distribution. Average diameters were calculated using a monoclonal method 
(NNLS cumulant or cumulative analysis) and reported as mean ± SD (n = 3) of 12 recorded runs. 
Zeta potentials were calculated from the mean electrophoretic mobility by applying the 
Smoluchowski approximation; data represent average and standard deviation (SD) values from 
measurements carried out in triplicate. Width at half peak height is indicative of the homogeneity 
of size and charge distribution. All data was analyzed using the ZetaSizer software version 6.30. 
 
3.2.6 Nucleic acid binding capacity of cationic liposomes by gel retardation 
 
3.2.6.1 Cationic liposome-pDNA interactions 
 
Complexation of cationic lipid dispersions with pDNA retards pDNA electrophoretic mobility 
thus enabling an evaluation of the charge ratio equivalent to complete pDNA binding. pCMV-luc 
Plasmid DNA:cationic liposome complexes with various increasing mass ratios were freshly 
prepared before use by vortexing a mixture of pCMV-luc plasmid DNA (1 µg) and cationic 
liposome (3-10 µg) at 2500 rpm for 1 min. The complex suspension was brought up to a total 
volume of 8 μL with HBS at pH 7.4 (Table 3.2). After 30 min incubation at room temperature, 3 
µL gel loading buffer (50% glycerol, 0.05% bromophenol blue, 0.05% xylene cyanol, 72 mM 
Tris-HCl, 60 mM NaH2PO4, 20 mM EDTA, pH 7.5) was added to the lipoplex suspensions and 
mixed. Agarose (1%) gels were prepared (0.2 g agarose, 18 mL ultrapure deionized 18 MΩ 
water, 2 mL 10× running buffer, 
w
/v), moulded and allowed to form for a minimum of 45 min. 
The gels were submerged in 1× Tris-acetate-EDTA running buffer (36 mM Tris-base, 30 mM 
NaH2PO4, 10 mM EDTA, pH 7.5), and a total volume of 11 µL of each sample was loaded onto 





 Basic, USA) in a Mini-Sub Cell
®
 GT apparatus (Bio-Rad, Richmond, CA, USA). 
Naked pCMV-luc plasmid DNA (DNAc) loaded into the outermost lane served as a positive 
control. Following electrophoresis, the agarose gel was stained in an ethidium bromide solution 
(1 µg mL
-1
) for 30 min, visualized under UV300 transillumination, and images digitally 
photographed on a Vacutec Syngene G:Box BioImaging System (Syngene, Cambridge, UK) 
using GeneSnap Imaging Software version 7.05 (Syngene). 
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3.2.6.2 Cationic liposome-siRNA interactions 
 
siGENOME non-targeting siRNA:cationic liposomes (0.32:2 - 12; 
w
/w) were combined in 
microcentrifuge tubes and diluted to 8 µL with HBS (Table 3.3). The suspensions were vortexed 
at 2500 rpm for 2 min to ensure proper mixing, and incubated at room temperature for 30 min 
prior to adding 3 µL gel loading buffer (50% glycerol, 0.05% bromophenol blue, 0.05% xylene 
cyanol, 72 mM Tris-HCl, 60 mM NaH2PO4 and 20 mM EDTA, pH 7.5). Naked siRNA loaded 
into the outermost lane served as a positive control. Samples were loaded into the wells of a 2% 
agarose gel and analyzed electrophoretically as described in Section 3.2.6.1. Migration patterns 























Table 3.2: Set up for gel retardation assays with varying amounts of cationic and PEGylated cationic 






2 3 4 5 6 7 8 
Chol-T:DOPE 0 
1        
(2.5 µg) 
 1.19     
(3 µg) 
1.59      
(4 µg) 
1.99      
(5 µg) 




3.18      
(8 µg) 




1.12      
(3 µg) 
1.30   
(3.5 µg) 
1.49      
(4 µg) 
1.86      
(5 µg) 
2.24      
(6 µg) 
2.61*    
(7 µg) 
2.98      
(8 µg) 




1.02      
(3 µg) 
1.36      
(4 µg) 
1.70      
(5 µg) 
2.04      
(6 µg) 
2.38*    
(7 µg) 
2.72      
(8 µg) 
3.06      
(9 µg) 
HBS 7 5.98 5.64 5.30 4.96 4.62 4.28 3.94 
MS09:DOPE 0 
0.73      
(2 µg) 
1.09      
(3 µg) 
1.46      
(4 µg) 
1.82      
(5 µg) 
2.18      
(6 µg) 
2.55*    
(7 µg) 
2.91      
(8 µg) 




1.37      
(4 µg) 
1.72      
(5 µg) 
2.06      
(6 µg) 
2.40      
(7 µg) 
2.75      
(8 µg)* 
3.09      
(9 µg) 
3.43    
(10 µg) 




1.26      
(4 µg) 
1.58      
(5 µg) 
1.89      
(6 µg) 
2.21      
(7 µg) 
2.53*    
(8 µg) 
2.84      
(9 µg) 
3.16    
(10 µg) 
HBS 7 5.74 5.42 5.11 4.79 4.47 4.16 3.84 
 
Abbreviations: Chol-T: 3β-[N-(N', N'-dimethylaminopropane)-carbamoyl] cholesterol; MS09: N, N-
dimethylaminopropylaminylsuccinylcholesterylformylhydrazide; DOPE: Dioleoylphosphatidylethanol- 
amine; PEG: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]; 
HBS: HEPES Buffered Saline. 
Note: In each reaction mixture pCMV-luc plasmid DNA was used at a constant concentration of (1μg).  












Table 3.3: Set up for gel retardation assays with varying amounts of cationic and PEGylated cationic 














































































































HBS 7 3.97 3.87 3.77 3.67 3.57 3.46 3.36 
 
Abbreviations: Chol-T: 3β-[N-(N', N'-dimethylaminopropane)-carbamoyl] cholesterol; MS09: N, N-
dimethylaminopropylaminylsuccinylcholesterylformylhydrazide; DOPE: Dioleoylphosphatidylethanol- 
amine; PEG: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]; 
HBS: HEPES Buffered Saline. 
Note: In each reaction mixture siGENOME non-targeting siRNA was used at a constant concentration of  
(0.32μg).  









3.2.7 Serum nuclease protection assay 
 
Protection of nucleic acid from serum nucleases is essential for efficient gene delivery both in 
vitro and in vivo. For serum resistance assays, liposome:pDNA/siRNA complexes containing 
pCMV-luc plasmid DNA (1 μg) or siRNA (0.2 μg) were assembled according to three weight 
ratios based on binding values obtained for gel retardation studies described in Section 3.2.6 
(Tables 3.4 and 3.5) and incubated at room temperature for 30 min. Serum stabilities of 
liposome:pDNA/siRNA mixtures were investigated by adding foetal bovine serum (FBS) to the 
complexes at a final concentration of 10% (1 μL, 
v
/v). The reaction mixtures were then incubated 
at 37 °C for a further 4 h in a 14 L digital temperature-controlled water bath (TriLab Scientific, 
Johannesburg, Gauteng, RSA). The enzymatic digestion reaction was terminated with 10 mM 
EDTA (1.1 μL, 
v
/v, pH 8) and lipoplexes disassociated using 0.5% SDS (1.33 μL, 
w
/v). After an 
incubation of 20 min at 55 °C, the gel loading buffer (4 μL) was added. The following control 
samples were tested: naked pDNA/siRNA containing an equal volume HBS instead of the 
cationic liposome not treated with FBS, and naked pDNA/siRNA in the presence of FBS. The 
pDNA/siRNA samples were carefully added to the wells of a 1% or 2% agarose gel respectively, 
and subjected to electrophoresis and visualized as described in Sections 3.2.6.1 and 3.2.6.2 for 















Table 3.4: Set up for serum nuclease protection assays with varying amounts of cationic and PEGylated 









1 2 3 1 2 3 
Liposome 0 0 
1.99     
(5 μg) 
2.38     
(6 μg) 
2.78     
(7 μg) 
2.18     
(6 μg) 
2.55     
(7 μg) 
2.91     
(8 μg) 
HBS 10 9 7.01 6.62 6.22 6.82 6.45 6.09 






Chol-T:DOPE:2% PEG Chol-T:DOPE:5% PEG 
1 2 3 1 2 3 
Liposome 0 0 
2.24     
(6 μg) 
2.61     
(7 μg) 
2.98     
(8 μg) 
2.04     
(6 μg) 
2.38     
(7 μg) 
2.72     
(8 μg) 
HBS 10 9 6.76 6.39 6.02 6.96 6.62 6.28 






MS09:DOPE:2% PEG MS09:DOPE:5% PEG 
1 2 3 1 2 3 
Liposome 0 0 
2.40     
(7 μg) 
2.75     
(8 μg) 
3.09     
(9 μg) 
2.21     
(7 μg) 
2.53      
(8 μg) 
2.84     
(9 μg) 
HBS 10 9 6.60 6.25 5.91 6.79 6.47 6.16 
FBS (10%) 0 1 1 1 1 1 1 1 
 
Abbreviations: Chol-T: 3β-[N-(N', N'-dimethylaminopropane)-carbamoyl] cholesterol; MS09: N, N-
dimethylaminopropylaminylsuccinylcholesterylformylhydrazide; DOPE: Dioleoylphosphatidylethanol- 
amine; PEG: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]; 
HBS: HEPES Buffered Saline; FBS: Foetal Bovine Serum. 















Table 3.5: Set up for serum nuclease protection assays with varying amounts of cationic and PEGylated 









1 2 3 1 2 3 













HBS 8.50 7.50 6.55 6.39 6.23 6.12 5.97 5.82 






Chol-T:DOPE:2% PEG Chol-T:DOPE:5% PEG 
1 2 3 1 2 3 
Liposome 0 0 
  1.64  
(4.4 μg) 






 2.52  
(7.4 μg) 
 2.65  
(7.8 μg) 
HBS 8.50 7.50 5.86 5.71 5.56 5.12 4.98 4.85 






MS09:DOPE:2% PEG MS09:DOPE:5% PEG 
1 2 3 1 2 3 













HBS 8.50 7.50 5.92 5.78 5.65 5.35 5.23 5.10 
FBS (10%) 0 1 1 1 1 1 1 1 
 
Abbreviations: Chol-T: 3β-[N-(N', N'-dimethylaminopropane)-carbamoyl] cholesterol; MS09: N, N-
dimethylaminopropylaminylsuccinylcholesterylformylhydrazide; DOPE: Dioleoylphosphatidylethanol- 
amine; PEG: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]; 
HBS: HEPES Buffered Saline; FBS: Foetal Bovine Serum. 
Note: In each reaction mixture, siGENOME non-targeting siRNA was used at a constant concentration of  
0.2 μg. 
 
3.2.8 Ethidium bromide dye displacement assay 
 
Fluorescence titrations of pDNA/siRNA-ethidium bromide (EtBr) complexes with cationic 
liposomes were adapted from the method previously described by Singh and Ariatti (2006). A 
solution of EtBr (10 µL, 100 µg mL
-1
) was added to 0.25 mL HBS in 96-well black flat-bottom 
FluorTrac plates, and a standard baseline reading of 0% relative fluorescence was established. 
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Subsequently, 3 µL pCMV-luc plasmid DNA (1 µg μL
-1
) or 10 µL siRNA (0.32 µg μL
-1
) was 
added to the mixture, and the fluorescence taken was set to represent 100% relative fluorescence 
intensity. Thereafter 1 μL aliquots of the complexation agents were sequentially added, the 
mixture was agitated for 30 s, and the fluorescence of the solution measured at excitation and 
emission wavelengths of 520 nm and 600 nm respectively using an automated 
spectrofluorometric microplate reader (SynergyMx ELX 800, BioTek Instruments, Winooski, 
VT, USA). Binding of the cationic liposomes to the nucleic acids caused condensation and 
displacement of intercalated EtBr, resulting in reduced fluorescence emission intensity until a 
plateau in readings was reached. All measurements were conducted in triplicate at 25 °C and 
relative fluorescence (Fr) was plotted against liposome lipid mass. Normalized fluorescence was 
calculated using the following equation: 
 
Fr (%) = (F - F0) / (F100 - F0) × 100 
 
where F represents the fluorescence of nucleic acid + EtBr + cationic liposome, F0 the 
fluorescence of EtBr alone, and F100 the fluorescence of nucleic acid + EtBr. 
 
3.3 Cell Lines and Routine Cell Culture Techniques 
 
3.3.1 Materials, chemicals and reagents 
 
Eagle’s Minimum Essential Medium (EMEM) containing ʟ-glutamine (4.5 g L
-1
), Trypsin-
EDTA mixture [Versene (EDTA) 200 mg L
-1
 and Trypsin 170.000 U L
-1
] and antibiotics (100×) 
containing penicillin G (10 000 U mL
-1
), streptomycin sulphate (10000 µg mL
-1
) and 
amphotericin B (25 μg mL
-1
) mixtures were purchased from Lonza BioWhittaker (Verviers, 
Liège, Belgium). Gamma-irradiated foetal bovine serum (FBS) and dimethyl sulfoxide (DMSO) 
were purchased from Hyclone, Thermo Scientific (Northumberland, UK). SKBR-3 cell line was 
purchased from American Tissue Culture Collection (ATCC) [HTB 30, University Boulevard, 
Manassas, VA, USA]. MCF-7 cells were supplied by the Department of Therapeutic and 
Medicines Mangement, Medical School, University of KwaZulu-Natal, Durban, South Africa, 
and the HEK293 cells were provided by the Anti-viral Gene Therapy Unit, Medical School, 
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University of the Witwatersrand, South Africa. Calbiochem
®
 phosphate buffered saline (PBS) 
tablets were obtained from Merck (Darmstadt, Hesse, Germany). All sterile tissue culture plastic 
consumables were obtained from Corning Incorporated (Corning, NY, USA). Milli-Q50 
ultrapure deionized 18 MΩ cm water was used throughout. All other chemicals and reagents 
were of analytical purity grade or higher, and purchased commercially. 
 
3.3.2 Cell lines and maintenance 
 
The SKBR-3 cell line is well known for the overexpression of the Her2/neu gene product. The 
SKBR-3 cell line was first isolated by G. Trempe and L.J. Old in 1970 from the malignant 
pleural effusion of a 43-year-old caucasian female with metastatic ductal adenocarcinoma of the 
breast. This cell line served as a positive BC cell line for Her2/neu gene knockdown using target 
specific siRNA. The MCF-7 cell line was also first isolated in 1970 from the malignant pleural 
effusion of a 69-year-old caucasian woman with adenocarcinoma of the breast tissue. In this BC 
cell line the Her2/neu gene product is not overexpressed, and was therefore used in this study as 
a negative control cell line together with the non-Her2/neu expressing human embryonic kidney 
cells (HEK-293). All routine cell culture procedures, including complete culture media 
preparartion, mammalian cell line propagation and maintenance, were carried out in a class II 
Airvolution biological safety cabinet (United Scientific (Pty) Ltd.) Cells were propagated in 25 
cm
2 
gas permeable screw-capped cell culture flasks containing 5 mL EMEM supplemented with 
10% (
v
/v) FBS and Pen./Strep. antibiotics. The cultures were incubated at 37 °C in a saturated 
humidified atmosphere containing 95% air and 5% CO2 (Labotec, ThermoElectron Corp., Steri-
Cult CO2 incubator, HEPA Class 100). Cells were maintained in monolayer culture, and were 
routinely trypsinized using 1 mL trypsin-EDTA and split at a 1:3-1:5 ratio every 3-4 days. The 
cells were then stored in a Nuaire Ultralow freezer at -80 °C in 0.9 mL complete medium 
containing 10% (
v








3.3.3 Cryopreservation and reconstitution of cells 
 
The cells were cryopreserved by first washing the confluent cells twice with 2 mL phosphate 
buffered saline (PBS), followed by addition of 1 mL trypsin-EDTA to dislodge the cells and 2 
mL complete medium (EMEM, 10% FBS, antibiotics). The cells were then transferred to a 
microcentrifuge tube and pelleted by centrifugation (Eppendorf Centrifuge 5415D, Germany) at 
1000 rpm for 5 min. The supernatant was decanted; the pellet was resuspended in 0.9 mL 
complete medium and 0.1 mL DMSO (10%), and then dispensed into 2 mL sterile cryogenic 
storage vials. To achieve a -1 °C min
-1 
rate of cooling, the sealed cryogenic vials were placed 
into a Nalgene
TM
 Cryo 1 °C freezing container containing 2-propanol, and the latter in turn 
placed overnight in an ultralow biofreezer. The next day the vials were transferred to cryo-boxes 
and stored in a -86 °C ultralow biofreezer (Nuaire, Lasec Laboratory and Scientific Equipment). 
When required, the cells were reconstituted by removing the required cryogenic vial from the 
bio-freezer (-80 °C) and immediately allowing it to thaw out in a 37 °C water bath. The vial was 
then wiped with alcohol and the cells pelleted by centrifugation at 3000 rpm for 2 min. The 
supernatant containing the DMSO was decanted, and the cells resuspended in 1 mL complete 
medium and transferred to a 25 cm
2 
screw-capped cell culture flask. An additional 5 mL of 
complete growth medium was added to the reconstituted cell suspension to dilute traces of 
DMSO and to facilitate cellular growth. The flask was incubated at 37 °C overnight under a 
humidified atmosphere with 5% CO2. The following day, the medium was replaced with fresh 
culture medium to further remove residual DMSO which is toxic to cells above 4 °C. The cells 
were monitored daily with frequent medium changes until they reached confluency. Prior to each 
experiment, cells were freshly cultured and plated to maintain the correct pH balance and to 
eliminate cellular waste.  
 
3.3.4 Examination of cultures 
 
Cell cultures were examined daily under an inverted phase contrast microscope (Nikon TMS-F 
6V, Tokyo, Japan) to monitor the general appearance of cells. Key features inspected were the 
cell shape and general health condition, as well as any signs of contamination. Cultures were also 





3.4.1 Materials, chemicals and reagents 
 
3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) salt and 
Calbiochem
®
 phosphate buffered saline (PBS) tablets were obtained from Merck (Darmstadt, 
Germany). Dimethyl sulfoxide (DMSO) was obtained from Highveld Biological (Pty) Ltd., 
Kelvin, South Africa. The luciferase assay kit was purchased from Promega Corporation 
(Madison, WI). The bicinchoninic acid (BCA) assay reagents and the protein standard bovine 
serum albumin (BSA) protein standards were purchased from Sigma-Aldrich (St. Louis, MI). 
The 48-well microtiter plates and all other tissue culture plastic consumables were from Corning 
Incorporated (Corning, New York, USA). 
 
3.4.2 MTT cell viability assay 
 
The cytotoxicity of pDNA/siRNA lipoplexes was determined to indicate the viability and 
proliferation of cells against transfection complexes. MTT [3-(4, 5-dimethyl-2-thiazolyl)-2, 5-
diphenyl-2H-tetrazolium bromide, a yellow tetrazole] is reduced in the mitochondria of viable 
cells to a purple formazan product. These reductions take place only when reductase enzymes are 
active, and are often used as a measure of viable cells. The cytotoxicity of cationic liposomes 
(steric stabilized and non-steric stabilized MS09 and Chol-T liposomal formulations) was 
assessed using the MTT viability assay against HEK-293, MCF-7 and SKBR-3 cells. Confluent 
HEK-293, MCF-7 and SKBR-3 cells were separately trypsinized, harvested and then seeded into 
48-well microtiter plates at the following densities: 1.9 × 10
4
, 1.8 × 10
4
 and 2.0 × 10
4 
cells per 
well respectively. Cell counts were conducted using a haemocytometer. To allow attachment and 
growth to semi-confluency, the cells were incubated in 0.25 mL of EMEM supplemented with 
10% (
v
/v) FBS and antibiotics at 37 °C in a 5% CO2 atmosphere for 24 h. The following day, 
pDNA/siRNA lipoplexes were prepared in triplicate volumes (30 µL) based on various 
optimized end-point ratios (
w
/w) in HBS, and incubated at room temperature for 30 min. The 
medium in the cell culture microtiter plates was then replaced with fresh EMEM (0.25 mL), and 
10 μL of the various lipoplexes were pipetted into the wells in triplicate. The plates were then 
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incubated at 37 °C for 48 h. The cells of positive control were incubated with EMEM (10% FBS, 
antibiotics) only and the cell viability was assumed to be 100%. After 48 h, the complete 
medium was removed from each well and replaced with 0.2 mL of a MTT stock solution (5 mg 
mL
-1
 in PBS) and 0.2 mL complete EMEM. Thereafter, the plates were incubated for an 
additional 4 h at 37 °C until the purple precipitates were visible. Following incubation, the MTT-
containing medium was carefully aspirated to avoid disturbing any formazan crystals formed by 
living cells, and 0.2 mL DMSO was added to each well. The plates were gently agitated at room 
temperature to dissolve the formazan crystals. Finally, the UV570 absorbance of the formazan 
products was measured by a Vacutec, Mindray MR-96A microplate reader using DMSO as a 
blank. The cell viability (%) was then calculated using the following equation: 
 
% Cell Survival (CS) = Average of treated cells / Average of control cells × 100 
 
3.4.3 Luciferase assay 
 
A day before transfection, HEK-293, MCF-7 and SKBR-3 cells were trypsinized and evenly 
seeded into 48-well microtiter plates at a density of 2.1 × 10
4
, 2.4 × 10
4
 and 2.2 × 10
4
 cells per 
well in 0.25 mL complete medium. The cells were allowed to attach to the bottom of the wells 
and grow to semi-confluence at 37 °C in a 5% CO2 atmosphere. The following day, pCMV-luc 
plasmid DNA lipoplexes were prepared in triplicate volumes (30 µL) based on various optimized 
end-point ratios (
w
/w) in HBS and incubated at room temperature for 30 min. The cells were 
prepared by decanting the medium from each well and replacing it with 0.25 mL complete 
medium. The lipoplexes (10 μL) were then added to each well and mixed gently by rocking the 
plate back and forth. The cells were incubated at 37 °C with 5% CO2 for 4 h. The medium was 
then removed and replaced with complete growth medium and further cultured for 48 h at 37 °C 
with 5% CO2. Following the incubation period, relative luc activity was assessed using a 
Glomax
TM 
Multi+ Detection System (Promega Biosystems, Sunnyvale, USA). The cells were 
prepared by gently aspirating the medium from each well and carefully washing twice with 0.2 
mL PBS. Thereafter, 80 μL cell lysis reagent was added to each well and the microtiter plate was 
placed on a platform shaker (Stuart Scientific Platform Shaker STR6, UK) for 15 min at 30 rev 
min
-1
. To facilitate cell lysis, each well was manually ‘scraped’, and the resultant cell lysates 
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were transferred to microcentrifuge tubes and briefly centrifuged (5 s at 12 000 rpm) to pellet 
cellular debris. The cell-free extracts were transferred into a 96-well white GLOMAX plate 
followed by the addition of 50 μL Promega luciferase assay reagent. The reaction mixture was 
briefly vortexed and the luc activity of each sample was immediately measured in relative light 
units (RLU) for a period of 10 s in a Promega GLOMAX® MULTI+ Detection system. 
Luciferase activity was expressed as RLU mg
-1
 protein. Protein determinations were performed 
on the cell-free extracts using the BCA protein assay. 
 
3.5 HER2/neu Silencing at mRNA and Protein Levels 
 




 protein extraction kit (total protein), 10× Tris/Glycine/SDS buffer, 5× transfer 









 long shelf life precast gels, 2× Laemmli 
sample buffer, Precision Plus Protein
TM
 dual extra standards, clarity Western ECL substrate and 
RT-PCR strip tubes were purchased from Bio-Rad Laboratories (Richmond, CA, USA). Tris 
(hydroxymethyl)-aminomethane (M 121.2 g mol.
-1
, Tris base), sodium chloride (M 58.44 g mol.
-
1
, NaCl), hydrochloric acid (HCl), absolute ethanol (EtOH, C2H6O), chloroform (CHCl3), and 





 3000, High Capacity cDNA Reverse Transcription Kit with RNase 
inhibitor, MicroAmp
®
 Fast optical 96-well reaction plates, MicroAmp
®
 Optical Adhesive Films, 
and distilled water DNase/RNase free were purchased from Life Technologies (Carlsbad, CA, 
USA). For all materials, chemicals and reagents used for the siRNA gene transfection refer to 
Section 3.1.1. The following antibodies were used for Western blotting: Neu (0.N.211); sc-
71667, a mouse monoclonal antibody raised against a synthetic peptide corresponding to amino 
acids 1242-1255 of human Neu (Mw 185 kDa), β-Actin (C4); sc-47778, a mouse monoclonal 
antibody raised against gizzard Actin of avian origin (Mw 43 kDa); and goat anti-mouse IgG-
HRP; sc-2005, an affinity purified secondary antibody raised in goat against mouse IgG and 
conjugated to horseradish peroxide (HRP). These antibodies were purchased from Santa Cruz 
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Biotechnology, Inc. (CA, USA). Ultrapure deionized 18 MΩ water (Milli-Q50) was used 
throughout. 
 
3.5.2 Transfection of siRNA 
 
Four different sequences of 19 nucleotides (ON-TARGETplus SMARTpool) were used as 
potential siRNAs targeting the HER2/neu gene (refer to Section 3.2.3). A non-targeting 
sequence siRNA was used as a non-specific siRNA control. For in vitro analysis, SKBR-3 cells 
were seeded into 6-well plates at a density of 1 × 10
5
 cells per well. This was conducted 24 h 
prior to transfection to allow the cells to attach and grow to semi-confluency. The following day, 
the culture medium was replaced with 1.5 mL fresh EMEM supplemented with 10% (
v
/v) FBS 
and antibiotics. Thereafter, 10 μL of pre-assembled siRNA lipoplexes (prepared according to 
end-point ratios) in HBS were added into each well in triplicate (Table 3.6). Lipofectamine
® 
3000 (Life Technologies, Carlsbad, CA, USA) was included as a positive transfection control 
and lipoplexes were assembled according to the manufacturer’s instructions. The cationic lipid 
complexes were prepared by incubating 5 μL Lipofectamine
®
 3000 Reagent and 2.5 μL siRNA 
in 250 μL EMEM medium for 5 min at room temperature. After 48 h and 72 h of transfection, 
the complete medium was removed from each well and cells were harvested for assessing 
HER2/neu gene knockdown status, using quantitative real time polymerase chain reaction (qRT-














Table 3.6: Set up for gene expression studies with varying amounts of cationic and PEGylated cationic 




Chol-T:DOPE Chol-T:DOPE:2% PEG Chol-T:DOPE:5% PEG 




















HBS 4.45 3.94 3.43 2.25 1.78 1.30 4.88 4.44 4.00 
siRNA 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
 
MS09:DOPE MS09:DOPE:2% PEG MS09:DOPE:5% PEG 




















HBS 3.07 2.61 2.14 2.45 2.01 1.57 5.63 5.23 4.82 
siRNA 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
 
Abbreviations: Chol-T: 3β-[N-(N', N'-dimethylaminopropane)-carbamoyl] cholesterol; MS09: N, N-
dimethylaminopropylaminylsuccinylcholesterylformylhydrazide; DOPE: Dioleoylphosphatidylethanol- 
amine; PEG: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]; 
HBS: HEPES Buffered Saline. 
Note: In each reaction mixture, ON-TARGETplus SMARTpool HER2/neu siRNA was used at a constant 
concentration of 0.64 μg. 
 
3.5.3 RNA extraction and qRT-PCR 
 
3.5.3.1  RNA extraction 
 
For qRT-PCR analysis, total cellular RNA from transfected cells was extracted using TRIzol
®
 
Reagent (Life Technologies, Carlsbad, CA, USA), following the manufacturer’s detailed 
protocol. The RNA isolation procedure was conducted at room temperature in a class II 
biohazard laminar flow cabinet under sterile RNase free conditions, and involved four primary 
steps: cellular homogenization, RNA precipitation, RNA wash and RNA resuspension. Firstly, 
the growth medium was removed from the culture plates and 1 mL TRIzol reagent was added 
directly to the cells in each well. The cells were lysed manually by homogenizing the samples 
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several times (35-40 strokes) using a pipette. To allow complete dissociation of the nucleoprotein 
complex, the homogenate was incubated at room temperature for 5 min. Samples were 
transferred into sterile 2 mL polypropylene microcentrifuge tubes prior to the addition of 0.2 mL 
chloroform. The tubes were securely capped and shaken vigorously by hand for 15 seconds; the 
samples were then left to stand at room temperature for 3 min before centrifuging (Eppendorf 
centrifuge 5424R) at 12,000 × g for 15 min at 4 °C. The mixture separated into a lower red 
phenol chloroform phase, an interphase, and a colourless upper aqueous phase. RNA remains 
exclusively in the upper aqueous phase which makes up ~50% of the total volume of the sample. 
The aqueous phase was gently removed by angling the tube at 45 ° and pipetting out the solution. 
Care was taken to avoid contamination with the inter- and organic phases. The aqueous solution 
was transferred into a new 2 mL tube and treated with 0.5 mL of 100% isopropanol for 10 min at 
room temperature before centrifuging at 12,000 × g for 10 min at 4 °C. The supernatant was 
removed and the gel-like RNA pellet formed on the side of the tube was washed by briefly 
vortexing the sample in 75% ethanol followed by centrifugation at 7500 × g for 5 min at 4 °C. 
The pellet was allowed to air dry. The RNA pellet was resuspended in 30 μL RNase free water 
(Life Technologies, Carlsbad, CA, USA) by pipetting the solution up and down several times 
and incubating the suspension for 15 min at 55 °C. The concentration and quality of the cellular 
RNA were assessed by the absorbance ratio at 260 nm and 280 nm on the NanoDrop 2000c 
spectrophotometer (Thermo Scientific, Wilmington, DE, USA). The integrity of the RNA was 
analyzed by electrophoresis on a 2% agarose gel, following the method described in Section 
3.2.6.2. 
 
3.5.3.2  Quantitative Real-Time PCR (qRT-PCR) 
 
The efficiency of HER2/neu siRNA interference was evaluated by qRT-PCR which serves to 
indicate the gene knockdown at the mRNA level. The total RNA was converted into cDNA by 
reverse transcriptase PCR using the High Capacity cDNA Reverse Transcription (RT) Kit with 
RNase inhibitor (Life Technologies, Carlsbad, CA, USA), following the manufacturer’s 
protocol. The kit components were mixed to afford a 2× RT master mix per 20 μL reaction 
(Table 3.7). The cDNA RT reactions were prepared by mixing 10 μL 2× RT master mix and 10 
μL (~0.2 μg μL
-1
) total RNA sample in RT-PCR strip tubes. The tubes were sealed and briefly 
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centrifuged to spin down the contents and to eliminate any air bubbles. Reactions with no 
MultiScribe
TM
 reverse transcriptase were included as negative controls in each run. The reverse 
transcription was performed in three phases: step 1 - 25 °C (10 min); step 2 - 37 °C (120 min); 
and step 3 - 85 °C (5 min) on a Bio-Rad C1000 Touch
TM 
Thermal Cycler. Thereafter the cDNA 
products were stored at 4 °C. 
 
Table 3.7: High Capacity cDNA Reverse Transcription Kit components required to prepare 2× RT master 
mix  
 
Component Volume per reaction (μL) 
10× RT buffer 2.0 
25× dNTP mix (100 mM) 0.8 
10× RT random primers 2.0 
MultiScribe
TM
 reverse transcriptase  1.0 
RNase inhibitor  1.0 
Nuclease-free H2O 3.2 
Total per reaction 10.0 
 
Abbreviations: RT: Reverse Transcription; dNTP: deoxyribonucleotide triphosphate. 
 
Next, gene expression was quantified by qRT-PCR using the TaqMan
®
 gene expression assays 
which are FAM
TM
 dye-labelled and possess minor-groove binding (MGB) probe. The primers 
and probe used were the gene of interest HER2/neu (Assay ID Hs01001580_m1) and the 
endogenous control glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Assay ID 
Hs03929097_g1) (Life Tachnologies, Carlsbad, CA, USA). Singleplex PCR reactions were 
conducted as triplicates for all samples tested. Each reaction mixture (20 μL) contained 10 μL 
TaqMan
®
 gene expression master mix [AmpliTaq Gold
®
 DNA polymerase, deoxyribonucleotide 
triphosphates (dNTPs) with deoxyuridine triphosphate (dUTP), UP (Ultra Pure), Uracil-DNA 
Glycosylase (UDG), ROX
TM
 Passive Reference, as well as buffer components optimized for 
specificity, sensitivity and precision], 1 μL 20× TaqMan
®
 gene expression assay mix, and 9 μL 
sample cDNA. Reaction mixtures were prepared and mixed in MicroAmp
®
 Fast optical 96-well 
reaction plates and covered with MicroAmp
®
 Optical Adhesive Films. The qRT-PCR 
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amplification was performed under the following conditions: initial setup 95 °C for 10 min 
(hold), followed by 40 cycles of 95 °C for 15 s (denature) and 60 °C for 1 min (anneal/extend) 
on a CFX 96
TM
 Real-Time System, C1000 Touch
TM 
Thermal Cycler using CFX Manager 
Software version 3.0 (Bio-Rad). Relative expression values of HER2/neu mRNA normalized to 
the level of GAPDH mRNA were determined using the 2
-∆∆Ct
 method (Livak and Schmittgen, 
2001). 
 
Fold difference = 2
-∆∆Ct 
∆Ct sample - ∆Ct calibrator = ∆∆Ct 
Ct GOI 
s
 - Ct norm 
s
 = ∆Ct sample 
Ct GOI 
c
 - Ct norm 
c
 = ∆Ct calibrator 
 
In the above equation, s represents the sample, c the calibrator (untreated cells), GOI the gene of 
interest HER2/neu, and norm the normalizer gene GAPDH. 
 
3.5.4 Protein extraction and Western blotting 
 
3.5.4.1 Protein extraction 
 
The extraction of total cellular proteins was performed 72 h after transfection, using the 
ReadyPrep
TM
 Protein Extraction Kit (Total Protein), following the manufacturer’s specifications 
(Bio-Rad, Hercules, CA, USA). The complete growth medium was aspirated from each well and 
1 mL of complete 2-D rehydration/sample buffer 1 [7 M urea, 2 M thiourea, 1% (
w
/v) ASB-14 
detergent, 40 mM Tris base, and 0.001% Bromophenol Blue] containing 10 μL of ReadyPrep 
tributylphosphine (TBP, 200 mM) reducing agent were added. The cells were lysed by gently 
‘scraping’ the bottom surface of the plate and then manually mixing the solution with a pipette 
several times. The samples were transferred into pre-cooled 2 mL microcentrifuge tubes and 
placed on ice for 1 min. To facilitate disruption of the cells and fragmentation of the genomic 
DNA, the suspension was vortexed for a total of 15 min and routinely chilled on ice every 3 min. 
The tubes were then centrifuged at 16 000 × g for 30 min at 18 °C to pellet cell debris. The 
supernatant, containing cellular proteins, was aspirated and transferred to clean microcentrifuge 
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tubes, and then quantified using a NanoDrop 2000c spectrophotometer (Thermo Scientific, 
Wilmington, DE, USA).  
 
3.5.4.2 Western blotting 
 
The Western blotting technique was used to analyze HER2/neu protein expression in SKBR-3 
cells. For the sample preparation, ~20 μg of protein from total cell lysate were treated with an 
equal volume of 2× Laemmli sample buffer (4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 
0.004% bromophenol blue, and 125 mM Tris-HCl, pH 6.8) and heated at 95 °C for 5 min in a 14 
L digital temperature-controlled water bath (TriLab Scientific, Johannesburg, Gauteng, RSA). 





long shelf life pre-cast gel cassettes (Bio-Rad Laboratories, Richmond, CA, USA) were placed in 
a Bio-Rad Mini-PROTEAN
®
 Tetra System, and the integrated upper buffer chamber was filled 
with chilled 1× Tris/Glycine/SDS running buffer [25 mM Tris, 190 mM Glycine and 0.1% (
w
/v) 
SDS, pH 8.3 (Bio-Rad Laboratories, Richmond, CA, USA)]. Each well was washed twice with 
running buffer. Thereafter, the lower buffer tank was filled with chilled 1× Tris/Glycine/SDS 
running buffer to the marked fill line. The protein samples were loaded into the wells and 





 Basic, USA). Three μL of the molecular weight marker (Precision Plus Protein
TM
 
Dual Extra Standards) was loaded into the first well.  





 transfer system and RTA transfer kits following the manufacturer’s 
protocol. The PVDF membranes were immersed in absolute ethanol until the membranes were 





 transfer buffer). Two transfer stacks (7 layers of filter pads each) 
were soaked in 50 mL of 1× transfer buffer for 3 min. The transfer cassettes were assembled in 
sandwich like order: one wetted stack was placed on the bottom of the cassette [serves as bottom 
ion reservoir on cassette electrode (anode)], PVDF membrane and gel, and the second wetted 
transfer stack on top of the gel [serves as top ion reservoir on cassette electrode (cathode)]. The 
assembled sandwich was made even and trapped air bubbles were expelled using a blot roller. 
The cassettes were tightly locked and placed in the instrument blotter bay. Transfer was 
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conducted at 2.5 A, 25 V for 10 min to promote high Mw transfer (> 150 kDa). After the 
transfer, the blotting sandwich was dissembled and both the blot and the gel were placed in 
deionized water.  
Prior to antibody incubation, unoccupied sites on the blot were saturated in a solution of 
3% blotting-grade blocker (non-fat dry milk) in Tris-buffered saline (20 mM Tris-HCl, pH 7.5, 
150 mM NaCl) containing 0.1% Tween 20 (TBST) for 1 h at room temperature. The membranes 
were incubated overnight at 4 °C in TBST containing either Neu, a mouse monoclonal antibody 
raised against a synthetic peptide corresponding to amino acids 1242-1255 of human Neu 
(1:5000) for HER2/neu protein detection, or β-Actin, a mouse monoclonal antibody raised 
against gizzard Actin of avian origin (1:200) used as an internal control for protein loading. The 
following day, the primary antibody was poured out and the membranes were washed in 20 mL 
TBST with continuous agitation for 5 min (total of 5 washes). Thereafter, the membranes were 
incubated at room temperature in goat anti-mouse IgG-HRP secondary antibody (1:2000) 
prepared in TBST. After 1 h, the secondary antibody solution was poured out and the membranes 
were washed again in 20 mL TBST with continuous agitation for 5 min (total of 5 washes).  
The membranes were developed using the commercially available Clarity
TM
 Western ECL 
substrate kit (Bio-Rad Laboratories, Richmond, CA, USA) following the manufacturer’s 
instructions. The membranes were placed, protein side up, on a clear surface and the substrate kit 
components [mixed in a 1:1 ratio (12 μL)] were gently added onto the blot ensuring that no air 
bubbles were formed and that the blot was completely covered with substrate. The blots were 
incubated for 5 min at room temperature and then visualized using the Bio-Rad digital imager 
ChemiDoc
TM
 MP system. Band intensity was determined using Image Lab Software version 
5.2.2. 
 
3.6 Statistical Analysis 
 
Data are presented as means ± SD (n = 3). Statistical analysis among mean values was performed 
using one-way ANOVA followed by the Tukey-Kramer multiple comparisons test between 
formulations. All statistics were performed using a 95% confidence interval and was considered 
significant when the P value was less than 0.05 (P<0.05). 












































4.1 Liposome/Lipoplex Formulation 
 
Two previously synthesized amphiphilic cholesterol derivatives bearing cationic charges were 
used to formulate the cationic liposomes (Singh and Ariatti, 2006; Singh et al., 2001). As 
illustrated in Figure 4.1 (A) and (B), cytofectins comprise four functional units: (1) a lipophilic 
anchorage system which is a large hydrocarbon moiety referred to as the non-polar or lipid tail; 
(2) a hydrophilic cationic head group capable of binding with the negatively charged phosphate 
backbone of the nucleic acids; (3) a spacer arm for the distancing of an anchor and cationic head 
group; and (4) a linker group connecting these modules (hydrophobic and hydrophilic domains). 
Both CCCs, Chol-T and MS09, were previously synthesized from cholesteryl chloroformate. 
They were designed to harbour a common cationic amine (R3NH
+
) functionalized head group 
and a fused lipophilic ring system, but differed in the length of the cytofectin spacer elements 




Figure 4.1: Structural representation of the cholesteryl cytofectins. (A) 3β-[N-(N', N'-dimethyl- 
aminopropane)-carbamoyl] cholesterol (Chol-T) and (B) N, N-dimethylaminopropylaminylsuccinyl 






4.1.1 Conventional and PEGylated cationic liposome components and formulation 
 
Liposome preparation techniques and the delicate physicochemical interactions amongst the 
various synthetic lipid classes are fundamental steps that govern the properties of cationic 
liposomes. Recently, in a review by Patil and Jadhav (2014), procedures for liposome 
preparation were divided into: (a) film methods which involved the deposition of lipids from an 
organic solvent onto a substrate and subsequent hydration of the film resulting in the formation 
of liposomes, and (b) bulk methods where liposomes are attained by transfer of phospholipids 
from an organic phase into an aqueous phase. In this study, six liposome formulations which 
included a synthetic CCC (Chol-T or MS09) for binding the negatively-charged nucleic acid 
(siRNA or pDNA) and a helper lipid (DOPE) were prepared using the dry-film method, first 
described by Bangham et al. (1965). The procedure involved dry-filming the phospholipids from 
solution in chloroform onto the sides of glass quickfit tubes, followed by hydration in sterile 
HBS. A constant concentration (2 mM) of the cytofectin (Chol-T or MS09) was retained in the 
preparation of all liposomes. The choice of bilayer components and optimization of formulation 
aspects determine the molecular fluidity or rigidity, interfacial elasticity and hydration of the 
resultant liposomes. In general, the bilayer thickness and Tm depend on the acyl chain length, and 
the bilayer fluidity is controlled by the acyl chain saturation (Kohli et al., 2014). With regard to 
cholesterol and cholesterol-containing derivatives, they do not readily form lipidic bilayer 
assemblies on their own. These molecules, due to their amphipathic structural property, permit 
their insertion into liposomes. Cholesterol is able to promote and stabilize homogeneous 
liposomal bilayers, thereby offering some degree of protection from mechanical fracture and 
protein binding (Yang et al., 2013c). Incorporation of cholesterol into liposome preparations was 
found to enhance the resistance of lipid-based carriers to serum-induced aggregation (Han et al., 
2008). In addition, formulations containing elevated quantities of cholesterol are not prone to 
metabolic degradation (Pozzi et al., 2012; Zhang et al., 2008). 
Cellular uptake and endosomal escape are two major barriers which need to be overcome 
in order to achieve efficient transgene expression. In a number of publications, Ewert et al. 
(2002; 2004; 2005; 2006) expatiated on the relationship between transfection efficacy and the 
supramolecular structures of lipoplexes using small angle X-ray scattering (SAXS). The merging 
of two lipid membranes (e.g. liposomal and endosomal membrane fusion) is mediated by a 
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lamellar phase (Lα) to inverted hexagonal phase (HII) transition (Gruner et al., 1985). This is 
accomplished by the amphiphile’s capacity to assume certain geometries when suspended in an 
aqueous environment. The phase structure of cationic lipids can be predicted as a function of 
their packing parameter; defined by the ratio of the hydrocarbon volume over the product of the 
hydrophilic head group area, and the critical length of the hydrophobic tail (Wasungu and 
Hoekstra, 2006). Lipids possessing a small hydrocarbon cross section area with a large head 
group (P < ½), form typical cone-shaped monomers, and self-assemble into micelles 
corresponding to a structure exhibiting positive membrane curvature. The formation of lipid 
bilayers or Lα structures is enhanced when the curvature of the self-assembled amphiphiles is 
negligible (½ < P > 1). In contrast, when P exceeds 1, the lipid tends to display a negative 
curvature, adopting the inverted hexagonal phases or inverted micelles (i.e., bilayer destabilizing 
structure) (Hsu et al., 2005; Šmisterová et al., 2001). Research suggests that liposomal 
formulations supplemented with the neutral or zwitterionic phospholipid, DOPE can 
significantly improve the transfection efficiency of cationic lipids (Farhood et al., 1995; Felgner 
et al., 1987; 1994; Zuhorn et al., 2002). DOPE is therefore referred to as a ‘helper’ co-lipid. In 
this study, DOPE was employed to further enhance the membrane fusion capacity of the cationic 
liposomes. Importantly, cationic liposomes that require DOPE as a helper do not exhibit HII 
formation when the lipids are mixed; they form ordered Lα structures.  In addition, supportive 
lipids like DOPE contribute to bilayer assemblies with cationic lipids that do not naturally 
display such properties (cationic lipids that repel each other) (ur Rehman et al., 2013a). Owing to 
its zwitterionic head, DOPE is pH sensitive; above pH 9.0 DOPE monomers form spherical 
micelles. However, when exposed to an acidic pH, a structural transition occurs forming an 
inverted hexagonal phase (Mochizuki et al., 2013). Internal endosomal environments (generally 
encountered on the transfection route) are characteristic of low pH ranges, allowing DOPE to 
undergo this phase change. Due to the propensity of DOPE to adopt an inverted hexagonal 
phase, this cone-shaped neutral lipid is known to play a critical role in membrane fusion within 
endosomes, thereby inducing strong destabilizing effects on the barrier properties of the 
endosomal membranes. Therefore, cationic liposomes containing DOPE promise effective lipid-
mediated siRNA gene delivery. 
In addition to formulating conventional liposomes featuring the CCCs (Chol-T and 
MS09), this study also investigated steric stabilization of the liposomes. Polyethylene glycol 
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(PEG) is arguably the most common hydrophilic, biocompatible and inert polymer currently 
employed to improve water solubility; prevent unspecific interactions with charged serum 
proteins (aggregation); and increase serum stability of cationic liposomes. PEGylated cationic 
liposomes were prepared by simply mixing solutions of the commercially available PEG-
conjugated lipid (DSPE-PEG2000), with the cationic cytofectin (Chol-T or MS09) and DOPE. 
Liposomes were formulated with 2 or 5 mol.% DSPE-PEG2000, Chol-T and MS09 were kept 
constant at 50 mol.%, and DOPE was adjusted to accommodate changes in PEGylation. This 
method of preparing PEGylated complexes is termed pre-PEGylation. The procedure entails 
inclusion complexation formation, as PEGylation occurs prior to lipoplex formation with pDNA 
or siRNA. PEGylation of conventional liposomes can occur with PEG chains of varying graft 
densities and length. DSPE-PEG2000 was incorporated into the liposomal mixture as this 
molecular weight PEG has been reported to optimize blood circulation times of liposomes (Pozzi 
et al., 2014; Zhang et al., 2012). 
 
4.2  Biophysical Characterization of Liposome and Liposome-Nucleic Acid Interactions 
 
4.2.1 Morphological observations using cryo-TEM 
 
Morphological and architectural characterization of liposomes and lipoplexes leads to a clearer 
understanding of their relative structure, orientation of the nucleic acid molecules, and 
arrangement of the complexes. The ultrastructure of cationic liposomes and lipoplexes was 
visualized by cryo-TEM, which enables direct examination of colloidal carriers in the vitrified, 
frozen-hydrated state. Transmission electron microscopy uses an electron gun and a system of 
electromagnetic lenses to focus an electron beam on a sample. Since electrons are easily 
refracted, the microscope column is maintained under high vacuum to avoid deflection of 
electrons by gas molecules (Kuntsche et al., 2011). The contrast is obtained by the interaction of 
the electrons with the specimen, during which the electrons are transformed to unscattered 
electrons, elastically scattered or inelastically scattered electrons. A series of electromagnetic 
lenses is then used to focus the unscattered or scattered electrons on a screen in order to generate 
a phase-contrast image (Lin et al., 2014). The sample preparation for cryo-TEM imaging is a 
rather sensitive process since electrons do not easily penetrate matter. To provide high contrast, a 
86 
 
negative stain containing a heavy metal salt (uranyl acetate) was used to stain the sample 
(Kuntsche et al., 2011). Basically, the stain allows the indicative evaluation of the liposomal 
structure by binding to the phosphate groups of phospholipids and poorly penetrating the lipid 
bilayer. Therefore, the outer surface of the liposome or lipoplex is black whilst the inner aqueous 
core is white (Ruozi et al., 2011). After drying, the sample was plunge frozen in liquid nitrogen; 
this technique preserves the biological material in the liposome/lipoplex inner core and also 
limits the formation of amorphous ice crystals (Friedrich et al., 2010). 
Figure 4.2 presents selected cryo-TEM micrographs of the Chol-T liposomes [(A) to 
(C)] and MS09 liposomes [(D) to (F)]. The images revealed a heterogeneous population of 
typically spherical or ellipsoidal shaped structures with a distinct bilayered membrane 
surrounding the internal aqueous core. The cationic liposomes appeared well dispersed with little 
aggregation. The majority of the liposomes appeared electron dense (dark regions), while some 




Figure 4.2: Transmission electron micrographs of cationic and PEGylated cationic liposomes prepared 
according to Table 1: A, Chol-T:DOPE; B, Chol-T:DOPE:2% PEG; C, Chol-T:DOPE:5% PEG; D, 
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In particular, two factors influence the bright/dark contrast in cryo-TEM images; (1) the atom 
positioning in the crystalline structure, and (2) the atomic number (Belletti et al., 2013; Rao and 
Biswas, 2009). In these samples it can be hypothesized that the presence of looped, twisted and 
invaginated structures is due largely to the amorphous nature or flexibility of the liposomal 
membranes (i.e., lipid reorganization). Moreover, liposomes formulated with cationic lipids 
bearing a longer spacer (MS09) revealed multi-lamellar liposomal vesicles, indicating that the 
morphology of the liposomes was influenced by the spacer length. A certain degree of distortion 
of the original vesicular structure was also observed. Although this electron microscopic 
technique allows direct investigations of thin transparent samples in their frozen-hydrated state, 
processes like staining, freezing and drying may result in possible artifacts and morphological 
changes accompanied by a reorganization of the fragile liposome vesicle (Kuntsche et al., 2010; 
2011; Wessman et al., 2010). Dehydration of the samples under vacuum may result in an 
osmotic imbalance between the liposome core and the outer aqueous phase causing vesicle 
deformation and bilayer invaginations (Kuntsche et al., 2011). All liposome preparations 
containing increasing mol.% of PEGylation (0% to 5%) were similar with no obvious effects on 
liposomal morphology. It is important to note, however, that surface modifications of liposomal 
vesicles with PEG-chains are not visible in cryo-TEM images due to the low contrast of 
polyethylene glycol (Kuntsche et al., 2011). The PEGylated liposomes appeared as defined 
structures which are well separated. This implies that the PEG coating provided physical stability 
to the liposomes, thereby aiding in dispersing the particles and preventing close contact between 
the vesicles.  
Figure 4.3 represents cryo-TEM images of pCMV-luc-associated liposomes. The 
combination of non-PEGylated cationic liposomes and DNA [Figure 4.3, (A) and (D)] appeared 
as predominantly large dense non-spherical multi-lamellar aggregates with a varying number of 
individual lipoplex per aggregate. These heterogeneous assemblies with a twisted reorganization 
revealed a particulate surface coating as well as small cavities in the interior of lipoplexes, which 
are absent in the corresponding liposome micrographs. These observations suggest that the DNA 





Figure 4.3: Transmission electron micrographs of cationic and PEGylated cationic pCMV-luc plasmid 
DNA complexes (lipid:pCMV-luc (+:–) charge ratios): A, Chol-T:DOPE (1.6:1); B, Chol-T:DOPE:2% 
PEG (1.7:1); C, Chol-T:DOPE:5% PEG (1.6:1); D, MS09:DOPE (1.7:1); E, MS09:DOPE:2% PEG 
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Moreover, these findings correlate with reports that have illustrated incongruent distribution of 
anionic DNA between bilayer membranes that tend to form concentric multi-layered structures 
or inverted hexagonal structures leading to the formation of small cavities on the surface of 
lipoplexes (Kapoor et al., 2012; Li et al., 2011). PEGylated pDNA lipoplexes appeared to have 
hazy indistinct edges and tended to aggregate to a lesser extent. This can be observed clearly in 
Figure 4.3 (E); the micrograph depicts few solitary uni-lamellar structures located at the 
periphery of aggregative structures. As mentioned previously, PEGylation provides steric 
stabilization by generating hydrated surfaces which ultimately reduces the surface-surface 
interactions and the aggregation of liposome-DNA complexes (Rangelov et al., 2010). 
As opposed to pDNA lipoplexes, both PEGylated and non-PEGylated siRNA-liposome 
complexes appeared as well defined spherical shaped structures with steady phase contrast 
[Figure 4.4]. The cryo-TEM images also revealed uni-lamellar complexes with distinct bilayered 
membranes. All lipoplexes appeared well dispersed and colloidally stable. The morphology of 
PEGylated liposome/siRNA complexes correlates with previous work in which PEGylated 
preformed liposomes formed small uni-lamellar vesicles with siRNA (Fenske and Cullis, 2008; 
Kim et al., 2010). However, micrographs obtained with the combination of siRNA and 
preformed non-PEGylated cationic liposomes differed from a previous report in which the 
siRNA self-assembled into multi-layered complexes (Desigaux et al., 2007; Weisman et al., 
2004). Therefore, it can be assumed that the siRNA was bound via electrostatic interactions to 





Figure 4.4: Transmission electron micrographs of cationic and PEGylated cationic liposome-siGENOME 
non-targeting siRNA complexes (lipid:siRNA (+:–) charge ratios): A, Chol-T:DOPE (3.9:1); B, Chol-
T:DOPE:2% PEG (6.3:1); C, Chol-T:DOPE:5% PEG (8.8:1); D, MS09:DOPE (5.4:1); E, 











4.2.2 Particle size distribution and zeta potential analysis 
 
The route of circulation and navigation of any lipid-based nanoparticle being developed for in 
vivo application is almost exclusively determined by the particle size distribution, lipid 
component variation and the physicochemical surface properties. The size of the particle has a 
great influence on its intrinsic propensity for site- and cell-specific localization as well as cellular 
interaction and uptake. Moreover, optimal particle size (50 - 250 nm) is a prerequisite to bypass 
elimination and clearance by the RES (Lorenzer et al., 2015; Resnier et al., 2013).  
Dynamic light scattering (DLS) using the Photon Correlation Spectroscopy (PCS) 
technique was used to determine three principal physical characteristics of liposomal 
formulations alone, and of their lipoplexes formed with pDNA or siRNA: hydrodynamic size of 
the particles (diameter); particle size distribution (polydispersity index, PDI); and zeta potential 
(overall charge exhibited by a particle in suspension). The principle of DLS is based on the 
measurement of the time-dependent intensity fluctuations of laser light scattered from particles 
experiencing Brownian motion. Brownian motion is defined as the random movement of 
particles in solution, which results from collisions between suspended particles and surrounding 
solvent molecules. The intensity fluctuation trace comprises a combination of constructive and 
destructive interferences of the scattered light at a given angle. The hydrodynamic diameter and 
size distribution can be derived from analysis of the motion-dependent autocorrelation function 
according to the Stokes-Einstein equation (Brar and Verma, 2011; Lin et al., 2014; Troiber et al., 
2013). The zeta potential of the liposome/lipoplex was measured by the LDV technique, and the 
values were calculated from the mean electrophoretic mobility by applying the Smoluchowski 
approximation equation. The main strengths of DLS for physicochemical characterization, 
include its ability to make measurements in native environments in a non-invasive manner, 
precision in determining the hydrodynamic size of particles in an entire monodisperse 
suspension, analyzing samples in a wide range of concentrations as well as measuring diluted 
samples, with the added advantage of being more reproducible than other methods (Laouini et 
al., 2012; Lin et al., 2014). 
Table 4.1 summarizes the mean particle size, polydispersity indices and zeta potential 
profiles of the liposomes and lipoplexes [prepared at optimal lipoplex (N/P) ratio (+:‒)]. With 
regard to hydrodynamic diameters, DLS characterization of all liposome compositions and 
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lipoplexes revealed nanometer (nm) sized particles which were accompanied by moderate to 
narrow PDI (in brackets) as follows: 65.47 nm (0.269) to 127.07 nm (0.321) liposome samples; 
114.55 nm (0.229) to 237.31 nm (0.149) pDNA lipoplex samples; and 103.24 nm (0.128) to 
187.97 nm (0.127) siRNA lipoplex samples. These measurements indicate that the colloidal 
suspensions are fairly stable and homogeneous and are within the range generally considered 
ideal for both cellular uptake and systematic circulation (Kapoor et al., 2012; Mével et al., 2010). 
Prior to complex formation with pDNA or siRNA, both Chol-T and MS09 liposomes had a 
particle size below 130 nm. However, the sizes of the lipoplexes were much larger (up to 237.31 
nm) than their corresponding liposomes. This might be due to the binding of the nucleic acid on 
the liposome surface which is in contrast with the entrapment of nucleic acid inside the 
liposomes. Of particular interest, the siRNA lipoplexes were smaller in size (except Chol-T 5% 
PEG) and had a lower PDI than the corresponding pDNA complexes. The largest lipoplexes 
were formed with non-PEGylated Chol-T liposomes at the following charge ratios: pDNA (1.6:1, 
+:‒) and siRNA (3.9:1, +:‒), with pDNA lipoplexes exhibiting greater hydrodynamic diameters 
than siRNA lipoplexes. This suggests that the formation of large lipoplexes occurred when the 
charge of the liposome was neutralized. Zhang et al. (2010) observed a similar trend with 
cationic complexes at various N/P ratios and reported larger lipoplexes at near neutral charge 
(low N/P ratio). 
Confirmed size measurements also suggested a significant decrease in particle size and 
narrow size distributions of Chol-T and MS09 liposomes when PEGylation was introduced at 
2%, and then increased to 5% in liposomal formulations. The primary role of PEG is to facilitate 
the self-assembly of lipid molecules, thereby stabilizing the liposome bilayers. The decrease in 
size may be attributed to the strong inter-bilayer repulsion that can overcome the attractive van 
der Waals forces, thus providing a steric barrier at the surface of nascent liposomes. PEG chains 
on the liposomal surface provide steric stabilization, which is known to prevent vesicle 
aggregation and encourage the formation of a homogeneous population of smaller liposomes 
with colloidal stability and biocompatibility (Kenworthy et al., 1995; Needham et al., 1992). 
Complex formation with pDNA or siRNA to form lipoplexes shifted the population toward 
larger vesicle sizes and wider size distributions compared to the non-PEGylated preparations. 
Once more, lipoplexes containing PEG afforded significantly smaller vesicles indicating the 
stabilization effect offered by PEG. Many formulation optimization studies have demonstrated 
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that the capacity of PEGylated liposomes to prevent inter-particle aggregation depends largely on 
the degree of surface coverage and the distance between graft sites. This, in turn, hinges on the 
molecular mass and concentration of the polymer, as well as the graft density (de Gennes, 1980; 
1987; Dos Santos et al., 2007; Immordino et al., 2006). 
Interestingly, with both Chol-T and MS09 siRNA lipoplexes PEGylation at 2 mol.% 
formed complexes which were stable (PDI ~0.2) and slightly smaller in diameter than lipoplexes 
containing a 5 mol.% of DSPE-PEG2000. As described in Section 2.11.1, when tethered on the 
surface of liposomes, PEG chains display various conformations depending on the PEG chain 
density. It has been documented that the PEG2000 chain extends ~5.6 nm from the surface of a 
liposome, and at polymer concentrations below 4 mol.% intermediate random coil-like 
“mushroom” structures are favoured that, span a distance of ~3.5 nm (Garbuzenko et al., 2005; 
Gjetting et al., 2010; Wang and Thanou, 2010). Increasing the concentration (> 5 mol.%) of 
PEG, results in larger surface coverage and an increase in the lateral pressure between PEG 
mushrooms; favouring low-coiled “brush” conformations (lengthening between 10 nm to 15 nm) 
(Garbuzenko et al., 2005, Perrier et al., 2010; Yao et al., 2013). Hence, the influence of grafted 
PEG polymers on the hydrodynamic size of a liposome particle is mainly due to changes in the 
spatial organization of the PEG, which is reliant on the type of configuration favoured, i.e., 
“mushroom” or “brush” (Chen et al., 2011). In the case of Chol-T pDNA lipoplexes, those 
formulated with 2 mol.% PEG formed larger complexes. This is probably due to the “mushroom-
structured” PEG arrangement, which does not shield the cationic liposome as effectively as the 
5% “brush” configuration, leading to some aggregation of complexes.  
The measurement of zeta potential (ζ) is generally used to predict the long-term stability 
of colloidal systems and provides a very good index of the interaction magnitude between 
charged particles (Honary and Zahir, 2013; Wiese and Healy, 1970). In a colloidal suspension, 
the liquid layer surrounding the charged particle consists of two regions: an inner thin liquid 
layer termed the Stern layer, where the ions are strongly bound to the surface of the particle; and 
an outer diffuse layer containing loosely associated ions (Clogston and Patri, 2011). In the 
interior of the diffuse layer there is a notional margin in which the ions form a stable shear plane. 
When particles experience tangential motion (e.g., Brownian motion), the movement of charged 
particle shears ions migrating with the charged particles in the diffuse layer, and ions beyond the 
“margin” stay with the bulk dispersant. The electrokinetic potential on the shear plane (surface of 
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hydrodynamic shear) is the zeta potential, which is usually determined by measuring the velocity 
of the charged particle towards the electrode using methods such as the LDV electrophoresis 
technique (Lin et al., 2014; Sapsford et al., 2011). 
 
Table 4.1: ZetaSizer measurements of the various cationic/PEGylated cationic liposomes and 




















(mV) ± SD 
Chol-T 127.07 (0.321) 44.09 ± 10.56 237.31 (0.149) 49.15 ± 1.539 187.97 (0.127) 47.26 ± 5.39 
Chol-T 
2% PEG 
71.64 (0.304) 32.51 ± 11.02 162.11 (0.358) 38.60 ± 6.212 149.61 (0.227) 39.05 ± 8.16 
Chol-T 
5% PEG 
74.18 (0.136) –1.12 ± 4.818 120.22 (0.113) 19.03 ± 10.94 153.24 (0.109) 9.78 ± 1.13 
MS09 113.02 (0.348) 53.21 ± 4.329 206.08 (0.411) 35.22 ± 13.62 169.13 (0.326) 44.61 ± 7.56 
MS09 
2% PEG 
66.68 (0.136) 39.43 ± 1.185 114.55 (0.229) 27.46 ± 5.093 103.24 (0.218) 20.88 ± 3.052 
MS09 
5% PEG 
65.47 (0.269) 16.08 ± 3.799 156.19 (0.475) 40.84 ± 2.816 138.64 (0.337) 41.26 ± 9.79 
Abbreviations: Chol-T: 3β-[N-(N', N'-dimethylaminopropane)-carbamoyl] cholesterol; MS09: N, N-
dimethylaminopropylaminylsuccinylcholesterylformylhydrazide; PEG: Polyethylene glycol; DNA: 
Deoxyribonucleic acid; siRNA: Small interfering RNA; PDI: Polydispersity index; SD: Standard 
deviation. 
Note: Values are represented as mean, n = 3 
 
The zeta potential of the cationic liposomes was also measured, and formed part of the 
pharmacokinetic prolife. As indicated in Table 4.1, the zeta potential of the cationic liposomes 
was highly positive, Chol-T 44.09 ± 10.56 mV and MS09 53.21 ± 4.329 mV. There seemed to be 
no obvious effects or differences elicited by the specific CCCs on the zeta potential between 
liposomes or lipoplexes formulated with Chol-T and MS09. A zeta potential value of ± 30 mV is 
generally a prognostic of satisfactory particle stability, with sufficient barrier to prevent 
aggregation and flocculation (Laouini et al., 2012). Interestingly, the zeta potential of the 
cationic liposomes gradually decreased with increasing content of the negatively charged PEG 
lipid. A decrease of 11.58 mV (Chol-T) and 13.78 mV (MS09) was observed upon 2% 
PEGylation, and a further decrease of 33.63 mV (Chol-T) and 23.35 mV (MS09) was recorded 
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when PEGylated with 5% PEG. Upon complexation with anionic charged nucleic acids, the zeta 
potential of the lipoplexes maintained a relatively high positive charge ranging from 19.03 ± 
10.94 to 49.15 ± 1.539 (pDNA lipoplexes) and 9.78 ± 1.13 to 47.26 ± 5.39 (siRNA lipoplexes). 
There was no significant difference in zeta potential between each liposome and its 
corresponding lipoplex. With regard to cationic lipid based delivery systems, in vivo results have 
suggested that high levels of positive charge on the surface favour interaction with negatively 
charged plasmatic proteins forming aggregates which are recognized by the innate immune 
system (Resnier et al., 2013). PEG has been incorporated into liposomal surfaces to create 
artificially a negative hydrophilic and flexible shroud to mask the positive charges of the cationic 
head groups. Moreover, PEG is able to form dipole interactions with water which alters the zeta 
potential of lipid carriers (Vonarbourg et al., 2005). As observed, the change in zeta potential of 
the cationic liposomes containing PEG lipids confirms the presence of the polymer layer on the 
liposomal surface. 
It is also important for the carrier system to maintain some degree of positive charge to 
enable interaction with the anionic nucleic acid. The zeta potential of the liposomes containing 
2% PEG still remained highly positive (above 30 mV), indicating that the tethering of PEG on 
the liposomal surface offers good stability and also provides a suitable milieu for nucleic acid 
attachment. Sonoke et al. (2008) developed PEGylated cationic liposomes bearing highly 
positive charges which allowed prolonged in vivo circulation and protection of siRNA. They 
attributed the efficient delivery of siRNA to the effectual steric repulsion due to the high 
flexibility and hydrophilicity of PEG. 
 
4.3 Lipoplex Binding Affinity and Protection Efficiencies 
 
4.3.1 Electrophoretic mobility shift assay 
 
The pDNA or siRNA condensation induced by a nanocarrier system is a prerequisite for 
successful gene transfection. The capacity to condense nucleic acids and form lipoplexes with a 
minimum amount of cationic liposome was assessed by the conventional gel electrophoretic 
mobility technique, across a range of N/P (+:‒) charge ratios. When a constant amount of the 
anionic nucleic acid is efficiently bound to the cationic liposomal carrier, the formation of a 
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complex reduces the electrophoretic mobility of the nucleic acid through the gel matrix. During 
the run, the electric field enables unbound nucleic acid to migrate towards the cathode; whereas 
nucleic acids that have been completely incorporated into the structure of cationic liposomes 
result in an increase in the size and neutralization of their negative charge within the complexes, 
and are therefore unable to migrate into the gel matrix (lipoplexes remain within the wells). In 
order to optimize the charge ratio for transfection, positively charged liposomes were mixed with 
negatively charged pCMV-luc plasmid DNA or siRNA to form lipoplexes via electrostatic 
interaction at various lipid:pDNA/siRNA (
w
/w) or N/P (+:‒) ratios. The agarose gel migration 
patterns illustrated that all liposomal formulations were effective in binding both pDNA and 
siRNA, as evidenced by the retardation of the electrophoretic mobility of nucleic acids. Figure 
4.5 (pCMV-luc) and 4.6 (siRNA) show the nucleic acid complexation profiles of the various 
cationic liposomal preparations. 
The pDNA control lane containing 1 µg of uncomplexed pCMV-luc DNA produced three 
distinctive conformations: nicked circular (least migration from well), linearized and supercoiled 
helical (migrates the furthest). The siRNA control lane containing 0.32 µg of naked siRNA, on 
the other hand, appeared as a single band. The lipid:pDNA/siRNA or N/P (+:‒) charge ratios at 
which the cationic liposomes were able to fully retard nucleic acid mobility are summarized in 
Table 4.2. As can be seen in Figure 4.5, between N/P ratios of 6:1 and 8:1 (+:‒), the anionic 
pDNA was entirely neutralized by the gradual increase in cationic liposome, resulting in 
complete DNA condensation. At these N/P ratios, lipoplexes were retained in the wells and no 
further migration of the pDNA was observed. This is known as the point of electroneutrality and 
commonly referred to as the end-point. The migration pattern of siRNA [Figure 4.6] changed at 
a charge ratio (+:‒) of 3.9:1 (Chol-T) and 5.4:1 (MS09). Below these ratios, the band fluoresced 
brightly and then gradually lightened until the band completely disappeared, signifying that the 
negatively charged siRNA was neutralized entirely at the respective N/P charge ratios. Beyond 
these charge ratios, no migration of siRNA was detected for non-PEGylated lipoplexes. 
Interestingly, all lipoplexes were capable of retarding the same amount of pDNA (1 μg) and 
siRNA (0.32 μg) at various N/P ratios despite the concentration of the cationic cytofectin (Chol-













Charge ratio [N/P (+:‒)] 
DNA siRNA DNA siRNA 
Chol-T 6 : 1 14 : 1 1.6 : 1 3.9 : 1 
Chol-T 2% PEG 7 : 1 24 : 1 1.7 : 1 6.3 : 1 
Chol-T 5% PEG 7 : 1 37 : 1 1.6 : 1 8.8 : 1 
MS09 7 : 1 21 : 1 1.7 : 1 5.4 : 1 
MS09 2% PEG 8 : 1 25 : 1 1.8 : 1 6.0 : 1 
MS09 5% PEG 8 : 1 36 : 1 1.7 : 1 7.9 : 1 
Abbreviations: Chol-T: 3β-[N-(N', N'-dimethylaminopropane)-carbamoyl] cholesterol; MS09: N, N-
dimethylaminopropylaminylsuccinylcholesterylformylhydrazide; PEG: Polyethylene glycol; DNA: 
Deoxyribonucleic acid; siRNA: Small interfering RNA. 
The theoretical N/P (+:‒) ratio represents the charge ratio of cationic lipid to nucleotide. Values were 
calculated assuming one positive charge per cytofectin molecule at pH 7.5 and one negative charge per 
nucleotide (average mass 330 Da).  
 
The inference, therefore, is that the differences in binding affinities among the various lipoplex 
suspensions were most likely due to the incorporation of PEG polymers. As described previously 
in Section 4.2.2 the reduced zeta potential values indicate that PEGylation reduced the surface 
charge of liposomes. The partial masking of the positive charges by PEGylation thus resulted in 
a reduction of cationic charge available for nucleic acid binding. This phenomenon can be 
observed clearly with the siRNA lipoplexes that had a far higher N/P charge ratio [from 6.3:1 to 
8.8:1 (Chol-T) and 6.0:1 to 7.9:1 (MS09); 2% to 5% PEG, respectively]. Ultimately, greater 
amounts of the PEGylated liposomes were required to fully bind siRNA compared to the non-
PEGylated liposomes, demonstrating a relatively weaker affinity toward the siRNA. 
Interestingly, MS09 cationic liposomes containing 5% PEG were able to gradually retard siRNA 


















Figure 4.5: Gel retardation analysis of binding interaction between varying amounts of cationic and 
PEGylated cationic liposome preparations with pCMV-luc plasmid DNA (1 μg) in HBS. A, lanes 1-8 (0, 
2, 3, 4, 5, 6, 7, and 8 μg Chol-T); B, lanes 1-8 (0, 3, 3.5, 4, 5, 6, 7, and 8 μg Chol-T 2% PEG); C, lanes 1-
8 (0, 3, 4, 5, 6, 7, 8, and 9 μg Chol-T 5% PEG); D, lanes 1-8 (0, 2, 3, 4, 5, 6, 7, and 8 μg MS09); E, lanes 
1-8 (0, 4, 5, 6, 7, 8, 9, and 10 μg MS09 2% PEG); F, lanes 1-8 (0, 4, 5, 6, 7, 8, 9, and 10 μg MS09 5% 
PEG). (     ) indicates end point ratios or point of electroneutrality.  
 
Figure 4.6: Gel retardation analysis of binding interaction between varying amounts of cationic and 
PEGylated cationic liposome preparations with siRNA (0.32 μg) in HBS. A, lanes 1-8 (0, 3.20, 3.52, 3.84, 
4.16, 4.48, 4.80, and 5.12 μg Chol-T); B, lanes 1-8 (0, 6.08, 6.40, 6.72, 7.04, 7.36, 7.68, and 8.00 μg 
Chol-T 2% PEG); C, lanes 1-8 (0, 10.56, 10.88, 11.20, 11.52, 11.84, 12.16, and 12.48 μg Chol-T 5% 
PEG); D, lanes 1-8 (0, 5.44, 5.76, 6.08, 6.40, 6.72, 7.04, and 7.36 μg MS09); E, lanes 1-8 (0, 6.08, 6.40, 
6.72, 7.04, 7.36, 7.68, and 8.00 μg MS09 2% PEG); F, lanes 1-8 (0, 9.60, 9.92, 10.24, 10.56, 10.88, 
11.20, and 11.52 μg MS09 5% PEG). (    ) indicates end point ratios or point of electroneutrality. (     ) 
indicates no clear end point.   
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It has been suggested that mixing preformed cationic liposomes with a siRNA solution to form 
lipoplexes negatively impacts cationic liposomes containing higher PEG densities on their 
surfaces. The likely explanation is that high PEG densities form ‘brush borders’ on the surface of 
liposomes. This structural feature of highly PEGylated liposomes prevents the formation of 
siRNA sandwiching lipid multilayers since the siRNA becomes loosely bound to the outer 
surface of such PEGylated liposomes (Buyens et al., 2009; 2012; Desigaux et al., 2007). 
 
4.3.2  Nuclease protection assay 
 
Following systemic administration, the protection of nucleic acids (DNA or siRNA) against 
enzymes in circulation, is crucial to maintain the integrity of the genetic material, so that their 
effects can be met at the transcriptional and/or translational level. Upon in vivo administration, 
lipoplexes are immediately surrounded by high concentrations of free charged serum 
components that interact with the particles (Caracciolo, 2015; Kawakami and Hashida, 2007; 
Tranchant et al., 2004). Such interactions are driven either by a potential energy gradient or by 
diffusion, resulting in a variety of dynamic changes (Lynch and Dawson, 2008; Rocks and 
Dawson, 2014; Walkey and Chan, 2012). The serum proteins interacting with the complexes 
establish a protein rich environment around the surface of each particle, termed the protein-
corona (refer to Section 2.11.1). A number of studies have detailed the various ways in which 
serum components affect nucleic acid containing nanocarriers. The protein corona can lead to 
changes in size through aggregation, zeta potential due to surface charge neutralization, and 
other related surface characteristics which destabilize the lipoplex structure (Li et al., 1999; 
Lundqvist et al., 2008; Scholz and Wagner, 2012; Zelphati et al., 1998). Furthermore, the 
presence of charged serum components may induce dissociation of the lipoplexes, leading to 
irregularities in the lipid bilayers or to vesicle disruption. This in turn exposes the nucleic acid to 
intrinsic enzymatic degradation or rapid opsonization (Audouy et al., 2000; Buyens et al., 2008). 
Despite their importance, studies on in vitro transfection behaviour in the presence of biological 
fluids (serum, for example) are limited, resulting in inconclusive extrapolations and poor 
correlations between in vitro and in vivo transfection efficiencies.  
Therefore, assessing the ability of a liposomal carrier system to protect its nucleic acid 
consignment is of paramount importance, since any factor which increases its circulation time is 
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critical for high transfection efficiencies. To examine the protective capabilities of the 
formulated cationic liposomes against serum nucleases in vitro, the lipoplexes were incubated in 
FBS (10%, 
v
/v) at physiological temperature for 4 h and subjected to an electrophoretic analysis. 
FBS is a heterogeneous fluid prepared from blood plasma in which the blood cells and 
fibrinogens have been extracted. It contains various biological macromolecules: albumin, 
immunoglobulins, apolipoproteins, glycoproteins, lipases, nucleases, fibronectin as well as small 
molecules such as amino acids, vitamins and inorganic salts. In particular, albumin (the most 
abundant protein) has been reported to destabilize both charged and neutral liposomes (Chonn et 
al., 1992). In general, siRNA is more sensitive to nucleolytic degradation owing to the 2' OH 
group of ribose, whereas DNA is less prone to alkaline hydrolysis (Kapoor et al., 2012). Naked 
siRNAs exposed to plasmatic enzymes having a dsRNA binding domain were completely 
degraded within 30 min into the bloodstream (White, 2008). As mentioned previously, despite 
the fact that liposomes offer protection to their gene cargo, disruption of the lipoplex structure 
will trigger release of the bound nucleic acid and subsequent degradation. Therefore, liposomes 
have to not only safeguard their gene cargo from serum, but also to form a strong enough 
interaction with the nucleic acids to enable delivery in a serum-resistant manner. 
Results from nuclease protection assays are presented in Figure 4.7 (pCMV-luc plasmid 
DNA) and Figure 4.8 (siRNA). In these studies two controls were included, viz., control 1 = 
untreated naked pCMV-luc; untreated naked siRNA (Figure 4.7 and 4.8 A, B, C; lane 1) and 
control 2 = naked pCMV-luc treated with 10% FBS; naked siRNA treated with 10% FBS 
(Figure 4.7 and 4.8 A, B, C; lane 2]. These were assigned positive and negative controls 
respectively and were used to assess the degree of serum nuclease digestion of both treated and 
untreated nucleic acids compared to those in association with cationic liposomes. From the gel 
patterns, untreated naked pDNA preparation produced three species of DNA in the plasmid, viz. 
low mobility nicked circular form, linearized form and high mobility compact supercoiled helical 
form. The untreated naked double stranded siRNA appeared as a single band. Based on EtBr 

















Figure 4.7: Nuclease protection assay of cationic and PEGylated cationic liposome-pDNA complexes in 
the presence of 10% FBS. Reaction mixtures (10 μL) contained pCMV-luc (1 μg) and varying amounts of 
liposome suspension. A, lanes 3-5 (5, 6, 7 μg Chol-T): lanes 6-8 (6, 7, 8 μg MS09); B, lanes 3-5 (6, 7, 8 
μg Chol-T 2% PEG): lanes 6-8 (6, 7, 8 μg Chol-T 5% PEG); C, lanes 3-5 (7, 8, 9 μg MS09 2% PEG): 
lanes 6-8 (7, 8, 9 μg MS09 5% PEG). In A-C, lane 1: FBS-untreated naked pCMV-luc plasmid DNA (1 















Figure 4.8: Nuclease protection assay of cationic and PEGylated cationic liposome-siRNA complexes in 
the presence of 10% FBS. Reaction mixtures (10 μL) contained siRNA (0.2 μg) and varying amounts of 
liposome suspension. A, lanes 3-5 (2.4, 2.8, 3.2 μg Chol-T): lanes 6-8 (3.8, 4.2, 4.6 μg MS09); B, lanes 3-
5 (4.4, 4.8, 5.2 μg Chol-T 2% PEG): lanes 6-8 (7.0, 7.4, 7.8 μg Chol-T 5% PEG); C, lanes 3-5 (4.6, 5.0, 
5.4 μg MS09 2% PEG): lanes 6-8 (6.8, 7.2, 7.6 μg MS09 5% PEG). In A-C, lane 1: FBS-untreated naked 
siRNA (0.2 μg) (control 1) and lane 2: FBS-treated siRNA (0.2 μg) (control 2). 
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With regard to pCMV-luc plasmid DNA, there was an increase in band intensities form each 
well, indicating that the pDNA existed mainly in the supercoiled helical form, followed by 
linearized, and then nicked circular. On the other hand, the naked FBS-treated (pDNA and 
siRNA) controls were completely digested within 4 h following exposure to serum enzymes. 
Compared to the fully digested controls, the pDNA associated with cationic liposomes remained 
relatively intact in the presence of FBS for all lipid:pDNA mass ratios (
w
/w) tested, indicating 
that the various liposomal formulations were able to sustain the integrity of the bound nucleic 
acids and offered some degree of protection to the relatively intact nucleic acid structure. 
A number of studies have reported the benefits of incorporating cholesterol and 
cholesterol-containing derivatives into nanocarrier systems (Ma et al., 2005b; Miyawaki-
Shimizu et al., 2006; Morrissey et al., 2005, Zimmermann et al., 2006). The inclusion of 
cholesterol and its derivatives into liposomal formulations increases the packaging densities of 
the phospholipid molecules, thus forming solid-ordered membranes and thereby reducing the 
penetration behaviour of solutes and ions (Arouri and Mouritsen, 2013; Mady, 2004; Pozzi et al., 
2012). Owing to the tight lipid arrangement facilitated by cholesterol, these membranes appear 
thicker and mechanically more stable. This maintained the liposomal integrity, by counteracting 
the disruptive effect of high density lipoproteins present in serum (Kraske and Mountcastle, 
2001; Mayer et al., 2000). However, findings related to pDNA confirm that the DNA underwent 
partial nicking, as evidenced by the relatively greater proportion of relaxed DNA and an 
accompanying decline of the supercoiled helical conformation compared to the undigested 
pDNA control. This has been a controversial issue; it has been shown that digestion of the 
supercoiled content by nucleases present in serum leads to decreased transfection efficiency 
(Kawabata et al., 1995). In contrast, it has also been reported that relative amounts of 
supercoiling in reporter plasmids do not significantly affect in vitro and in vivo gene transfection. 
Further, the relaxed, covalently closed forms of the plasmid are not less efficient than 
supercoiled forms in gene delivery (Bergan et al., 2000). In essence this study’s assessment of 
pDNA serum stability confirmed that the cationic liposomes were able to offer substantial 
protection in a nuclease rich environment. 
With regard to siRNA protection from serum nucleases, both non-PEGylated Chol-T and 
MS09 offered better protection to their siRNA cargo compared to their PEGylated counterparts 
[clear bands present in each lane, [Figure 4.8 (A)]. Han et al. (2008) reported an increase in 
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delivery efficiency of siRNA in serum with cationic liposomes containing an amine-based 
cholesterol derivative compared to cationic liposomes containing ordinary cholesterol in their 
structure. Hence, the cholesterol derivatives employed in this study helped preserve liposomal 
stability in the presence of FBS. Liposomal formulations containing 5% PEGylation offered the 
least protection as evidenced by lighter bands. However, the bands appeared brighter at the 
supraoptimal cationic liposome:siRNA (
w
/w) ratios compared to the optimal and suboptimal 
concentrations for both Chol-T and MS09. ZetaSizer measurements of non-PEGylated liposomes 
showed that they formed stable lipoplexes with zeta potentials of 47.26 mV (Chol-T) and 44.61 
mV (MS09) corresponding to proficient serum protection abilities. With regard to liposomes 
tethered with 5% PEG, there were variations in zeta potentials; Chol-T 5% PEG (9.78 mV ± 
1.13) and MS09 5% PEG (41.26 ± 9.79). The low zeta potential indicates liposomal instability 
and, therefore, reduced siRNA protection from nucleases. On the other hand, although MS09 5% 
PEG attained a more positive zeta potential, the PDI (0.337) was higher, suggesting that these 
lipoplexes do experience a certain degree of instability. Silvander et al. (1998) observed a similar 
trend with liposomes containing 5 mol.% PEG, where the sterically stabilized liposomes did not 
offer substantial stabilization against serum proteins.  
 
4.3.3 Ethidium bromide (EtBr) fluorescence quenching assay 
 
The EtBr fluorescence quenching assay further quantitatively investigated the electrostatic 
interactions between the cationic liposomes and nucleic acids (pDNA and siRNA). It also 
corroborated end-point ratios derived from the gel retardation assay. Intercalation of the classical 
planar molecule EtBr (an aromatic cationic fluorophore) between nucleic acid base pairs has 
been explored using various techniques over the past 5 decades (LePecq and Paoletti, 1967, Pohl 
et al., 1972; Celedon et al., 2010). Binding of EtBr between contiguous base pairs on the double 
helix structure results in more intense fluorescence and a ~10-fold higher emission intensity than 
when in water or buffer (Lakowicz, 1999). The high fluorescence emitted from EtBr 
intercalation into double stranded nucleic acids is primarily due to the hydrophobic milieu found 
between the base pairs. By moving into this hydrophobic environment, away from the bulk 
hydrophilic solvent, the EtBr cation dispels any water molecules that were associated with it. As 
water is a particularly efficient fluorescent quencher, elimination of these water molecules allows 
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EtBr to fluoresce. The binding of Et cation results in a decrease in the helical twist (~26 °) 
causing the distance between bases flanking an EtBr molecule to increase, thus creating an 
opening of ~0.34 nm (Hayashi and Harada, 2007; Tsai et al., 1975; Wang, 1974). Therefore, the 
unwinding of the helical twist induces local and structural changes, such as elongation or 
lengthening of the ds-DNA strand as illustrated in Figure 4.9 (Bugs and Cornelio, 2001; Nafisi 
et al., 2007; Palchaudhuri and Hergenrother, 2007). 
 
Figure 4.9: Schematic representation of preferred intercalation between EtBr and the nucleic acid helix 
which illustrates the lengthening and untwisting of the helical structure (Bugs and Cornelio, 2001; Nafisi 
et al., 2007; Palchaudhuri and Hergenrother, 2007). 
 
According to the assay principle, the fluorescence emission intensity of EtBr is greatly enhanced 
upon intercalative complexation between nucleic acid base pairs. This heightened fluorescence 
can be quenched, or partly assuaged when displaced upon titration with compounds having a 
higher affinity for nucleic acid binding (Huang et al., 2012). As such, quantification of the 
cationic liposome-induced compaction of pDNA and siRNA was assessed by determining the 
relative fluorescence of EtBr intercalation (excitation λ = 520 nm, emission λ = 600 nm) in the 
double helix when cationic liposomes were added. Figure 4.10 represents the EtBr fluorescence 
quenching assay where percentage relative fluorescence (Fr) with pDNA (A) and siRNA (B) was 
plotted as a function of the number of micrograms of cationic liposome Chol-T and MS09. 
Sequential addition of cationic liposomes to EtBr pretreated with pDNA or siRNA caused 
appreciable diminution of EtBr fluorescence, indicating that the EtBr was displaced by the 
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displacement by the cationic liposome). The (
w
/w) or N/P (+:‒) ratios at which the liposome 
maximally displaced the EtBr and compacted the respective nucleic acid are presented in Table 
4.3. All liposomal formulations containing Chol-T or MS09 were able to successfully displace 
the intercalated EtBr cation and bind the nucleic acid to varying degrees, indicating good 
compaction abilities. The maximum percentage fluorescence quenching for pDNA was between 
42% - 58% (Chol-T based liposomes) and 42% - 68% (MS09 based liposomes), whereas for 
siRNA fluorescence decay ranged from 29% - 72% (Chol-T based liposomes) and 35% - 49% 
(MS09 based liposomes). Interestingly, for both pDNA and siRNA, high amounts of EtBr were 
displaced with the sequential addition of Chol-T (58% and 72% respectively) and MS09 2% 
PEG (68% and 49% repectively). 
 
Table 4.3: EtBr fluorescence quenching by the various cationic/ PEGylated cationic liposomes recorded 
at points of inflection  
 
Cationic liposome 
Cationic liposome : nucleic acid (
w
/w) Charge ratio [N/P (+:‒)] 
DNA siRNA DNA siRNA 
Chol-T 11 : 1 14.9 : 1 2.9 : 1 4.2 : 1 
Chol-T 2% PEG 16 : 1 26 : 1 3.9 : 1 6.8 : 1 
Chol-T 5% PEG 15 : 1 38.6 : 1 3.4 : 1 9.2 : 1 
MS09 13 : 1 16.3 : 1 3.0 : 1 4.2 : 1 
MS09 2% PEG 13 : 1 21.9 : 1 2.9 : 1 5.3 : 1 
MS09 5% PEG 13 : 1 43.6 : 1 2.7 : 1 9.6 : 1 
Abbreviations: Chol-T: 3β-[N-(N', N'-dimethylaminopropane)-carbamoyl] cholesterol; MS09: N, N-
dimethylaminopropylaminylsuccinylcholesterylformylhydrazide; PEG: Polyethylene glycol; DNA: 
Deoxyribonucleic acid; siRNA: Small interfering RNA; EtBr: Ethidium bromide. 
The theoretical N/P (+:‒) ratio represents the charge ratio of cationic lipid to nucleotide. Values were 
calculated assuming one positive charge per cytofectin molecule at pH 7.5 and one negative charge per 











Figure 4.10: Ethidium bromide fluorescence quenching assay of the cationic and PEGylated cationic 
liposomes in a total of 0.25 mL incubation mixtures containing (A) 3 μg pCMV-luc plasmid DNA, (B) 
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4.4  In Vitro Cell Culture 
 
4.4.1 Cell lines 
 
The SKBR-3 (overexpressed HER2/neu - positive cell line), MCF-7 and HEK-293 (negative 
cell lines) were used in this study [Figure 4.11]. HEK-293 cells are fibroblastoid semi-
adherent cells that grow as monolayer cultures. Colony morphologies of BC cell lines in 3-D 
culture fall into four distinct classes: round, mass, grape-like and stellate (Kenny et al., 2007). 
SKBR-3 cells appear as spherical structures and form loosely cohesive grape-like colonies 
displaying poor cell to cell contacts; whereas MCF-7 cells fit into the mass category of cells 
which form tightly interconnected structures with robust connections among cells. Both these 
BC cell lines predominantly adopted monolayer morphologies but tended to ‘clump’ and form 
small multicellular structures. 
 
4.4.2 MTT cytotoxicity assay 
 
One of the most important features of gene delivery systems is their safety. The 3-(4, 5-dimethyl-
2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) quantitative colorimetric assay was 
used to assess the metabolic viability of cell cultures exposed to transfection complexes. This 
assay is based on the ability of viable cells to produce a dark purple strongly lipophilic fomazan 
product by reducing the water-soluble yellow coloured tetrazolium dye (van Meerloo et al., 
2011). These reductions take place only in metabolically active cells when mitochondrial 
reductase enzymes are active. The quantity of formazan product formed is proportional to the 
metabolic activity of viable cells, which was determined spectrophotometrically (UV570 
absorbance), after dissolving the purple formazan crystals in dimethyl sulfoxide. The 
cytotoxicity of the different lipoplex formulations is depicted in Figure 4.12 (pCMV-luc) and 
Figure 4.13 (siRNA). Values are expressed as percentage cell viability against untreated control 


































































Figure 4.11: Colony morphologies of the three cell lines used in this study. (A) and (B) SKBR-3, (C) and 
(D) MCF-7, (E) and (F) HEK-293. Cells were viewed as a monolayer at semi-confluency under a 100 × 







Cell viabilities of HEK-293 (A), MCF-7 (B) and SKBR-3 (C) cells treated with pDNA 
lipoplexes ranged as follows: Chol-T (92 – 86%, 96 – 85% and 96 – 101%), Chol-T 2% PEG (94 
– 79%, 96 – 79% and 92 – 91%), Chol-T 5% PEG (83 – 78%, 96 – 74% and 89 – 87%), MS09 
(113 – 100%, 99 – 90% and 93 – 86%), MS09 2% PEG (91 – 81%, 96 – 83% and 96 – 98%), 
MS09 5% PEG (109 – 96%, 95 – 81% and 86 – 80%). As shown in Figure 4.12, after 48 h 
incubation, cell viability with non-PEGylated pDNA lipoplexes remained above 80% when 
compared with untreated cells. Similarly, pDNA lipoplexes with the incorporation of PEG did 
not show notable cytotoxicity in all three cell lines either. Cell viabilities of HEK-293, MCF-7 
and SKBR-3 cells treated with siRNA lipoplexes ranged as follows: Chol-T (89 – 85%, 89 – 
88% and 101 – 102%), Chol-T 2% PEG (84 – 76%, 90 – 81% and 94 – 92%), Chol-T 5% PEG 
(82 – 74%, 78 – 70% and 96 – 88%), MS09 (101 – 93%, 98 – 91% and 87 – 89%), MS09 2% 
PEG (87 – 82%, 87 – 85% and 87 – 74%), MS09 5% PEG (84 – 78%, 80 – 76% and 51 – 49%). 
These results show that the three cell lines maintained a viability of over 70% after treatment 
with the various siRNA lipoplexes, except for the SKBR-3 cells exposed to MS09 5% PEG 
lipoplexes which caused a 50% decrease in cell viability (P<0.001). Nevertheless, these findings 
suggest good biocompatibility with all three cell lines over the range of N/P charge ratios (+:‒) 
tested. Furthermore, these findings on cell viabilities are favourable when compared to that 
attained using the commercially available transfection reagent, Lipofectamine
®
 3000. The low 
cytotoxicities observed could be attributed to the use of monovalent cationic lipids which are 
known to be less toxic than multivalent cationic lipids (Spagnou et al., 2004). It is also very 
likely that the incorporation of DOPE and cholesterol into the liposomal formulations 
contributed to the lipoplexes biocompatibility and stability and therefore low levels of 
cytotoxicity. 
As shown in Figure 4.12 and Figure 4.13, HEK-293 (A) and MCF-7 (B) cells revealed a 
decrease in cell viability with an increase in lipid:nucleic acid N/P ratios (+:‒) for all tested 
liposomal formulations irrespective of degree of PEGylation, indicating a dose-dependent 
cytotoxic effect. This trend of visibly reduced cell viability at higher lipid to nucleic acid N/P 
ratios has been reported in previous studies (Dass, 2002; Lv et al., 2006). Research has shown 
that the cytotoxic effect of cationic liposomes is primarily determined by their cationic nature, 
since at high charge ratios N/P (+:‒) the presence of free or excess cationic liposomes is 
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Figure 4.12: Cell cytotoxicity studies of cationic and PEGylated cationic liposome-pCMV-luc plasmid 
DNA complexes in (A) HEK-293, (B) MCF-7 and (C) SKBR-3 cells in vitro using MTT reagent. 
Incubation mixtures (0.25 mL) contained 0.5 μg of pDNA with varying amounts of liposome from 
suboptimal to supraoptimal N/P (+:‒) charge ratios: Controls - Untreated cells; Lipofectamine
®
 3000; 
Chol-T (1.1, 1.6, 2.1); Chol-T 2% PEG (1.2; 1.7, 2.2); Chol-T 5% PEG (1.1, 1.6, 2.1); MS09 (1.2, 1.7, 
2.2); MS09 2% PEG (1.4, 1.8, 2.3); MS09 5% PEG (1.3, 1.7, 2.1). The viability percentage of cells was 
expressed relative to Untreated control cells. Data are presented as means ± SD (n = 3). Statistical 
analysis among mean values was performed using one-way ANOVA followed by the Tukey-Kramer 
multiple comparisons test between formulations. Asterisks denote a significant difference compared to the 
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Figure 4.13: Cell cytotoxicity studies of cationic and PEGylated cationic liposome-siGENOME non-
targeting siRNA complexes in (A) HEK-293, (B) MCF-7 and (C) SKBR-3 cells in vitro using MTT 
reagent. Incubation mixtures (0.25 mL) contained 0.32 μg of siRNA with varying amounts of liposome 
from suboptimal to supraoptimal N/P (+:‒) charge ratios: Controls - Untreated cells; Lipofectamine
®
 
3000; Chol-T (3.4, 3.9, 4.4); Chol-T 2% PEG (5.8, 6.3, 6.8); Chol-T 5% PEG (8.3, 8.8, 9.3); MS09 (4.9, 
5.4, 5.9); MS09 2% PEG (5.5, 6.0, 6.5); MS09 5% PEG (7.4, 7.9, 8.4). The viability percentage of cells 
was expressed relative to Untreated control cells. Data are presented as means ± SD (n = 3). Statistical 
analysis among mean values was performed using one-way ANOVA followed by the Tukey-Kramer 
multiple comparisons test between formulations. Asterisks denote a significant difference compared to the 
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As such, formulated lipoplexes are in general far less cytotoxic than free cationic liposome 
components (van Gaal et al., 2011). 
Interestingly, for both the pDNA and siRNA lipoplexes, Chol-T containing treatments 
were in general slightly more toxic to the HEK-293 and MCF-7 cell lines compared to the MS09 
containing lipoplexes. As discussed previously, the structural property of these cytofectins 
features a cholesterol ring anchor, a monovalent dimethylamino head group, a biodegradable 
carbamoyl linker and a spacer element. It is well established that each segment of the cationic 
cytofectin has dramatic effects on cell toxicity (Lv et al., 2006). The distinguishing feature 
between the Chol-T and MS09 cytofectins is the length of the spacer element. The MS09 
cytofectin containing the longer spacer element was observed to be slightly less toxic than the 
Chol-T cytofectin. This trend of reduced cytotoxicity with MS09 compared to Chol-T can be 
clearly observed with HEK-293 cells exposed to pDNA lipoplexes (viability decrease of 21% 
and 14%) and siRNA (viability decrease of 12% and 8%), at both low and high charge ratios N/P 
(+:‒) respectively. Interestingly, MS09 N/P 4.9 and 5.4 (siRNA), MS09 N/P 1.2 and 1.7 and 
MS09 5% PEG N/P 1.3 and 1.7 (pDNA) lipoplexes were non-toxic to HEK-293 cells and in fact 
led to an increase in cell numbers and therefore increased cell viability above 100% was 
observed. This pattern of visibly reduced cytotoxicity corroborates previous studies by Floch et 
al. (2000), who reported that an increase in the length of the spacer segment resulted in 
decreased cytotoxicity in culture format. Moreover, carbamate-linked lipids offer lower 
cytotoxicity as this bond is stable under neutral conditions, and is prone to acid-catalyzed 
hydrolysis at low pH values (in the endosome), where lipids may be degraded into less toxic by-
products or low molecules within the cell (Boomer et al., 2002; Liu et al., 2005a; b). 
As observed in Figure 4.13 (A), (B), and (C), PEGylated siRNA lipoplexes resulted in an 
increase in cellular toxicity as evidenced by a decrease in cell viability in all three cell lines 
tested. At supraoptimal concentrations the non-PEGylated Chol-T siRNA lipoplexes (N/P 4.4) 
resulted in minimal cytotoxicities in HEK-293 (15%), MCF-7 (12%) and SKBR-3 (0%) cells, 
compared to their PEGylated counterparts: Chol-T 2% PEG N/P 6.8 (24%, 19% and 8%); Chol-
T 5% PEG N/P 9.3 (26%, 30% and 12%). In the same way, the non-PEGylated MS09 siRNA 
lipoplexes (N/P 5.9) elicited marginal cell deaths in HEK-293 (7%), MCF-7 (9%) and SKBR-3 
(11%) cells, compared to their PEGylated counterparts: Chol-T 2% PEG N/P 6.5 (18%, 15% and 
26%); Chol-T 5% PEG N/P 8.4 (22%, 24% and 51%). Although the chemical modification of 
116 
 
cationic liposomes with PEG resulted in increased stability (Chol-T and MS09 siRNA lipoplexes 
at 2 mol.% PEG) as well as smaller particle sizes, PEGylated cationic liposomes were still more 
cytotoxic than their non-PEGylated equivalents. Zhang et al. (2010) reported similar trends with 
PEGylated DC-Chol/DOPE siRNA lipoplexes. These authors suggested that the increase in 
cytoxicity was probably due to the higher cationic liposome concentration.  
With regard to SKBR-3 cells, a dose-independent decease in cell viability was observed 
with pDNA (Chol-T and MS09 2% PEG) and siRNA (MS09) lipoplexes, and in some instances 
MS09 was more toxic than Chol-T. Reports on cationic liposome cytotoxicity have shown that in 
some instances these lipids generate reactive oxygen species (ROS) (Park et al., 2004; Soenen et 
al., 2009), and that cancer cells exhibit greater ROS stress than normal cells. The mechanism of 
action of ROS within cells has been described as a two-edged sword. In one occurrence ROS 
activates receptor tyrosine kinases and growth factors, which facilitates cell-cycle progression 
and cell survival. Conversely, the presence of high levels of ROS can suppress cell growth via 
continuous activation of cell-cycle inhibitors which leads to apoptosis (Ramsey and Sharpless, 
2006; Scherz-Shouval and Elazar, 2007; Takahashi et al., 2006). Therefore, the variations in 
SKBR-3 cell viability may be attributable to the fluctuations of ROS production within these 
cells. Taken together, these findings indicate that the cationic liposomes synthesized in this study 
show relatively low cytotoxic effects on HEK-293, MCF-7 and SKBR-3 cell lines, and have the 
potential for future in vivo applications.  
 
4.4.3  Luciferase activity 
 
Plasmids are extra-chromosomal circular DNA molecules which have the ability to replicate 
autonomously within a suitable host. Moreover, modified plasmids encoding for a particular 
gene of interest and a promoter have the ability to be expressed within the nucleus of transfected 
cells in a temporary manner. The reporter gene pCMV-luc which comprises a cytomegalovirus 
promoter and the firefly luciferase (luc) gene was used to investigate the ability of the PEGylated 
and non-PEGylated Chol-T and MS09 cationic liposomes to stably transfect pDNA. The pCMV-
luc plasmid is a widely used reporter gene since it can be easily identified and gene expression 
can be measured quantitatively. The pDNA transfection capability of liposomal formulations was 
evaluated on the three cells lines, namely, HEK-293, MCF-7 and SKBR-3 cells, in an in vitro 
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transfection experiment using the luciferase reporter gene assay. Attached cells were transfected 
with lipoplexes comprising 1 µg pCMV-luc at predetermined N/P charge ratios (+:‒) and the 
RLU measured 48 h after transfection. Luciferase activity was normalized using the BCA protein 
assay and relative expression was recorded as RLU mg
-1
 protein. The performance of the 
PEGylated and non-PEGylated Chol-T and MS09 lipid vectors was compared to the established 
non-viral delivery vector Lipofectamine
®
 3000 Reagent (positive control). Assay controls also 
included cells unexposed to liposome or pDNA and cells treated with free pDNA (negative 
controls). The luciferase reporter assay offers unparalleled sensitivity and versatility to assess or 
study gene expression (Fan and Wood, 2007). Basically, the reporter technology involves the 
interaction of the luc enzyme with luciferin (luminescent substrate) and, via different 
chemistries, light is emitted by the process of bioluminescence. Two chemical reactions take 
place; firstly, ᴅ-luciferin is adenylated by Mg-ATP to generate luciferyl adenylate and 
pyrophosphate. Secondly, luciferyl adenylate is activated by ATP, resulting in oxidation by 
molecular oxygen to form a dioxetanone ring. A decarboxylation reaction forms oxyluciferin in 
an electronically excited state, and finally the reaction releases a photon of light as oxyluciferin 
returns to the ground state (Baldwin, 1996). This reaction is highly energetically efficient as all 
energy incorporated into the reaction is rapidly converted into light (Allard and Kopish, 2008). 
Plasmid DNA transfections of the three cell lines are depicted in Figure 4.14; HEK-293 (A), 
MCF-7 (B) and SKBR-3 (C). As expected, the transfection efficiency of free pDNA was very 
low. Naked or free pDNA is prone to enzymatic degradation in the presence of serum; on the 
other hand pDNA that is internalized is rapidly destroyed by DNAses present in the endosome or 
cytoplasm, prior entry into the nucleus (Audouy et al., 2000; Buyens et al., 2008; Lv et al., 
2006).  
On the other hand, the commercial product Lipofectamine
®
 3000 increased transfection 
by about 7.02-fold (HEK-293), 7.30-fold (MCF-7) and 10.90-fold (SKBR-3) compared to free 
pDNA. As mentioned previously, the incorporation of high levels of cholesterol and/or 
cholesterol-containing derivatives in liposomal formulations offers several advantages for gene 
delivery; these include enhanced transfection efficiency as well as resistance to serum-induced 
aggregation (Islam et al., 2009; Pozzi et al., 2012; Samadikhah et al., 2011; Zhang et al., 2008; 
Zidovska et al., 2009). It has been suggested that the increase in transfection offered by 
cholesterol may be a result of phase transition. Strong repulsive ‘hydration forces’ exist between 
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lipid membranes, which forms a major barrier for membrane-membrane interaction and fusion. 
The presence of cholesterol in the lipid membrane reduces the average hydration repulsion layer 
of the membrane, prompting phase transition toward a non-lamellar transfecting phase and/or 
enhanced fusion between the cationic lipoplex membrane and the anionic cell membrane (Pozzi 
et al., 2012; Zidovska et al., 2009). As such, the cholesterol containing lipoplexes employed in 
this study were able to stably transfect the various cell lines tested, albeit at varying degrees, by 
most likely favouring the interaction with cellular membranes and aiding in fusion-driven 
cellular uptake and endosomal release. 
The pDNA gene transfection efficiencies amongst the different cells lines varied. In 
general, SKBR-3 cells appeared to be most difficult to transfect amongst the three cells lines, as 
evidenced by the lower luciferase activity. This difference in transfection between the cell lines 
is mainly due to the surface charge of the cellular membrane as well as the cells doubling time. 
The surface charge influences electrostatic interaction between the lipoplexes and the cell 
membrane affecting the cellular uptake efficiency. On the other hand it could also affect the 
entry of pDNA into the nucleus (Brunner et al., 2000; Obata et al., 2010; Zuhorn and Hoekstra, 
2002). 
Transfection efficiency of non-PEGylated Chol-T and MS09 lipoplexes was considerably 
limited as compared to pDNA alone (negative control) for almost all N/P (+:‒) charge ratios 
analyzed, except for MS09 tested at suboptimal (N/P 1.2) and supraoptimal (N/P 2.2) ratios 
against MCF-7 (P<0.01) and HEK-293 (P<0.001) cells, respectively. It is well established that 
the first important step for transfection is entry into the cytoplasm. Liposome-mediated 
transfection is further dependent on the size and surface charge of the cationic liposomes. 
ZetaSizer measurements indicated that these lipoplexes displayed a highly positive zeta potential, 
and were larger than their corresponding PEGylated counterparts. Therefore, it can be assumed 
that although these pDNA containing complexes displayed a cationic charge on their surface 
which was favourable for binding to the anionic cell membrane and internalization into the 
cytoplasm, ineffective release of the pDNA from the lipoplex within the cell was most likely 
associated with low transfection. Reduced pDNA release can be further supported by the EtBr 
intercalation assay, particularly with regard to Chol-T complexes which demonstrated increased 
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Figure 4.14: In vitro gene transfection data of PEGylated and non-PEGylated lipoplexes studied in (A) 
HEK-293, (B) MCF-7, and (C) SKBR-3 cell lines. Lipoplexes were formulated with pCMV-luc plasmid  
DNA (1 µg) at various N/P charge ratios (+:‒): Control 1 (untreated cells, negative control); Control 2 
(pCMV-luc DNA alone, negative control) and Lipofectamine
®
 3000 (positive control); Chol-T (1.1, 1.6, 
2.1); Chol-T 2% PEG (1.2; 1.7, 2.2); Chol-T 5% PEG (1.1, 1.6, 2.1); MS09 (1.2, 1.7, 2.2); MS09 2% 
PEG (1.4, 1.8, 2.3); MS09 5% PEG (1.3, 1.7, 2.1). Transfections were carried out in the presence of 10% 
foetal bovine serum. Luciferase activity in terms of normalized light units was expressed as RLU mg
-1
 
protein. Data are presented as means ± SD (n = 3). Statistical analysis among mean values was performed 
using one-way ANOVA followed by the Tukey-Kramer multiple comparisons test between formulations. 
Asterisks denote a significant difference *P<0.05, **P<0.01, and ***P<0.001.  
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Maitani et al. (2007) reported similar cellular associations using DC-Chol:DOPE (molar ratio 1/2 
and 3/2) liposomes. DC-Chol:DOPE (1/2), however, demonstrated significantly greater 
transfection efficiency compared to DC-Chol:DOPE (3/2). These authors also suggested that it 
was the release of the DNA from the lipoplex and not the increase in cellular association that 
played a crucial role in efficient transfection. 
In general, cationic lipoplexes containing DSPE-PEG2000 resulted in increased luciferase 
activity compared to their non-PEGylated counterparts. A comparison of PEGylated Chol-T and 
MS09 lipoplexes revealed that the latter was more efficient in pDNA-luc transfection as 
indicated by the significant increases in luciferase activity, particularly with lipoplexes 
containing 5% PEG. The following fold-increases were recorded with MS09 lipoplexes at 
optimal N/P charge ratios (i.e. end-point) PEGylated at 2% and 5% compared to the non-
PEGylated MS09 lipoplexes: HEK-293, 3.6-fold (P<0.001) and 7.2-fold (P<0.001); MCF-7, 2.4-
fold (P<0.001) and 3.4-fold (P<0.001); SKBR-3, 1.6-fold and 4.1-fold (P<0.001), respectively. 
With regard to PEGylated Chol-T lipoplexes at suboptimal N/P charge ratios, the following 
findings were observed and recorded: HEK-293, 3.7-fold and 1.9-fold; MCF-7, 1.4-fold and 3.0-
fold; SKBR-3, 3.0-fold and 2.0-fold increase in luciferase activity, upon 2% and 5% PEGylation 
respectively. Although PEGylated Chol-T lipoplexes did result in an increase in luciferase 
activity, in general, these increases were not clinically significant. As discussed in Section 4.2.2, 
PEGylation induced a size stabilizing effect, forming lipoplexes which were significantly smaller 
than non-PEGylated lipoplexes. It has also been suggested that when PEGylated lipoplexes are in 
association with blood plasma or serum, they become restricted, causing a reduction in entropy 
between PEG chains. This in turn leads to the escalation of a repulsive force, preventing the 
attachment of plasma proteins as well as other components. In vitro transfection experiments 
performed in the presence of serum, suggested that PEGylation of the lipoplexes did in fact 
provide a stabilizing effect on the lipoplexes by resisting the formation of a protein corona 
around their surfaces. Moreover, the DSPE-PEG2000 polymer contains a pH sensitive carbamate 
bond which links the DSPE component to the PEG polymer. Therefore, under reduced pH 
conditions such as the endosomal compartments, these components are easily disassembled, 
facilitating the release of the pCMV-luc cargo, and thus contributing to increased luciferase gene 
expression. On the other hand, non-PEGylated lipoplexes formed larger-sized particles, most 
likely due to the formation of a protein corona and/or aggregation of the lipoplexes. Under these 
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conditions, the cationic charge of the lipoplexes tends toward neutralization, leading to reduced 
association between the lipoplexes and the cellular membrane and a consequent decrease in the 
expression of the luciferase gene.  
Interestingly, with regard to N/P charge ratios, a similar trend in luciferase activities was 
observed in HEK-293 and SKBR-3 cell lines. Basically, an increase in N/P charge ratio from 
suboptimal to optimal concentrations resulted in escalated luciferase activity for all tested 
lipoplexes, except Chol-T 2% PEG in HEK-293 cells, and all Chol-T containing lipoplexes in 
SKBR-3 cells. This result correlates with previous studies which confirmed increase in 
transfection levels due to increases in lipid/pDNA charge ratios. For example, Candiani et al. 
(2010) reported low transfection levels when using DOPC/DOPE lipid formulations with a 
charge ratio of 1.25 (close to isoneutrality). However, when the charge ratio was increased to 5, 
so did the degree of transfection. On the other hand, a further increase from optimal to 
supraoptimal concentrations led to a decline in luciferase activity. This decrease in luciferase 
activity was observed with all lipoplex formulations tested excluding MS09 in HEK-293 and 
Chol-T 2% PEG and MS09 2% PEG in SKBR-3 cells. Balbino et al. (2012) reported similar 
results. Firstly, when lipoplexes are prepared in close proximity to the isoneutrality region, there 
is an excess of pDNA that may induce the formation of larger particle aggregates via the 
construction of saturated liposomal surfaces retaining pDNA within their bilayers. Although this 
offers good pDNA packaging and protection, these multiple bilayers compromise DNA release 
within cells thus decreasing transfection activity. Secondly, it has been suggested that further 
increase in N/P charge ratio and the consequent decline in luciferase activity may be a result of 
the presence of an excess of liposomes. These compete with lipoplexes for cellular 
internalization thereby limiting the intake of pDNA lipoplxes, and ultimately reducing 
transfection levels. In most cases, however, the differences in luciferase activity based on N/P 
charge ratios were not significant. The MS09 5% PEG lipoplexes, in particular, resulted in the 
abovementioned trends being observed in all three tested cell types; a significant dose-dependent 
increase in luciferase signals was seen from suboptimal to optimal concentrations: HEK-293 
(P<0.001); MCF-7 (P<0.01); SKBR-3 (P<0.01). This result echoes the findings of Gjetting et al. 
(2010). Using DOTAP/cholesterol-based lipoplexes incorporating PEG (range 0 – 10%), they 
demonstrated that lipoplexes containing 5% PEG-lipid exhibit a threshold in physical properties, 
and particularly a size-stabilizing effect. Here the stabilizing effect was more pronounced in the 
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PEGylated MS09 containing lipoplexes than the Chol-T complexes as indicated by a superior 
PDI obtained with MS09. 
 
4.4.4 HER2/neu Gene Silencing in SKBR-3 Breast Cancer Cells 
 
4.4.4.1 Quantitative Real-Time PCR 
 
Quantitative Real-Time PCR (qRT-PCR) is a powerful technique in molecular biology. It is 
superior to other gene profiling methods because of its facility, sensitivity, precise detection, 
dynamic range, reliability, robustness and high-throughput potential for gene expression studies. 
This technology offers several advantages over traditional PCR: monitoring the progress of the 
qRT-PCR reaction in real time; allowing for an improved dynamic range of detection; enabling 
highly accurate measurements of the initial quantity of target amplicons; and omitting post-PCR 
handlings as amplification and detection of the PCR product take place in a single reaction tube 
(Derveaux et al., 2010; Stratford et al., 2008; Yuan et al., 2006).  
In this technique, mRNA is firstly reverse transcribed to generate a single-stranded 
cDNA template, which is then amplified via PCR. A PCR reaction occurs in three phases, 
namely, exponential, linear and plateau. In the exponential phase, under ideal conditions 
assuming 100% reaction efficiency, amplification of the amplicon occurs exponentially, i.e., the 
kinetics of the reaction favour doubling of the product since reagents are not limited. As the 
reagents become limited during the linear phase, the reaction starts to slow down, and there is a 
linear increase of the PCR product. As the reaction continues and the reagents become depleted, 
the reaction eventually reaches the plateau phase where the quantity of product formed does not 
change (Heid et al., 1996; Yuan et al., 2006). 
Real-Time PCR exploits the exponential phase for quantification data due to the fact that 
under ideal conditions initial amplicon doubles after every cycle, producing the most accurate 
and reproducible data. During this phase two values are calculated: the threshold fluorescence 
and the threshold cycle (Ct). Threshold fluorescence is defined as the level of signal that reflects 
a statistically significant increase in fluorescent intensity over the background fluorescent signal, 
and the Ct refers to the cycle number of the PCR reaction at which the florescent signal of the 
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reporter dye reaches the threshold. The Ct value is known as the quantitative end-point and it is 
used in both absolute and relative quantification (Pfaffl, 2001; Schmittgen and Livak, 2008).  
The chemically synthesized Chol-T and MS09 cationic liposomal formulations were 
tested for their ability to efficiently deliver target HER2/neu siRNA into SKBR-3 cells. 
Transfection experiments were conducted using the PEGylated and non-PEGylated cationic 
liposomes in parallel with the control samples: calibrator, non-targeting siRNA and HER2/neu 
target siRNA alone. Lipofectamine
®
-3000 Reagent is one of the most common transfection 
reagents and it is recommended for siRNA gene transfection experiments. Hence the researcher’s 
use of it as a positive control to compare the transfection activity with the liposomes synthesized 
in this study. Total cellular RNA was isolated from the treated cells 48 h post transfection, and 
thereafter gene expression and silencing were monitored using qRT-PCR with primers specific 
for the HER2/neu gene. Relative expression of the HER2/neu gene was normalized in relation to 
the GAPDH gene. The concentration of extracted cellular RNA was between 0.32 – 0.38 µg μL
-1
 
and of a relatively good quality with 
260
/280 ratio between 1.75 – 1.88. 
Quantitative RT-PCR results were analyzed using the 2
-∆∆Ct
 method for comparative or 
relative quantification; the results are presented as the fold-change in gene expression relative to 
the calibrator (SKBR-3 cells alone). According to the qRT-PCR results depicted in Figure 4.15, 
the calibrator revealed high levels of the HER2/neu gene; by definition the fold-change in gene 
expression of the untreated control is approximately one, since ∆∆Ct equals zero and 2
0
 equals 
one. The non-targeting siRNA (NT-siRNA) showed no knockdown, whereas the uncomplexed 
HER2/neu target siRNA resulted in a slight decrease of the HER2/neu gene at the mRNA level. 
The gene expression levels of the housekeeping normalizer gene GAPDH did not differ 
significantly among the control and test samples. 
Quantitative RT-PCR with HER2/neu-spanning primers revealed that each of the 
liposomal formulations was able to deliver siRNA against the HER2/neu gene in the SKBR-3 
BC cells in the presence of serum, as indicated by down-regulation of HER2/neu at the mRNA 
level (P<0.001). As described in Section 4.1.2, the cationic liposomes were formulated with 
DOPE, a neutral helper fusogenic lipid. Due to the propensity of DOPE to assume an inverted 
hexagonal phase, this cone-shaped neutral lipid is known to play a critical role in membrane-
membrane fusion events (Fletcher et al., 2008), thereby inducing strong destabilizing effects on 
the barrier properties of the endosomal membranes and offering efficient gene delivery into the 
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cytoplasm. A cationic cholesterol derivative in combination with DOPE has also been reported to 
provide serum-stable transfection of siRNA (Han et al., 2008; Spagnou et al., 2004). Also, it has 
been suggested that the cholesterol moiety may bind to certain ligand components present in the 
serum, thereby enabling uptake of the delivery system and its gene cargo into cells via ligand-
mediated endocytosis (Han et al., 2008). In this study, we cannot exclude the possibility that the 





Figure 4.15: Analysis of HER2/neu gene expression in SKBR-3 cells by qRT-PCR. Incubation mixtures 
(1.5 mL) contained 0.64 µg of siRNA with varying amounts of liposome from suboptimal to supraoptimal 
concentrations: Chol-T:DOPE (7.68, 8.96, 10.24 μg); Chol-T:DOPE:2% PEG (14.08, 15.36, 16.64 μg); 
Chol-T:DOPE:5% PEG (22.40, 23.68, 24.96 μg); MS09:DOPE (12.16, 13.44, 14.72 μg); 
MS09:DOPE:2% PEG (14.72, 16.00, 17.28 μg); MS09:DOPE:5% PEG (21.76, 23.04, 24.32 μg). 
Calibrator (non-treated SKBR-3 cells), NT-siRNA (non-targeting siRNA) and siRNA (HER2/neu 
targeting siRNA alone) served as negative controls. Lipofectamine
®
 3000-siRNA was included as a 
positive control. The vertical axis represents the relative quantification of HER2/neu normalized against 
GAPDH mRNA level using the comparative quantification algorithm 2
-∆∆Ct
 (Livak and Schmittgen, 








































A comparison of the non-PEGylated Chol-T and MS09 lipoplexes at different N/P charge ratios 
(+:‒) revealed that the Chol-T/siRNA complexes induced the highest HER2/neu silencing effect 
at all tested concentrations as indicated by the significant fold-difference in gene expression (> 
10 000-fold, P<0.001). Non-PEGylated MS09 lipoplexes yielded relative HER2/neu mRNA 
levels of 0.57, 0.45 and 0.50 which corresponds to a 1.87, 2.34, and 2.13-fold reduction in 
mRNA expression compared to the SKBR-3 untreated control (P<0.001). Moreover, the level of 
gene knockdown by Chol-T lipoplexes exceeded the knockdown level of Lipofectamine-3000 
(i.e., relative HER2/neu gene expression of 0.26 which represents a 4.1-fold decrease). 
Biophysical characterization of the Chol-T/siRNA complexes showed that these lipoplexes 
appeared as well-defined, spherical-shaped, uni-lamellar structures with distinct bilayered 
membranes which appeared well dispersed and colloidally stable [Figure 4.4 (A)]. These 
liposomes also formed the largest siRNA lipoplexes [187.97 nm (PDI 0.127)] with the highest 
zeta potential measurements (47.26 ± 5.39 mV), and were the least cytotoxic in SKBR-3 cells. In 
addition, the electrophoretic mobility shift assay indicated that the lowest charge ratio at which 
the liposomes were able to completely condense siRNA was obtained with the non-PEGylated 
Chol-T liposome [charge ratio (+:‒) 3.9:1]. These findings suggest that the Chol-T siRNA 
complexes formed condensed positively charged structures with low cytotoxic effects at a 
relatively low charge ratio. These characteristics of lipid based delivery systems have been 
previously reported to favour efficient gene delivery. In addition, larger lipoplexes have been 
generally described as being more efficient at gene delivery in vitro due to the fact that larger 
structures settle out from solution easily leading to fast sedimentation and increased contact with 
cellular membranes, as well as easier dissociation of the lipoplexes post endocytosis (Zhu and 
Mahato, 2010). Moreover, larger lipoplex formation has been shown to increase serum stability 
and effectively protect DNA from attack by DNAseI (Almofti et al., 2003; García et al., 2007). 
As shown in Figure 4.15, PEGylated Chol-T and MS09 lipoplexes reduced HER2/neu 
mRNA gene level at all concentrations tested (2% and 5% PEG). However, the effect of 
PEGylation on siRNA gene delivery differed with each of the cytofectins in the liposomal 
formulation. The following fold-changes in HER2/neu gene levels were recorded at different N/P 
(+:‒) charge ratios from suboptimal to supraoptimal concentrations: Chol-T 2% PEG (20.78, 
15.86 and 7.00); Chol-T 5% PEG (12.68, 12.14 and 1208.19); MS09 2% PEG (8.86; 31.01 and 
16.05) and MS09 5% PEG (72.37, 314.73 and 25.77). From the graph, a clear difference on the 
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effect of PEGylation can be observed. In the case of Chol-T lipoplexes, the effect of PEGylation 
at both 2% and 5% reduced the silencing efficiency of the Chol-T liposomes. Results indicated 
that PEGylation reduced the size and the zeta potential of Chol-T liposomes (Table 4.1). The 
reduced gene silencing effect, therefore, is most likely a result of the physical changes. This 
remarkable reduction in gene transfection efficiency accords with a previous report by Zhang et 
al. (2010). They suggested that PEGylation of DC-Chol/DOPE siRNA lipoplexes caused a 
decrease in particle size and zeta potential, and that the anti-HER2 siRNA DC-Chol/DOPE 
lipoplexes did not elicit any HER2 silencing in SKBR-3 cells. 
On the other hand, PEGylated MS09 lipoplexes significantly increased the HER2/neu 
gene silencing efficiency. An increase of 4.73-fold, 13.23-fold and 7.55-fold was observed upon 
2% PEGylation (P<0.001), and a further increase of 8.17-fold, 10.15-fold and 1.61-fold was 
recorded when PEGylated with 5% PEG (P<0.001). Interestingly, PEGylation also caused a 
decrease in particle size and zeta potential of MS09 liposomes. It was shown, however, that the 
high siRNA gene transfection efficiency of the PEGylated MS09 lipoplexes is concomitant with 
high cytotoxicity [Figure 4.13 (C)]. A comparison of the cell toxicity profiles of PEGylated 
MS09 siRNA complexes with those of non-PEGylated MS09 lipoplexes showed that there was 
up to 39.20% reduction in cell viability for the lipoplexes containing 5% PEG. 
 
4.4.4.2 HER2/neu protein expression  
 
To evaluate the modulation of HER2/neu target siRNA gene delivery into SKBR-3 cells via 
PEGylated and non-PEGylated Chol-T and MS09 cationic liposomal formulations, HER2/neu 
protein expression levels were analyzed using the Western blotting technique. Total protein 
lysate was firstly separated via electrophoresis using the sodium dodecyl sulphate-
polyacrylamide gel electrophoresis system (SDS-PAGE) and subsequently transferred onto a 
PVDF membrane. This was followed by specific primary and secondary antibody incubation, 
either Neu for HER2/neu protein detection or β-actin, an internal control for protein loading.  
The experimental set-up for Western blotting paralleled that implemented for qRT-PCR, 
except that protein extraction was conducted 72 h post transfection. The control samples 
included; SKBR-3 cells alone, non-targeting siRNA, HER2/neu target siRNA alone and 
Lipofectamine
®
-3000 Reagent. Results were analyzed based on densitometric values, and β-actin 
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control was used to determine normalization or equivalency of lane loading. Western blot 
analysis revealed high levels of HER2/neu protein expression (ratios) in negative control 
treatments relative to β-actin (SKBR-3 cells alone - 2.77, non-targeting siRNA - 2.57 and 
HER2/neu target siRNA alone - 1.93) [Figure 4.16 (A)]. In contrast, dramatic decreases in 
HER2/neu protein expression levels were observed for all siRNA delivery systems (PEGylated 
and non-PEGylated Chol-T and MS09) employed in this study. 
As indicated in Figure 4.16 (B) and (C), Western blot analysis demonstrated that non-
PEGylated Chol-T and MS09 liposomes resulted in a dose dependent decease in HER2/neu 
protein expression levels. Normalized HER2/neu protein expression levels were 0.017, 0.017 and 
0.013 (Chol-T) and 0.880, 0.231 and 0.217 (MS09). These values correspond to a 160.28, 163.89 
and 212.80 (Chol-T) and 3.15, 12.02 and 12.77 (MS09)-fold decrease in protein expression 
relative to the untreated SKBR-3 cells (alone). Comparing free HER2/neu target siRNA delivery 
(control, no liposome treatment) with the cationic liposomal delivery systems, a 111.39, 113.89 
and 147.89 (Chol-T) and 2.19, 8.35 and 8.89 (MS09)-fold decrease in protein expression was 
observed. These results indicate that as the N/P (+:‒) charge ratio increased from suboptimal to 
supraoptimal concentrations, a decrease in protein expression was observed. Reports have 
indicated that the charge ratio of lipoplexes significantly influences their morphology and 
capacity to transfect (Zhu and Mahato, 2010). The formation of lipoplexes with excess cationic 
liposomes (i.e., higher N/P charge ratio) tends toward developing spherical-shaped structures, in 
which the nucleic acid is effectively condensed and the resulting complexes are relatively more 
stable, making it easier for cellular internalization (van Gaal et al., 2011). To date, there are 
limited studies which specifically analyze the interaction between siRNA lipoplexes and cells 
membranes. Since siRNA lipoplexes formed from monovalent cationic liposomes have 
demonstrated successful gene silencing efficiency in vitro (Hattori et al., 2015; Xia et al., 2016; 
Zhang et al., 2010), two mechanisms have been postulated based on DNA lipoplexes. The first is 
a non-specific ionic interaction, where the proteoglycans on the cell membrane are involved in 
the internalization process (Mounkes et al., 1998). The second is an ion-pair mechanism where 
the cationic lipids form ion pairs with anionic lipids (e.g., phosphatidylserine) on the endosomal 
membrane. Subsequently, the ion-pairs lead to destabilization and disassembly of the lipoplexes 
and the endosome membrane, which in turn, enables release of the target siRNA into the 
cytoplasm (Xia et al., 2016; ur Rehman et al., 2013b). 
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Comparing the non-PEGylated Chol-T and MS09 HER2/neu target siRNA lipoplexes, the Chol-
T liposome resulted in a 50.85, 13.64 and 16.67-fold decrease in HER2/neu protein expression 
compared to the MS09 liposome at different N/P charge ratios (+:‒). These results corroborate 
qRT-PCR findings; the Chol-T/siRNA complexes induced the highest HER2/neu silencing effect 
at all tested concentrations as indicated by the significant-fold difference in gene expression 
[Figure 4.15]. Furthermore, there was a 5.61 (N/P 3.4), 5.73 (N/P 3.9) and 7.44 (N/P 4.4)-fold 
decrease in protein expression levels with non-PEGylated Chol-T lipoplexes compared to 
Lipofectamine
®
 3000 Reagent [Figure 4.16 (A)]. In a recent publication by Shi et al. (2016), 
cationic liposomes bearing shorter aliphatic chains offered better pDNA transfection efficiency 
than those containing longer chains. They postulated that increased transfection efficiencies with 
shorter hydrocarbon chains are due possibly to increased fluidity of the bilayer, leading to a 
greater degree of inter-membrane transfer and the subsequent mixing of the lipid membrane. 
These factors could be extrapolated to the siRNA delivery and be the reason why the Chol-T 
lipoplexes were most effective in gene silencing. Also, the size and zeta potential of a delivery 
system are important factors which must be considered for transfection. In particular, the size of 
the lipoplex has been reported to play a significant role in the entry pathway of complexes into 
the cells. Two main entry pathways have been suggested based on size of the lipoplex, namely, 
the clathrin coated and the caveolae-mediated pathways. A size range of ~300 nm or less favour 
the clathrin pathway. On the other hand, complexes which are > 500 nm enter basically via the 
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Figure 4.16: Analysis of HER2/neu oncoprotein expression by Western blotting. (A) Non-treated SKBR-3 cells, NT-siRNA (non-targeting siRNA) 
and siRNA (HER2/neu targeting siRNA alone) served as negative controls. Lipofectamine
®
 3000-siRNA was included as a positive control. (B) 
SKBR-3 cells were treated with HER2/neu target siRNA (0.64 µg) with varying amounts of the cationic liposomes from suboptimal to supraoptimal 
ratios: Chol-T (7.68, 8.96, 10.24 μg); Chol-T 2% PEG (14.08, 15.36, 16.64 μg); Chol-T 5% PEG (22.40, 23.68, 24.96 μg); (C) MS09 (12.16, 13.44, 
14.72 μg); MS09 2% PEG (14.72, 16.00, 17.28 μg); MS09 5% PEG (21.76, 23.04, 24.32 μg). HER2/neu receptor expression was determined in 
































Interestingly, it has also been suggested that only the latter pathway produces an efficient 
transfection strategy, since it is capable of supressing lysosomal digestion as well as allowing for 
an efficient endosomal release mechanism (Rejman et al., 2006). In the presence of serum, 
lipoplexes in general tend to form structurally unstable complexes which lead to reduced or low 
transfection efficiencies (Cheung et al., 2005; Lundqvist et al., 2008). In this study, however, the 
significant gene silencing effect demonstrated by Chol-T/siRNA complexes at both the mRNA 
and protein levels indicates that these lipoplexes were most efficient at delivering the HER2/neu 
target siRNA into SKBR-3 in the presence of serum. The unusually high transfection efficiency 
in the presence of serum has been previously described by Caracciolo et al. (2010). These 
researchers used both dynamic light scattering measurements and proteomic experiments to 
show that in the presence of serum, the size of DC-Chol-DOPE/DNA complexes was regulated 
by the formation of a protein corona on the surface of the lipoplex which was concomitant with 
an inherent increase in particle size. They suggested that the formation of a protein-rich layer on 
the surface of lipoplexes caused the lipoplexes to aggregate due to decreased inter-bilayer 
electrostatic repulsions between the cationic lipoplexes, and that the larger size was most likely 
accompanied by caveolae-mediated internalization and an increase in transfection efficiency. 
With regard to Chol-T and MS09/siRNA lipoplexes, a similar trend is likely as these complexes 
were relatively larger with a higher ζ potential measurement, thereby enabling greater affinity for 
serum protein binding. However, MS09/siRNA complexes were less efficient than Chol-
T/siRNA in protecting the siRNA cargo from serum nuclease degradation [Figure 4.8]. 
Therefore, although MS09/siRNA lipoplexes possessed larger particle sizes for entry via 
caveolae-mediated endocytosis, insufficient internalization of the HER2/neu target siRNA 
resulted in low levels of siRNA gene silencing.  
As mentioned previously, in order to improve the stability of lipidic complexes in vivo, 
the effect of PEGylation (2 – 5 mol.% of DSPE-PEG2000 with respect to CholT:DOPE and 
MS09:DOPE) on the cationic liposomal delivery system was investigated. Both PEGylated Chol-
T and MS09 cationic liposomes resulted in HER2/neu gene silencing, as detected at the mRNA 
and the protein levels. Depicted in Figure 4.16, normalized HER2/neu protein expression levels 
decreased by: 53.50, 56.48 and 51.89-fold (Chol-T 2% PEG); 41.29, 41.96 and 48.28 (Chol-T 
5% PEG); 14.18, 17.60 and 22.61 (MS09 2% PEG); 6.94, 15.55 and 16.68 (MS09 5% PEG) 
compared to the untreated SKBR-3 cells (alone). qRT-PCR and Western blot results indicated 
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that PEGylated Chol-T (2% and 5%) reduced the siRNA gene silencing ability of the Chol-T 
liposome. Characterization of PEGylated complexes confirmed a decrease in particle size and 
zeta potential (Table 4.1). The phenomenon observed with PEGylated Chol-T lipoplexes 
correlates with the above-mentioned premise that a decrease in zeta potential (less cationic 
charge) most likely reduces the attraction of serum proteins and therefore favours cellular 
internalization via the clathrin-dependent pathway. It has also been suggested that preformed 
PEGylated liposomes have a tendency to form unstable complexes with siRNA, as the PEG 
chains are known to create a hydrophilic barrier that prevents the electrostatic interaction 
between the siRNA gene material and the cationic lipid carrier (Belletti et al., 2016). The siRNA 
molecules tend to form loose interactions and are usually exposed on the surface of the 
PEGylated liposomal structure. These siRNA molecules are in most cases unprotected and easily 
attacked by nucleases present in serum. Characterization of the PEGylated MS09/siRNA 
complexes indicated that these lipoplexes do experience a certain degree of instability. It was 
observed, however, that PEGylated lipoplexes were somewhat more efficient in HER2/neu gene 
silencing than their non-PEGylated counterparts, albeit lower than Lipofectamine
®
 3000 
Reagent. Moreover, serum nuclease digestion analysis indicated variations in siRNA gene 
protection. It can be suggested that during siRNA lipoplex formulation, the high energy 
transmission induced by vortexing may allow for these rather small siRNA molecules to 
manoeuver between the PEGs and harmoniously accommodate themselves on the cationic 
liposome. These siRNAs may then be internalized into the cell, enabling siRNA gene silencing 
(Barichello et al., 2012).  
Reports suggest that a 2% - 5% PEG concentration (relative to the lipidic composition) is 
required to stabilize particles (Belletti et al., 2016; Peeters et al., 2007). The pre-PEGylated 
lipoplexes, with only a minimal amount of PEG (2 mol.%), was able to efficiently form 
lipoplexes, offer adequate protection to their siRNA cargo, and deliver the HER2/neu target 
siRNA into SKBR-3 cells. At the protein expression level the Chol-T 2% PEG demonstrated a 
1.30, 1.35 and 1.08-fold decrease while MS09 2% PEG revealed a 2.04, 1.13 and 1.36-fold 
decrease compared to their 5% PEGylated equivalents. Belletti et al. (2016) reported a similar 
finding using the cationic lipid DOTAP and DSPE-PEG2000. Post-PEGylation at 2 mol.% was 
capable of effectively stabilizing Blimp-1 siRNA, efficiently delivering it into the BCBL-1 cell 
line and significantly reducing the BLIMP-1 protein levels. It was also demonstrated that when 
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the PEG concentration was increased to 5 mol.%, micelles on preformed lipoplexes did not 




































































5.1 Concluding Remarks 
 
The potential of siRNA to silence the expression of a number of oncogenes at the transcriptional 
level offers an attractive and powerful therapeutic route for the treatment of BC. The RNAi 
pathway enables target-specific interference of genes which are expressed at abnormally high 
levels; these include either pathogenic genes or gene targets involved in cancer progression 
and/or cell cycle regulation. The application of siRNA-based therapeutics offers several 
advantages over traditional treatments with minimal side effects. It makes use of an innate 
cellular pathway, requiring the introduction of either a synthetic siRNA duplex molecule or a 
dsRNA trigger molecule. Despite recent progress in developing nanocarrier systems, cell toxicity 
and the reduced cellular uptake efficiency of siRNA in the presence of serum nucleases are still 
major drawbacks for in vitro and in vivo applications. This leaves BC gene therapy at a juncture 
where the need for an optimal gene delivery vector has become the rate limiting step. Further 
advances in the field of siRNA-gene based therapy depend on the discovery of a competent 
nanocarrier system which promotes specific tissue and cellular internalization of the therapeutic 
siRNA, as well as its efficient endosomal escape into the cytoplasm. Therefore, the development 
of safe nanocarrier delivery systems with the capacity for whole organism application still 
remains a formidable challenge in the continued quest to optimize the success of siRNA-based 
therapeutics. 
This study evaluated the ability of six cationic lipid-based delivery systems (PEGylated 
and non-PEGylated) to efficiently deliver intact siRNA which would target the HER2/neu 
oncogene in a BC cell model. Both Chol-T and MS09 cationic cholesterol cytofectins co-
formulated (1:1) with the neutral lipid DOPE were able to form liposomes with favourable 
physicochemical characteristics (particle size and zeta potential measurements) and was capable 
of binding and protecting nucleic acids (pDNA and siRNA). These delivery systems were 
reproducible and able to withstand long-term storage at 4 °C. Translation of siRNA lipofection 
from in vitro to in vivo applications requires stability of the lipid-based delivery system in the 
physiological milieu. Noted disadvantages with administration of cationic lipoplexes included: 
aggregation and poor control of the particle size, adsorption of biomolecules such as plasma 
proteins, rapid uptake by the reticuloendothelial system, as well as adverse toxicity effects due 
mainly to the cationic charge. PEGylation has become the most successful and popularly 
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employed strategy to impart promising pharmacodynamic and pharmacokinetic properties to 
increase the longevity of lipoplexes in circulation. In this study, grafting DSPE-PEG2000 on the 
surface of liposomal formulations did indeed provide a steric barrier at the surface of nascent 
liposomes. This prevented vesicle aggregation and encouraged the formation of a homogeneous 
population of smaller liposomes with colloidal stability and biocompatibility. On the other hand, 
the partial masking of the positive charges by PEGylation ultimately led to greater amounts of 
the PEGylated liposome being used to fully bind pDNA or siRNA compared to the non-
PEGylated liposomes. This was most apparent with siRNA, as indicated by the EtBr 
intercalation assay, where greater quantities of the PEGylated liposomes were required to 
successfully displace the intercalated EtBr cation and bind the siRNA, demonstrating a relatively 
weaker affinity toward the nucleic acid. As such, PEGylated cationic liposomes were more 
cytotoxic than their non-PEGylated equivalents due mainly to the higher concentration of the 
cationic cytofectin. 
Preliminary studies testing the ability of these lipid-based delivery systems to transfect 
pDNA collectively demonstrated that the non-viral cholesterol containing lipoplexes, Chol-T and 
MS09 (0%, 2% and 5% PEG), were able to stably transfect pDNA into the various cell lines 
tested, albeit to varying degrees. Results have indicated that PEGylated cationic lipoplexes were 
more efficient in transfecting the pCMV-luc gene and increasing luciferase activity than their 





 protein) at N/P charge ratio 1.7. Furthermore, these liposomes displayed 
significant improvement in pCMV-luc plasmid DNA transfection [7.2-fold increase, (P<0.001)] 
compared to the non-PEGylated MS09 lipoplexes in the presence of serum. Interestingly, the 
MS09 5% PEG lipoplexes demonstrated a significant dose-dependent increase in luciferase 
signals from suboptimal (N/P 1.3) to optimal (N/P 1.7) charge ratios, and then a decrease in 
activity at supraoptimal ratios (N/P 2.1) in all three tested cell types. Along with mediating 
improved cellular uptake and transfection efficiency, MS09 5% PEG pDNA lipoplexes also 
assured their safety and biocompatibility in vitro as indicated by low levels of cytotoxicity (> 
80% cell survival).  
With regard to HER2/neu siRNA gene delivery, gene expression studies indicated that 
the Chol-T:DOPE (0% PEG)/siRNA complexes induced the highest HER2/neu silencing effect 
at all tested N/P charge ratios as indicated by the significant decrease in gene expression (> 10 
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000-fold, P<0.001). In addition, Western blot analysis confirmed the above profile and revealed 
a dose-dependent decrease in HER2/neu protein expression levels as indicated by a 160.28, 
163.89 and 212.80-fold decrease in protein expression relative to the untreated SKBR-3 cells 
(alone). Furthermore, the most active non-PEGylated Chol-T formulations were less cytotoxic 
and exceeded the knockdown level of Lipofectamine
®
 3000 control (4.1-fold decrease). 
PEGylated Chol-T and MS09 lipoplexes reduced HER2/neu mRNA gene level at all 
concentrations tested (2% and 5% PEG); however, the effect of PEGylation on siRNA gene 
delivery differed with each of the cytofectins in the liposomal formulations. In the case of Chol-
T lipoplexes, qRT-PCR and Western blot results indicated that PEGylated Chol-T (2% and 5%) 
reduced the siRNA gene silencing ability of the Chol-T liposome. On the other hand, although 
PEGylated MS09 lipoplexes significantly increased the HER2/neu gene silencing efficiency in 
an N/P charge ratio dependent manner (evidenced by protein expression levels), cytotoxicity was 
also increased with up to 39.20% reduction in cell viability for lipoplexes containing 5% PEG 
compared to non-PEGylated MS09 lipoplexes. 
These results reflect the immense potential of these PEGylated and non-PEGylated 
cationic liposomes in HER2/neu siRNA gene silencing in the BC cell model utilized in this 
study. The findings of this study support the hypothesis that these non-viral cationic liposome 
systems have the ability for future-therapeutic siRNA and DNA gene delivery. However, with 
the caveat that PEGylated cationic liposomes be used with caution, as their effects varied with 
each of the cytofectins used in this study. Post-inserting PEG on preformed siRNA lipoplexes is 
conceivably a viable option to ameliorate some of the negative effects of using PEG. This 
strategy demonstrably offers better siRNA binding capacity, as well as the potential for masking 
siRNAs and protecting them from nuclease attack.  
Future recommendations may involve optimizing PEGylated liposomal formulations by 
varying the percentage of PEG derivatives as well as the use of different molecular weights of 
PEG. Future studies aims at testing the ability of these cationic lipid based nanocarriers to safely 
and efficiently deliver target siRNA into a HER2/neu overexpressed animal model for evaluation 
in vivo. Although the conclusions obtained from this study provide evidence of efficient siRNA 
gene delivery in the presence of serum, it should be noted that the most efficient nanocarrier in 
cell culture may not always be the best performer in vivo. Additional work to evaluate modes of 
cell association, as well as, elucidating how the various formulations influence cellular 
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internalization capacity and endosomal release mechanisms may also be explored. Both 
pharmacokinetic and pharmacodynamic profiles are necessary to effectively predict the kinetic 
routes and the association of HER2/neu siRNA to its target. To conclude, given their 
biocompatibility and superior transfection efficiency as compared with the commercial 
transfection agent, the use of these cationic liposomes offers a promising and attractive 
alternative for siRNA gene therapy in vivo. 
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 Cholesterylformylhydrazide (MS04)  
 
3β-[N-(N’, N’-dimethylaminopropane)-carbamoyl] cholesterol (Chol-T)  
Chol-T: 
1
H NMR (250 MHz, CDCl3): δ 0.65 (s, 3H, CCH3), 0.83 (d, 6H, J = 5.2 Hz, CH(CH3)2), 
0.89 (d, 3H, J = 6.5 Hz, CHCH3), 2.19 (s, 6H, (CH3)2NCH2CH2)), 2.30 (t, 2H, J = 6.6 Hz, 
(CH3)2NCH2CH2CH2), 3.21 (q, 2H, J = 6.1 Hz, (CH3)2NCH2CH2CH2NH), 4.46 (m, 1H, Chol-
H3α), 5.35 (d, 1H, J = 5.3 H, H6). (HRMS) (M
+





H NMR (300 MHz, DMSO d
6
): δ 0.66 (s, 3H, CCH3), 0.86 (d, 6H, CHCH3), 0.91 (d, 3H, 
CHCH3), 0.99 (s, 3H, CCH3), 3.88 (bs, 2H, NH2), 4.38 (m, 1H, Chol-H3α), 5.33 (d, 1H, Chol-H6), 
7.93 (s, 1H, NH). MS, m / z, ES-TOF: 445.4358 [M+ H
+






 Cholesterylformylhydrazide hemisuccinate (MS08)  
N-hydroxysuccinimide ester of MS08 (NHS-MS08)  
MS08: 
1
H NMR (300 MHz, DMSO d
6
): δ 0.64 (s, 3H, CCH3), 0.83 (d, 6H, CHCH3), 0.89 (d, 3H, 
CHCH3), 0.96 (s, 3H, CCH3), 4.3 (m, 1H, Chol-H3α), 5.34 (d, 1H, Chol-H6). MS, m / z, ES-TOF: 
545.09 [M+ H
+






H NMR (300 MHz, CDCl3): δ 0.68 (s, 3H, CCH3), 0.87 (d, 6H, CH-CH3), 1.01 (s, 
3H, C-CH3), 2.72 (s, 2H, CONH-CH2), 2.82 (bs, succinimide –CH2CH2-), 2.92 (d, 2H, OCO-




N, N-dimethylaminopropylaminylsuccinylcholesterylformylhydrazide (MS09)  
MS09: 
1
H NMR (300 MHz, CDCl3): δ 0.65 (s, 3H, CCH3), 0.84 (d, 6H, CHCH3), 0.88 (d, 3H, 
CHCH3), 0.98 (s, 3H, CCH3), 2.26 (s, 6H, NCH3), 3.28 (q, CH2CH2NH), 4.48 (m, 1H, Chol-H3α), 
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Breast cancer is prevalent globally as the second leading cause of cancer-related mortality among women, 
with approximately 1.4 million new cases diagnosed annually. The genetic perturbations associated with 
this serious public health problem are emerging in the face of intense scientific enquiry thus facilitating its 
classification, prognostication, and treatment. RNA interference (RNAi) technology, utilizing short 
interfering RNA (siRNA), has emerged as a novel and potentially powerful approach in the treatment 
strategy to silence disease-causing genes such as those associated with breast cancer. RNAi is an 
evolutionarily conserved biological mechanism of post-transcriptional gene silencing mediated by either 
degradation or translation arrest of target mRNA. In spite of its promise as a novel class of therapy, 
instability of the therapeutic nucleic acid and its poor cellular uptake have limited its usefulness and 
application as an ideal clinical therapeutic approach. Nanocarriers have emerged as essential components 
in siRNA delivery systems and their further development in this role is crucial for the successful 
achievement of gene silencing based therapeutics. In this review, we highlight research efforts exploring 
breast cancer therapeutic targets particularly suitable for siRNA strategies, such as angiogenesis, 
apoptosis, cell cycle regulation, and HER-2/neu gene targets. We further explore non-viral nanocarriers 
based on the use of lipids and polymers which show potential as safe and effective delivery systems. 
 










Cationic lipid based nanosystems associated with siRNA: Enhanced HER2/neu gene silencing in a 
breast cancer cell model in the presence of serum 
Adhika Balgobind, Mario Ariatti and Moganavelli Singh* 
Department of Biochemistry, Non-Viral Gene Delivery Laboratory, School of Life Sciences, College of 
Agriculture, Engineering and Science, University of KwaZulu-Natal (Westville Campus), Private Bag 
X54001, Durban 4000, South Africa; E-Mails: adhikab@gmail.com (A.B); ariattim@ukzn.ac.za (M.A); 
singhm1@ukzn.ac.za (M.S)  
*Author to whom correspondence should be addressed; E-Mail: singhm1@ukzn.ac.za 




RNA interference technology, based on the use of siRNA, has emerged as a promising approach in the 
treatment strategy to suppress disease-causing genes such as those associated with breast cancer (BC). 
Despite its potential as a form of therapy, instability and poor cellular uptake of the therapeutic nucleic 
acid have posed daunting challenges. The major hurdle for siRNA-based therapy is the evolution of 
nontoxic, stable and efficient delivery systems to channel siRNA into target cells. Accordingly, this study 
assesses the efficacy of two cationic lipid-based delivery systems to deliver intact siRNA which would 
target the Human Epidermal Growth Factor Receptor 2 (HER2/neu) oncogene in a BC cell model.  
 Two cholesteryl cytofectins, 3β-[N-(N', N'-Dimethylaminopropane)-carbamoyl] cholesterol 
(Chol-T) and N, N-Dimethylaminopropylaminylsuccinylcholesterylformylhydrazide (MS09), were 
synthesized for the purposes of this study. A series of cationic liposomes were formulated using an 
equimolar ratio of the respective cytofectins together with the neutral lipid 
dioleoylphosphatidylethanolamine (DOPE). Sterically stabilized or stealth liposomes contained a 0-5 
mol.% 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] 
(DSPE-PEG2000) grafting.  
 Cryogenic-transmission electron microscopy (cryo-TEM) and dynamic light scattering 
measurements revealed that PEGylation generated smaller, defined structures when compared to their 
non-PEGylated counterparts. The hydrodynamic size ranges of the liposomal formulations and lipoplexes 
were 65-127 nm and 103-188 nm respectively, with moderate particle size distributions (polydispersity 
indices were <0.4). Liposomes bound and efficiently compacted siRNA as evidenced in band shift and 
ethidium bromide intercalation assays respectively, while nuclease digestion assays demonstrated that the 
degradative effect of serum on lipoplex-associated nucleic acid was minimal.  
 Cytotoxicity studies, involving the reduction of 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-
tetrazolium bromide (MTT), indicated that the siRNA lipoplexes elicited a dose-dependent cytotoxic 
effect, with cell viability remaining above 50% respectively. Gene expression studies indicated that the 
Chol-T:DOPE (0% PEG)/siRNA complexes induced the highest HER2/neu silencing effect at all tested 
N/P charge ratios, as observed from the significant fold-increase in gene expression (> 10 000-fold, 
P<0.001). Western blot analysis further confirmed this trend and revealed a dose-dependent decrease in 
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HER2/neu protein expression levels as indicated by a 160.28, 163.89 and 212.80-fold decrease in protein 
expression relative to the untreated SKBR-3 cells. Furthermore, the most active non-PEGylated Chol-T 
formulations were less cytotoxic and exceeded the knockdown level of Lipofectamine
®
 3000 control (4.1-
fold decrease). Results suggest that these cytofectin-based cationic liposomes with moderate degree of 
PEGylation have potential as vectors for trans-gene expression and HER2/neu siRNA gene silencing in 
BC cells. 
Keywords: HER2/neu, small interfering RNA (siRNA); breast cancer; cationic lipids, PEGylation 
 
